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During gonad development and fetal life, the germ cells (GC) undergo a range of 
different developmental processes necessary for correct postnatal gametogenesis and 
the production of the next generation. If these fetal events are disrupted by genetic or 
environmental factors, there could be severe consequences that may not present until 
adulthood. This is of particular importance in relation to human testicular GC 
tumours (TGCT), the most common cancer of young men, as TGCT is thought to 
arise from fetal GCs that have failed to differentiate normally during development 
and thus persist into adulthood, eventually becoming tumourigenic. TGCT is one of 
several related disorders of male reproductive health thought to comprise a Testicular 
Dysgenesis Syndrome (TDS), in which faulty testis development in fetal life may 
predispose to the development of cryptorchidism, hypospadias, reduced sperm count 
and TGCT.  
 
Currently there is no accepted animal model for TGCT, but some insight into human 
TDS has been gained through the use of a rat model using in utero Di (n-Butyl) 
Phthalate (DBP) exposure to induce cryptorchidism, hypospadias, low sperm count 
and reduced fertility (but not TGCT). However, a previous study suggested that DBP 
exposure can disrupt GC differentiation, resulting in significantly reduced GC 
number prior to birth and postnatal consequences. This thesis has been directed at 
investigating the normal process of GC development in the fetal rat and how this is 
altered by DBP exposure; such understanding may give insights into the origins of 
human TGCT by showing how and when disruption of normal fetal GC 
differentiation can occur.   
 
The first objective was to characterise GC development in both the rat testis and 
ovary to understand the normal events that occur between embryonic day (e)13.5 and 
e21.5, as most data in the literature is based on the mouse. Analysis by 
immunohistochemical, stereological and mRNA expression indentified that during 
this time period, a GC will undergo a dynamic sequence of changes involving 
migration, proliferation followed by differentiation (manifested by loss of specific 
    iv 
 
protein markers), whilst undergoing germ-line specific remethylation. Whilst whole 
gonad development is vastly different between testes and ovaries, GC development 
was broadly the same with only minor differences up to the point where GCs in the 
ovary enter meiosis. 
 
Having established the normal process of GC development in the fetal rat testis, the 
effects of in utero DBP exposure was then investigated. DBP exposure reduced GC 
number at all ages investigated even after only 24 hours of exposure and 
simultaneously prolonged GC proliferation. As apoptosis was unaltered by DBP 
exposure, the consistent reduction in GC number was suggested to be due to an 
initial reduction in GC number that does not recover to control levels. GC 
differentiation was assessed by the expression and localization of specific protein 
markers (OCT4, DMRT1 and DAZL). The pattern of expression of OCT4 and 
DMRT1 was altered by DBP exposure. GCs in DBP exposed animals also showed a 
delay in disaggregation from within the centre of seminiferous cords. These results 
suggested that a delay in GC differentiation was occurring with DBP exposure. This 
delay in GC development persisted into early postnatal life, following cessation of 
DBP exposure. Thus at postnatal day (D)6, GC specific re-expression of DMRT1, 
GC migration to the basal lamina and resumption of GC proliferation all showed a 
delay. DBP also induced an increase in the presence of multinucleated gonocytes.  
 
DNA methylation in the fetal rat testis was also investigated as a mechanism that 
could be disrupted by DBP exposure. DNA methylation of GCs increased during the 
last week of fetal life by global methylation of the GC genome and the increased 
expression of DNA methyl transferases. No effect of DBP exposure was detected. 
Inhibition of methylation by 5-aza-2’deoxycytidine was then investigated as a way to 
block GC differentiation in fetal rat testes and this resulted in a similar transient 
delay in GC differentiation but was perinatally lethal to the fetus. Bisulphite 
sequencing of the OCT4 promoter was also performed but proved inconclusive. 
Methylation patterns may be being altered by DBP exposure, but such changes could 




To complement the in vivo DBP exposure studies, an in vitro testis explant system 
using e14.5 testes was investigated. These in vitro testis explants showed some GC 
effects with MBP, the active metabolite of DBP, and also suggested a novel role for 
Hedgehog signalling in GC survival in the fetal rat testis. 
 
The studies in this thesis have characterised several aspects of fetal GC development 
in the rat and identified which of these are affected by DBP exposure, resulting in a 
delay in GC development. As DBP exposure delays but does not block GC 
differentiation, this may explain why TGCT is not induced in the DBP exposure rat 
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AIS    Androgen Insensitivity Syndrome 
AMH    Anti Müllerian Hormone 
AZC    5-aza-2’deoxycytidine 
B    Bound cell fraction 
BORIS   Brother Of Regulator of Imprinted Sites 
BrdU    5-Bromo-2’deoxyuridine-5’monophosphate 
BSA    Bovine Serum Albumin 
cKIT    c-KIT receptor of KIT/Stem cell factor 
CIS    Carcinoma in Situ 
CpG    Cytidine-Guanosine dinucleotide 
Cyc    Cyclopamine    
CYP26B1   Cytochrome P450 member 26B1 
D    Postnatal Day 
DAB    3,3 DiAminoBenzidine 
DAPI    4’,6-diamidino-2-phenylindole 
DAZL    Deleted in Azoospermia Like 
DBP    Di (n-Butyl) Phthalate 
DEHP    Di (2-EthylHexyl) Phthalate 
DHH    Desert Hedgehog 
DMRT1   Doublesex- and Mab-3 Related Transcription factor  
DMSO    Dimethyl sulfoxide 
DNA    Deoxyribose Nucleic Acid 
DNase    Deoxyribonuclease 
DNMT   DNA Methyl Transferase 
DNMT1   DNA Methyl Transferase 1 
DNMT3A   DNA Methyl Transferase 3A 
DNMT3L   DNA Methyl Transferase 3L 
em    Embryonic day (mouse) 
er or e    Embryonic day (rat) 
ES    Embryonic Stem cell 
EtOH    Ethanol  
EW    Early window of DBP treatment (e13.5-e15.5) 
Ext    Extended window of DBP treatment (e11.5-e20.5) 
FS-PBS   Filter Sterilised Phosphate Buffered Saline 
GC    Germ Cell 
IHC    Immunohistochemical  
INSL3    Insulin-like 3 
iPS    induced Pluripotent State 
MACS    Magnetic-Activated Cell Sorting 
    viii 
 
MBP    Monobutyl Phthalate 
MEHP    Mono EthylHexyl Phthalate 
MNG    Multinucleated Gonocyte 
mRNA    messenger Ribonucleic Acid 
MW    Middle window of DBP treatment (e15.5-e17.5) 
OCT4    Octamer-binding transcription factor 3/4 
PBS    Phosphate Buffered Saline 
PGC    Primordial Germ Cell 
PTCH1   Patched 1 
PTMC    Peritubular Myoid Cell 
Q RT-PCR   Quantitative Real-Time Polymerase Chain Reaction 
RA    Retinoic Acid 
RNA    Ribonucleic Acid 
rpm    revolutions per minute   
RT-PCR   Real-Time Polymerase Chain Reaction 
SC    Sertoli Cell 
SEM    Standard Error of the Mean 
SSEA1   Stage-Specific Embryonic Antigen 1 
Std or DBP500  Standard window of DBP exposure (e13.5-e20.5) 
SMA    Smooth Muscle Actin 
SMO    Smoothened  
SOX9    SRY-related HMG box gene 9 
SRY    Sex-determining region of the Y-chromosome 
TBS    Tris Buffered Saline 
TDS    Testicular Dysgenesis Syndrome 
TGCT    Testicular Germ Cell Tumour 
TUNEL Terminal deoxynucleotidyl transferase dUTP Nick End 
Labelling 
UB    Unbound cell fraction 
US     Unsorted cell fraction 
VASA    Vasa/Mouse Vasa Homologue/DDX11 
3β HSD   3β-Hydroxysteroid Dehydrogenase 
5MeC    5-Methyl Cytidine 
H2O    Water 
 
N.B. Throughout this thesis, the abbreviation GC stands for germ cell, regardless of 
sex or age, unless otherwise stated. All embryonic ages stated are for the rat, unless 
otherwise stated. For gene nomenclature the following convention is used, when 
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1 Literature Review 
During gonad development and fetal life, the germ cells (GC) undergo a range of 
different developmental processes necessary for correct postnatal gametogenesis and 
the production of the next generation. If these fetal events are disrupted by genetic or 
environmental factors, there can be severe consequences that may not present until 
adulthood. This is of particular importance in relation to human testicular GC 
tumours (TGCT), the most common cancer of young men, as TGCT is thought to 
arise from fetal GCs that have failed to differentiate normally during development 
and thus persist into adulthood, eventually becoming tumourigenic (Rajpert-De 
Meyts, 2006; Skakkebaek, 1978). TGCT is one of several related disorders of male 
reproductive health thought to comprise a Testicular Dysgenesis Syndrome (TDS), in 
which faulty testis development in fetal life may predispose to the development of 
cryptorchidism, hypospadias, reduced sperm count and TGCT (Sharpe, 2003; 
Skakkebaek et al., 2001).  
 
Currently there is no accepted animal model for TGCT, but some insight into human 
TDS has been gained through the use of a rat model using in utero Di (n-Butyl) 
Phthalate (DBP) exposure to induce cryptorchidism, hypospadias, low sperm count 
and reduced fertility (but not TGCT) (Fisher et al., 2003). However, a previous study 
suggested that DBP exposure can disrupt GC differentiation, resulting in 
significantly reduced GC number prior to birth and postnatal consequences (Ferrara 
et al., 2006). This thesis has been directed at investigating the normal process of GC 
development in the fetal rat and how this is altered by DBP exposure; such 
understanding may give insights into the origins of human TGCT by showing how 
and when disruption of normal fetal GC differentiation can occur.   
 
1.1 Sex determination 
The first event of sex determination in mammals occurs at fertilisation when genetic 
sex is established by the presence or absence of the Y chromosome (from the sperm). 
However phenotypic sex of the organism is dependent on the establishment of either 
an ovary or a testis later in development. Both the testis and ovary arise from 
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bipotential undifferentiated gonad pairs. When the undifferentiated gonad is removed 
in utero in rabbits (Jost, 1947), the resulting embryo has female anatomical 
development, illustrating the need of the testis for the subsequent sexually dimorphic 
duct structures and external genitalia, leading to the hypothesis of an active “male 
sex determining pathway” with female morphogenesis as the default developmental 
pathway. In the mouse, the bipotential gonads originate as paired thickenings of the 
ventral-medial surface of the mesonephros by mouse embryonic day (em)11.0 (Capel, 
2000) and comprises layers of undifferentiated somatic cells that are eventually 
joined by migrating Primordial Germ Cells (PGC, which are discussed in Section 
1.3.1). By around em12.5 seminiferous cords can be seen, indicating the earliest sign 
of testis differentiation (Brennan and Capel, 2004; Capel, 2000). During this 36 hour 
period of time a careful balance of signals is required for commitment to this testis 
fate.  
1.1.1 Sry 
The dependence on the Y-chromosome for testis determination eventually led to 
identification of the gene required for initiation as Sry (Sex-determining region of the 
Y-chromosome) (Hacker et al., 1995; Koopman et al., 1990; Sinclair et al., 1990). 
The importance of Sry was further established by mouse transgenic studies in which 
it was shown that genetic XY mice lacking Sry developed ovaries, whilst XX 
expressing Sry mice resulted in formation of testes (Koopman et al., 1991; Lovell-
Badge and Robertson, 1990). Sry is expressed in a wave from the centre to anterior 
and posterior poles of the gonad and is restricted to pre-Sertoli cells, driving these to 
differentiate into Sertoli cells (Koopman et al., 1990; Palmer and Burgoyne, 1991).  
 
Sry expression is first evident at em10.5 but its expression in the mouse is transient 
and is not required for Sertoli cell maintenance as expression is lost by em12.5 
(Hacker et al., 1995). It is primarily thought to act as a transcription factor that 
regulates expression of downstream target genes such as Sox9, Fgf9 and Dax1 
(Colvin et al., 2001; Kent et al., 1996; Meeks et al., 2003), which are themselves 
necessary for testis determination. A further role of Sry is to down regulate pro-
ovarian genes such as Wnt4 and Rspo1 (Jeays-Ward et al., 2003; Tomizuka et al., 
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2008). The current theory is that if pre-Sertoli cells are exposed to Sry, they will 
upregulate Sox9, which then promotes Fgf9, which in turn then reinforces Sox9 
expression whilst inhibiting and lowering expression of Wnt4 and Rspo1. As a result, 
the “balance” of Sox9/Fgf9 against Wnt4/Rspo1 decides between a Sertoli or 
granulosa cell fate and thus ultimately whether a testis or an ovary forms (Cool and 
Capel, 2009). 
  
Sry driven Sertoli cell differentiation is what ultimately decides the fate of the gonad 
and involves the recruitment of non-Sry expressing cells, as illustrated by chimaeric 
studies in the mouse in which XX somatic cells (without autonomous Sry) are 
recruited to a Sertoli cell fate (Palmer and Burgoyne, 1991) by paracrine signals 
(Wilhelm et al., 2009). These same studies have also established that a certain 
threshold of Sertoli cells is required to permanently differentiate the gonad into a 
testis, as gonads with less than 30% of XY cells fail to become Sertoli cells and 
instead express ovarian markers (Palmer and Burgoyne, 1991).   
 
Sry also drives both cell proliferation in the fetal gonad (Schmahl et al., 2000) and 
triggers the migration of cells from the mesonephros that is necessary for the 
formation of the seminiferous cords by em12.5 (Capel et al., 1999). Once cord 
formation has occurred, the gonad is committed to testis formation and the 
subsequent phenotypic sex of the embryo decided. The initiation of Sry expression 
and the downstream events of testis formation have been studied extensively in the 
mouse, but have also been examined in several other species in which similar events 
occur. Table 1.1 summarizes the timings of these events in the human, mouse and 
rat.  
Table 1.1 Timings of early testis development in the human, mouse and rat. Taken 











week  5 6 7 7-8 
Mouse embryonic 
day (em) 9-10 10-11.5 10.5 11.5-12.5 
Rat embryonic day 
(er) 10-11 11.5-12.5 12 13.5-14 
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1.2 Gonad formation and development  
Once the eventual fate of the gonad has been decided by the presence or absence of 
sufficient Sertoli cells, distinct morphological changes begin to occur that 
permanently distinguish a testis from an ovary. These changes include an increase in 
size due to Sry driven cellular proliferation and migration from the mesonephros 
combined with the organisation of Sertoli and PGCs into the seminiferous cords by 
em12.5 and, in the rat, on embryonic day er14.5 (Buehr et al., 1993a; Jost et al., 
1981), whilst ovarian development begins later with the organization of granulosa 
and GCs into follicles from em18.5 (Brennan and Capel, 2004).  
 
The organization of the testis is needed to fulfil the two requirements of the fetal 
testis, normally to create the correct environment for the development of the germ-
line and for the hormone production needed to masculinise the embryo. Migration of 
cells from the mesonephros is required for both of these functions, as cords fail to 
form when such  migration is blocked by separating the gonad from the mesonephros 
(Buehr et al., 1993a) or by mechanically blocking migration (Tilmann and Capel, 
1999), and endothelial cells that migrate into the gonad are also required within the 
interstitium. This migration is male-specific as exemplified by in vitro studies of 
gonads that form ovotestes, as these cultures show no cellular migration into ovarian-
like regions of the gonad, but in areas where testis cords arise migration does occur 
(Albrecht et al., 2000).   
 
1.2.1 Seminiferous cord formation  
Following the same pattern of Sry expression in the gonad, is the organization of the 
Sertoli cells (at around em10.5) and Peritubular Myoid cells (PTMC) around the 
aggregates of PGCs to form the seminiferous cords that become visible by em12.5 
and er14.5 (Buehr et al., 1993a; Jost et al., 1981). For the correct establishment of the 
cords, both differentiated Sertoli cells and PTMCs are required but not the GCs 
themselves (McLaren, 1991; Merchant, 1975). PTMCs were originally believed to be 
a subset of cells that migrated in from the mesonephros, but recently they have been 
suggested to be induced from pre-existing cells in the gonad (Cool et al., 2008). 
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Sertoli cells and PTMCs also cooperate to lay down the basement membrane that 
surrounds the seminiferous cords and which effectively separates the cords from the 
interstitium (Skinner and Fritz, 1985; Tung and Fritz, 1986; Tung and Fritz, 1987).  
 
1.2.2 Sertoli cells 
The origin of the pre-Sertoli cells, prior to sex determination by Sry, is from 
epithelial cells that have migrated from the coelomic epithelium of the genital ridge 
(Karl and Capel, 1998). The fate of these migrating epithelial cells is temporally 
regulated, as labelling studies in the mouse showed that migrating epithelial cells 
prior to the 18 somite stage become both Sertoli and interstitial cells, while after the 
18 somite stage these cells will contribute only to the interstitium (Karl and Capel, 
1998). This migration from the coelomic epithelium eventually ceases by em12.5 
with the creation of the tunica albuginea from the basement membrane layer below 
the coelomic epithelium. This tunica acts as a capsule that surrounds the testis and 
may physically block further migration into the gonad (Karl and Capel, 1998) and 
also corresponds with the first appearance of seminiferous cords.  
 
Postnatally, mature Sertoli cells are required to support the germ-line and facilitate 
spermatogenesis by maintaining the spermatagonial stem cell niche (Hess et al., 
2006; Orth et al., 1988). This supporting role involves complex signalling between 
Sertoli cells to PTMCs (Skinner and Fritz, 1985; Tung and Fritz, 1987) and to GCs 
(Griswold, 1995; Loveland et al., 2005). 
 
Once seminiferous cord formation has occurred, the Sertoli cells have another 
important role in fetal life by producing Anti Müllerian Hormone (AMH or 
Müllerian Inhibiting Substance MIS) necessary for the correct regression of the 




AMH is a member of the transforming growth factor-β (TGF-β) family, and this 
glycoprotein is produced by Sertoli cells in fetal life (Fitzpatrick et al., 1998) from 
em11.5 onward (Arango et al., 1999; Munsterberg and Lovell-Badge, 1991) to induce 
regression of the Müllerian ducts. In the absence of AMH, the Müllerian ducts persist 
and differentiate into the upper vagina, uterus and oviducts. To induce this sexual 
dimorphism AMH binds and acts through its receptor AMHR2, which is present on 
the surface of the Müllerian duct mesenchymal cells, to cause apoptosis of the 
Müllerian epithelial cells, probably through production of matrix metalloproteinase 2 
(Roberts et al., 2002). In the rat, the timing of Müllerian duct regression occurs 
between er14-17 (Behringer, 1994; Mishina et al., 1996). AMH is also expressed 
within the postnatal ovary where it is produced from granulosa cells with a role in 
ovarian folliculogenesis (Weenen et al., 2004), but this postnatal ovarian role is of 
little relevance in this thesis. AMH is used as a marker for Sertoli cells from er14.5 
onwards. 
1.2.2.2 DMRT1 
Another important gene associated with fetal Sertoli cells is doublesex- and mab-3 
related transcription factor 1 (Dmrt1), a gene that regulates postnatal testis 
differentiation (Raymond et al., 2000). Dmrt1 is expressed from the genital ridge 
stage and persists in the testis throughout adult life in a variety of vertebrates 
(Kettlewell et al., 2000; Marchand et al., 2000; Raymond et al., 1999a). Dmrt1 
encodes a transcription factor containing a DNA binding motif called a DM domain. 
These DM domains were first identified as being crucial in sexual regulation in 
model organisms  Drosophila (Doublesex gene)  and C. elegans (MAB-3 gene) and 
DM domain containing genes have subsequently been identified as important in 
sexual differentiation for species beyond vertebrates (Zarkower, 2001). In the human, 
deletions of the chromosome region containing the Dmrt1 gene is associated with 
dysgenetic areas being present in the adult testis (Raymond et al., 1999b), while 
amplification of this same region is associated with a type of testicular germ cell 
cancer (spermatocytic seminoma, (Looijenga et al., 2006)). 
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In the fetal mouse, Dmrt1 is expressed in the undifferentiated gonad from em10.5 
before being localized to the seminiferous cords in the testis after em12.5, whilst in 
the ovary Dmrt1 expression (by whole mount in situ hybridisation data) is absent by 
em15.5 and is undetectable in the adult ovary (Raymond et al., 1999a). Within the 
seminiferous cords, DMRT1 protein is expressed in both Sertoli and germ cells and 
in adulthood expression is restricted to Sertoli and pre-meiotic germ cells, suggesting 
that DMRT1 has a role in co-ordinating the entry of GCs into meiosis (Raymond et 
al., 2000). In mice, in which the Dmrt1 gene has been knocked-out, fetal testis 
development occurs as normal, but by postnatal day (D)10 GCs are severely reduced 
in number and do not enter meiosis. GCs are absent by D14 leaving Sertoli cell-only 
cords and abnormally smaller testes (Raymond et al., 2000). Dmrt1 deleted female 
mice were apparently normal and fertile. 
 
The use of two further Dmrt1 mutant mouse lines has been used to elucidate the role 
of DMRT1 protein in each of two testis cell types. A Sertoli cell specific knockout of 
Dmrt1 has established that DMRT1 protein is needed in Sertoli cells for their 
maturation (Kim et al., 2007a) and is also needed for GC meiotic progression and 
survival, whilst in the GC-specific Dmrt1 knockout there were only effects on GC 
processes (Kim et al., 2007a). Loss of DMRT1 protein in the GCs affects postnatal 
migration to the periphery of the cords, mitotic and meiotic progression and GC 
survival (Kim et al., 2007a).  The role of Dmrt1 gene within rat fetal testis 
development will be further investigated within this thesis. 
 
1.2.3 Leydig cells  
Leydig cells outside of the seminiferous cords provide the steroidogenic machinery 
required for correct masculinisation of the developing embryo, otherwise female 
phenotypic development occurs even with the presence of testes (Jost, 1972). This 
requirement for androgens is most drastically illustrated in humans with complete 
Androgen Insensitivity Syndrome (AIS) where defects in the androgen receptor 
produce karyotypically 46, XY humans with undescended testes and external female 
genitalia (Chang et al., 1995).  
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In the rat, androgen synthesis must occur in a temporally regulated manner to 
correctly masculinise the embryo (Welsh et al., 2008), and both androgen receptor 
antagonism in males and exogenous testosterone exposure in females have suggested 
a “masculinisation programming window” for androgen action. In brief, androgens 
are required during er15.5-18.5 to program later masculinisation effects; including 
Wolffian duct development, prostate formation and eventual size, seminal vesicle 
size, penis formation and final length and anogenital distance (Welsh et al., 2008). 
Fetal androgen action is also required for brain masculinisation in both rat and 
primates but this occurs at a later age than masculinisation of the reproductive tract 
(Knickmeyer and Baron-Cohen, 2006; Perakis and Stylianopoulou, 1986). 
 
From rodent studies, the steroidogenic Leydig cells are divided into two sub types 
due to different morphology and gene expression profiles; fetal Leydig cells and 
adult Leydig cells (Baker et al., 1999; O'Shaughnessy et al., 2003; Roosen-Runge 
and Anderson, 1959). These two populations are thought to arise from two distinct 
lineages, with fetal Leydig cells appearing shortly after testis differentiation and 
remaining until birth, where upon their numbers decline until fully replaced by the 
adult Leydig cells at puberty (Habert et al., 2001; Kerr and Knell, 1988).  In humans, 
there is another population known as infantile Leydig cells that drive the primate-
specific testosterone surge of “minipuberty” in early postnatal life; these infantile 
Leydig cells are also replaced by adulthood (Andersson et al., 1998; Griswold and 
Behringer, 2009; McKinnell et al., 2001). As this thesis is focussed on prenatal 
events, fetal Leydig cells alone will be discussed further in this review.     
 
1.2.3.1 Fetal Leydig cells  
The origin of fetal Leydig cell progenitors remains unknown but several different 
sources for migrating cells been suggested, such as neural crest cells, cells from the 
mesonephros or from the coelomic epithelium (reviewed in Griswold and Behringer, 
2009). Regardless of their origin, fetal Leydig cell number increases throughout fetal 
life in the rat and peaks prior to birth; this increase is through differentiation of the 
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precursor population rather than through proliferation of the fully differentiated 
Leydig cells, which do not divide (Habert et al., 2001; Kerr and Knell, 1988). These 
differentiated cells have greater testosterone production per cell than adult Leydig 
cells (Huhtaniemi and Pelliniemi, 1992), so that testosterone production starts by 
er15.5 and increases until the end of fetal life (Haider, 2004). In this way, fetal 
Leydig cells produce the majority of androgens required for virilisation of the 
embryo.  
 
In addition to androgens, fetal Leydig cells also produce insulin like factor three 
(INSL3) that plays a role in testicular descent. INSL3 is a hormone that binds to the 
relaxin/insulin-like family peptide receptor 2 in the gubernacular ligament (Adham 
and Agoulnik, 2004; Scott et al., 2005), such that INSL3 induces the contraction and 
thickening of the gubernaculum that is responsible for the first stage of testis descent, 
the transabdominal movement (Adham and Agoulnik, 2004; Hughes and Acerini, 
2008; Nef and Parada, 1999; Scott et al., 2005). When the Insl3 gene is knocked out, 
the testes do not descend and remain within the body cavity, are smaller and have 
defects in spermatogenesis and infertility in adulthood as a result (Nef and Parada, 
1999).  The later stage of testis descent, inguinoscrotal movement, is driven by 
androgen action (Hutson et al., 1997) and is usually complete by birth in humans but 
postnatally in rodents around postnatal D21-23. The failure of one or both testes to 
descend is known as unilateral or bilateral cryptorchidism, and may be associated 
with the Testicular Dysgenesis Syndrome which is discussed in Section 1.5.2.  
 
1.2.3.2 Androgen synthesis 
Androgen synthesis within the Leydig cells requires the correct series of enzymatic 
reactions and intermediate products to convert cholesterol into testosterone or, by the 
further action of 5α-reductase, dihydrotesterone (DHT). This process is summarized 




Figure 1.1 Summary of the steroid biosynthetic pathway. Taken from (Griswold and 
Behringer, 2009) 
 
Fetal Leydig cells in the rat begin to express 3β-Hydroxysteroid Dehydrogenase (3β 
HSD) at er13.5 and become fully steroidogenic by er15.5 (Haider, 2004). In adult 
Leydig cells androgen synthesis is regulated by luteinising hormone (LH) through 
the hypothalamic-pituitary-gonadal axis. Fetal Leydig cells are, at least initially, 
gonadotrophin independent and can function in the absence of LH or LH receptor 
based on mice knock out studies (O'Shaughnessy et al., 1998; Zhang et al., 2004). 
The switch from gonadotrophin independent to dependent control seems to occur 
prior to birth around er19.5 (Migrenne et al., 2001; O'Shaughnessy et al., 1998). 
There have been several suggestions as to what drives the gonadotrophin 
independent Leydig cell stimulation including; vasoactive intestinal peptide (El-
Gehani et al., 1998), pituitary adenylate cyclase-activating polypeptide (El-Gehani et 
al., 1998) and adrenocorticotropic hormone (Johnston et al., 2007). In this thesis, the 
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steroidogenic enzyme 3β HSD is used as a marker for Leydig cells within the 
testicular interstitium.   
 
Testosterone or DHT must bind to the Androgen receptor (AR) to effect its action, 
with DHT having a higher receptor affinity, and seemingly more important role 
physiologically for virilisation (Imperato-McGinley, 2002). In addition, androgen 
synthesis is a process that is affected by Di (n-Butyl) Phthalate (DBP) exposure and 
will be discussed in Section 1.5.3.1. 
 
1.2.3.3 Desert Hedgehog signalling 
One of the cell signalling molecules important in both fetal and adult Leydig cell 
differentiation is Desert Hedgehog (DHH), a member of the Hedgehog signalling 
pathway (Clark et al., 2000; Yao et al., 2002). In the testis DHH is produced by the 
Sertoli cell and acts through the Patched 1 (PTCH1) receptor on the Leydig cell 
surface and other interstitial cells (Bitgood and Rozum, 1996). In mice with a Dhh 
gene knock-out, fetal Leydig cells fail to differentiate while their initial migration 
and survival are unaffected, (Yao et al., 2002). Postnatally, Dhh knock-out male mice 
were often feminised (92.5% of males) and lacked adult Leydig cells and had very 
limited spermatogenesis (Clark et al., 2000). In addition, DHH signalling must occur 
in a stage specific manner, as in vitro gonad organ culture using the DHH signalling 
inhibitor cyclopamine (which inactivates Smoothened, the first downstream target of 
activated PTCH1) showed that blocking DHH signalling on em11.5 prevented Leydig 
cell differentiation but, in 24 hour older (em12.5) testis cultures, cyclopamine did not 
prevent differentiation (Yao et al., 2002). Dhh null mice also have irregular cords by 
em16.5, and some GCs are found outside the cords, although these do not persist after 




1.2.4 Testicular vasculature 
The final aspect of testis development to be discussed is formation of the testis 
specific vasculature that is needed for the export of androgens out of the testis so that 
virilisation of the whole embryo can occur. Briefly, a subset of the epithelial cells 
that migrate into the gonad become organized into a new vascular network starting at 
em11.5 and results in the prominent coelomic blood vessel on the surface of the testis 
(Brennan et al., 2002). These vascular structures are restricted to the interstitium and 
do not enter the seminiferous cords themselves, and have been suggested to have an 
associated role in seminiferous cord formation by partitioning the gonad (Brennan 
and Capel, 2004; Brennan et al., 2003).   
 
1.2.5 Ovarian development 
Whilst the events of testis formation are well studied and summarised above, 
mention should be made of the “default” gonad pathway that produces an ovary. In 
the absence of Sry-driven Sertoli cell differentiation ovary formation will occur. In 
stark contrast to the testis this process involves few morphological changes from the 
undifferentiated gonad. The main change occurs towards the end of gestation 
(em18.5) with the rounding off of the gonad and the internal formation of follicles 
within the ovarian cortex (Brennan and Capel, 2004).  These ovarian follicles contain 
meiotically arrested GCs supported by granulosa cells and in contrast to seminiferous 
cords, it is the GCs that are necessary for follicular formation, as loss of GCs results 
in follicular degeneration (Merchant-Larios and Centeno, 1981; Merchant, 1975). 
The development of GCs within the ovary is discussed in Section 1.3.6. 
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1.3 Germ cells 
The correct development of an ovary or testis and the establishment of secondary 
sexual tissues provide the necessary environment and machinery for sexual 
reproduction, but it is the germ cells that are responsible for the correct inheritance of 
the genome from one generation to the next.  While the development of the somatic 
cells of the gonad occur within the gonad later in gestation, the GCs are specified 
earlier and then later migrate into the gonad at around the time of sex determination. 
Once in the gonad, the development of GCs into gonocytes or oocytes is dependent 
on the somatic environment and the GCs must develop and mature to ensure correct 
postnatal gametogenesis. 
 
As with sex determination and gonad formation, the majority of studies have been 
done in mice and thus enables use of transgenic possibilities. From these mouse 
studies, it has been generally assumed that similar mechanisms occur in both the rat 
and human with different timings.  
 
1.3.1 Primordial germ cells 
The specification of primordial germ cells (PGC) occurs earlier in embryogenesis 
than sex determination, when after the implantation of the blastocyst signals from the 
extraembryonic ectoderm and visceral endoderm induces a small number of 
embryonic epiblast cells to become PGCs. The extraembryonic mesoderm and 
visceral endoderm give rise to the extraembryonic tissues needed to support the 
embryo that develops from the epiblast. Only one region of the epiblast will give rise 
to PGCs, the proximal epiblast which is adjacent to the extraembryonic ectoderm 
(Ginsburg et al., 1990; Lawson and Hage, 1994). This region, rather than a pre-
existing cell type, is necessary for PGC specification, as transplantation of cells from 
the proximal to the distal end does not lead to their becoming PGCs, whilst 
transplantation of distal cells to the proximal epiblast does result in PGCs (Tam and 
Zhou, 1996).  
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The specification of the PGC fate from previously undifferentiated somatic cells of 
the proximal epiblast requires correct temporal and spatial signalling from both the 
extraembryonic ectoderm and visceral endoderm to the epiblast cells (de Sousa 
Lopes et al., 2007; Hayashi et al., 2007). Mouse knockout studies have identified 
several members of the Bone Morphogenic Protein family (BMP) as essential for this 
induction; including BMP2, 4 and 8b (Lawson et al., 1999; Ying et al., 2000; Ying et 
al., 2001; Ying and Zhao, 2001). BMP signalling is important in several 
embryogenic processes in which BMP dimers act on their receptors that signal 
through SMADs and induce their effect (reviewed in Gazzerro and Canalis, 2006). 
When either Bmp4 or Bmp8b genes are knocked out, GCs fail to form suggesting 
these two proteins may work together to induce GCs (Lawson et al., 1999; Ying et 
al., 2001). BMP4 appears to be the earlier signal, as Bmp4 knock-out epiblast cells 
from em5.5-6.0 can be induced to become PGCs by exogenous BMP4, but after em6.0 
exogenous BMP4 cannot induce this (Pesce et al., 2002; Ying et al., 2001). BMP8b 
can act on later epiblast cells, and BMP2 seems to a have an additive effect to BMP4 
(Ying et al., 2001; Ying and Zhao, 2001). 
 
Several SMADs have been identified as being involved in PGC specification 
downstream of BMP signalling, including SMAD1 (Tremblay et al., 2001), SMAD5 
(Chang and Matzuk, 2001) and SMAD4 (Saitou et al., 2003). These SMADs induce 
the expression of FRAGILIS, an interferon-inducible transmembrane protein within 
the proximal epiblast (Saitou et al., 2002), although not all cells that express 
FRAGILIS become PGCs. At em6.25, around 6 cells begin to express BLIMP1 from 
within the FRAGILIS positive population and this is the first germ cell lineage 
specific marker (Ohinata et al., 2005). BLIMP1 is a PR-domain containing zinc-
finger transcriptional repressor that has a key role in PGC specification by repressing 
genes involved in the somatic fate (Hoxa1 and Hoxb1) and upregulates PGC-specific 
and pluripotency associated genes (Stella, Nanos3, Nanog and Sox2) (Kurimoto et 
al., 2008; Ohinata et al., 2005). The BLIMP1 expressing cell population increases by 
either increased proliferation or, more likely, by increased induction of other 
FRAGILIS positive cells in the proximal epiblast (McLaren and Lawson, 2005), until 
by em7.25, there is a tight cluster of ~45 committed PGCs identified by expression of 
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Alkaline phosphatase (Ginsburg et al., 1990; McLaren and Lawson, 2005). One of 
the first genes expressed by the lineage committed PGCs is Stella, but it is not 
required for PGC specification as Stella knockout mice have normal fertility (Bortvin 
et al., 2004).  This process of PGC induction is summarized in Fig 1.2. 
 
 
Figure 1.2 Specification of primordial germ cells in early mouse embryos from em5.0-
7.5. Proximal epiblast cells receive signals from the extraembryonic cells (ExE), 
inducing Fragilis. A subset of Fragilis expressing cells then express Blimp1 and 
eventually Stella. In this figure: E refers to mouse embryonic day (em), PGC to 




1.3.2 Migration into the developing gonad 
Once the PGC population has been specified, these cells begin to migrate by em8.5 
before arriving at the genital ridge at around the time of sex determination, between 
em10.5-em11.5 (Clark and Eddy, 1975; Molyneaux et al., 2001). The route of these 
migrating PGCs has been elucidated using transgenic mice expressing green 
fluorescent protein from a truncated Oct4 promoter (Anderson et al., 2000; 
Molyneaux et al., 2001). The initial migration involves moving into the embryonic 
endoderm until by em7.5-8.5 the PGCs have become embedded in the developing 
hind-gut epithelium (Anderson et al., 2000; Molyneaux et al., 2001). Not all of the 
PGCs correctly migrate into the hind-gut epithelium and instead move into the 
extraembryonic mesoderm and do not contribute to embryonic tissue or the germ-line 
(Anderson et al., 2000). This initial migration into the endoderm may be due to 
active migration, as PGCs start to develop motility by em8, as seen in cultured cells 
from this age (Godin et al., 1991), or due to passive movement as the morphogenic 
remodelling of the embryo occurs. By em8.5, PGCs have altered morphology with 
small pseudopodial projections becoming visible that may be involved in GC 
motility (Clark and Eddy, 1975). Between em9-9.5, PGCs undergo active movement 
through the hind-gut and dorsal mesentery until they arrive at the developing gonad 
at em10.5-11.5 (Clark and Eddy, 1975; Molyneaux et al., 2001). Not all of these 
PGCs successfully arrive at the gonad, and some PGCs become situated ectopically 
and most may eventually enter meiosis until they are lost through apoptosis (Bendel-
Stenzel et al., 1998; McLaren, 1983). 
 
During the course of this migration, PGCs must be correctly targeted to the gonad, 
escape apoptosis and undergo several rounds of proliferation so that around 4000 
PGCs arrive at the gonad (Tam and Snow, 1981). Mice knockout studies have 
identified several genes involved in PGC migration, such as Nanos3, Dnd1 and most 
interestingly cKit.  
 
NANOS3 is an RNA-binding protein that is expressed from em7.5 in the presumptive 
PGCs and is maintained during migration (Suzuki et al., 2008). In Nanos3 knockout 
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mice, the PGCs are induced as normal but do not survive the migration (Tsuda et al., 
2003). From this, NANOS3 is thought to repress both Bax-dependent and Bax-
independent apoptosis (Suzuki et al., 2008). Another PGC gene associated with 
apoptotic suppression is Dead end (Dnd1), which encodes an RNA-binding protein. 
This gene was first identified from the Ter mutation in Dnd1 that results in a 
recessive condition that involves progressive loss of PGCs between em8.5-em12.5 
(Noguchi and Noguchi, 1985; Sakurai et al., 1994; Youngren et al., 2005). Mutation 
of Dnd1 is also linked with development of testicular germ cell tumours postnatally 
in the mouse (Youngren et al., 2005). 
 
cKit has a major role in the PGC migration process and has been suggested to be 
involved in survival, proliferation and directing the migration. cKit is expressed in 
PGCs from em7.5 and encodes a cell surface receptor with tyrosine kinase activity 
(Matsui et al., 1990). cKIT is activated by KIT ligand, a pleiotropic growth factor 
that is expressed by somatic cells along the migratory route and by the developing 
genital ridge itself (De Felici et al., 1996; Keshet et al., 1991; Matsui et al., 1990). In 
mice with mutations in either the ligand or receptor gene loci, there is a reduction in 
PGC number (Buehr et al., 1993b; McCoshen and McCallion, 1975) and 
hypomorphic KIT ligand mutants form PGC clumps that do not migrate (Besmer et 
al., 1993; Mahakali Zama et al., 2005). In vitro cultures of PGCs have identified that 
KIT signalling can prevent apoptosis and increase proliferation (Dolci et al., 1993; 
Runyan et al., 2006) and is also involved in the necessary adhesion of PGCs to 
somatic cells (Pesce et al., 1997). Recently KIT ligand has been suggested to be the 
crucial single chemoattractant for PGC migration and is responsible for reorganizing 
the actin skeleton to facilitate movement (Farini et al., 2007). Several other 
molecules exhibit evidence of a chemoattractant effect on PGCs, such as 
SDF1/CXCR4, TGFβ and BMP signalling and highlight the importance of somatic 
cell-PGC communication (Dudley et al., 2007; Godin and Wylie, 1991; Molyneaux 
et al., 2003). In addition, mutations in the cKit gene/chromosome region are often 
associated with Testicular Germ Cell Tumour in humans (Biermann et al., 2007; 
Rapley et al., 2009), discussed in Section 1.5.1.  
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1.3.3 Germ cell pluripotency  
After specification, PGCs must undergo two further processes for correct function in 
the germ-line; epigenetic reprogramming (which is discussed further in Section 1.4) 
and acquiring GC-specific pluripotency in differentiated cells. Recently the Prdm14 
gene has been identified as critical for both of these roles (Yamaji et al., 2008). 
PRDM14 is a PR-domain containing transcriptional regulator like BLIMP1, and is 
expressed from around em7.0 until around em14.0 specifically in PGCs and starts 
earlier than Stella expression (Yamaji et al., 2008). In Prdm14 knockout mice, PGCs 
undergo the normal repression of somatic fate but do not upregulate pluripotency 
genes such as Sox2 and Stella and do not undergo epigenetic reprogramming, while 
leaving other crucial genes for PGC development unaffected (Oct4, Dnd1, cKit and 
Nanos3). Further highlighting the importance of Prdm14, is its induction by BMP4 
independently of BLIMP1, although to maintain/upregulate this expression BLIMP1 
is required (Yamaji et al., 2008). 
 
The first of the pluripotency genes induced is Sox2, which encodes a transcription 
factor member of the Sox (SRY-related HMG box) gene family that is involved in 
early mouse development, with loss of Sox2 gene having peri-implantation lethality 
(Avilion et al., 2003). In embryogenesis, SOX2 protein is restricted to the anterior 
neuroectoderm of the epiblast (by em7.5) and to the PGCs from em6.75 (Western et 
al., 2005; Yabuta et al., 2006). SOX2 can work as a heterodimer with OCT4 to 
regulate the expression of itself and other pluripotency genes (Avilion et al., 2003; 
Tomioka et al., 2002). In the human fetal gonad SOX2 is not induced and it has been 
suggested that the related factor SOX17 may fulfil this role in the human (de Jong et 
al., 2008; Perrett et al., 2008).  
 
Octamer-binding transcription factor 3/4 (OCT4) is a POU domain containing 
protein that is expressed in the epiblast where it is required for establishing and 
maintaining pluripotency in early embryogenesis (Nichols et al., 1998). Oct4 
expression is lost during development, until by em7.5 it is restricted to PGCs, where 
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it is necessary for PGC survival (Kehler et al., 2004; Pesce and Scholer, 2000). Oct4 
expression is discussed in reference to promoter methylation in Section 1.4.5.1.   
 
NANOG is a homeobox-containing transcription factor that is also essential for 
pluripotency maintenance and becomes upregulated in PGCs by em7.75 (Yamaguchi 
et al., 2005). This upregulation could be driven by OCT4/SOX2 heterodimers 
(Rodda et al., 2005). Chimaeric mouse studies that allow Nanog-null PGCs to escape 
early embryonic lethality have suggested a maintenance role for Nanog, where 
Nanog-null PGCs are still recruited to the genital ridge but are lost by em11.5 
(Chambers et al., 2007).  
 
These pluripotency genes can be used to induce pluripotency in terminally 
differentiated somatic cells in both mouse and human (Takahashi et al., 2007; 
Takahashi and Yamanaka, 2006) and Oct4 in particular is also associated with 
human testicular germ cell tumour which will be discussed in Section 1.5.1. 
 
1.3.4 Gonocyte or oocyte determination 
Once the PGCs arrive in the gonad, they change their morphology and lose their 
motility and proliferate until by em12.5 around 26,000 GCs are present. Then they 
develop into meiotic oocytes or quiescent gonocytes (Donovan et al., 1986; Kocer et 
al., 2009; Tam and Snow, 1981). Until their arrival in the genital ridge, the PGCs are 
bipotential and require somatic signals to induce sex-specific behaviour (McLaren, 
1995). Studies using chimaeric gonads have illustrated that the chromosomal sex of 
PGCs is unimportant in this decision as, regardless of genetic sex, PGCs will enter 
meiosis in an ovary but will not in a testis (Palmer and Burgoyne, 1991). However, 
postnatal gametogenesis does require the correct chromosomal content in the GCs 
(Burgoyne, 1987). At around em12.5-13.5, GCs in both testis and ovary have a post-
mitotic/pre-meiotic morphological appearance and begin expressing some meiotic 
genes (McLaren, 2003). The expression of these meiotic genes are gradually lost as 
PGCs commit to spermatogenesis in the testis after em12.5, whilst it is maintained in 
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ovarian PGCs that commit to oogenesis a day later on em13.5 as evidenced by co-
culturing experiments (Adams and McLaren, 2002; McLaren, 2003).  
 
The factors that regulate whether a GC will enter meiosis or not are currently not 
fully understood, and it remains unclear whether there is a testis expressed meiotic 
preventing substance, or an ovarian expressed meiotic inducing substance, or a 
combination of the two (Kocer et al., 2009). However, as PGCs begin to express 
meiotic genes, such as SCP3 (Di Carlo et al., 2000), regardless of the gonad, and that 
both in vivo ectopic PGCs (in the adrenal gland) and cultured PGCs without 
testicular signalling enter meiosis around the same time as ovarian PGCs (McLaren 
and Southee, 1997; Zamboni and Upadhyay, 1983), suggests that the meiotic 
pathway is the default pathway of fetal GC development, with a local diffusible 
signal responsible for preventing meiosis in the testis. Recently, retinoic acid (RA), 
the small diffusible active metabolite of vitamin A, has been suggested to have a role 
in meiotic control (Bowles et al., 2006). RA signalling is involved in many aspects of 
embryogenesis and organogenesis and acts through activation of RA response 
elements in RA-responsive genes (Chambon, 1996; Mark et al., 2006).  
 
One such RA-responsive gene is Stra8, which is expressed in female PGCs in an 
anterior-posterior wave around em12.5, and is followed by a similar wave of early 
meiotic genes (Bullejos and Koopman, 2004; Menke et al., 2003). Stra8 is also 
expressed in premeiotic GCs of pubertal and adult mice testes (Oulad-Abdelghani et 
al., 1996). Stra8 knock out mice fail to enter meiosis, so it is an essential gene for 
meiotic progression (Baltus et al., 2006). This suggests that it may be sexually 
dimorphic differences in levels of RA between fetal testes and ovaries that cause the 
initiation of Stra8 expression and meiosis in the ovary only. This was supported by 
reports of expression of CYP26B1 enzyme, which metabolizes RA, in developing 
testes from em12.5 (Bowles et al., 2006). This has led to the hypothesis that RA, 
synthesized within the mesonephros, diffuses into the adjacent gonad where the local 
action of CYP26B1 in the testis creates a difference in RA levels in male and female 
gonads, such that Stra8 expression and then meiosis is restricted to the female 
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(Bowles et al., 2006; Bowles and Koopman, 2007; MacLean et al., 2007). This role 
of RA is summarized in Fig 1.3.  
 
Figure 1.3 Diagram of regulation of germ cell entry into meiosis by retinoic acid 
levels. Retinoic acid, produced by the mesonephros, is degraded in the testis by 
upregulated CYP26B1 expression after sex determination. Retinoic levels are 
maintained in the ovary and upregulate Stra8, and thus promote meiosis. Adapted 
from Bowles and Koopman (2007). 
 
 
The role of RA in meiotic induction is explained for adrenal ectopic and cultured 
GCs by the high levels of RA throughout the embryo and within culture media 
(Bowles and Koopman, 2007). However, it is unlikely that RA signalling is solely 
responsible for meiotic initiation, as some migratory PGCs in the human that become 
ectopic do not enter meiosis and can become GC tumours (Oosterhuis et al., 2007). 
In fact, several  factors have been identified (Kocer et al., 2009), including the 
importance of secretion (most probably from Sertoli cells) of unknown molecules for 
correct mitotic arrest of GCs in the testis (Best et al., 2008).  
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One important downstream target in GC sex determination is Nanos2, which is 
expressed solely in male PGCs from em13.5. In Nanos2 knockout mice, in which  
Bax-dependent apoptosis cannot occur, PGCs in a male environment abnormally 
express Stra8 and enter meiosis by em17.0 (Suzuki and Saga, 2008). When the 
Nanos2 gene is expressed within an ovary, Stra8 expression is downregulated and 
meiosis avoided, highlighting the importance of Nanos2 to effect sex-specific 
expression in PGCs (Suzuki and Saga, 2008). 
 
1.3.5 Germ cells in the developing testis 
In the developing testis, PGCs become organised into seminiferous cords and 
committed to the spermatogenic fate at around the same time at around em12.5-13.5 
(McLaren, 2003). After this point, sex specific differences begin to occur and PGCs 
become identified as gonocytes. By this time the PGCs have lost their motility and 
become morphologically fixed as round cells with a large nucleus and scant 
cytoplasm. These PGCs start to express genes associated with GC differentiation, 
such as Vasa, Dazl and Dmrt1 and lose the expression of pluripotency genes like 
Oct4 and Nanog.  
 
Mouse Vasa Homologue (Mvh or Vasa) encodes an ATP-dependent RNA helicase 
that is expressed in PGC cytoplasm once they reach the gonad and then has germ-
line specific expression throughout mouse life (Toyooka et al., 2000). In Vasa -/- 
mice, GC proliferation is reduced and OCT4 expression is reduced and postnatal 
meiosis fails at the zygotene stage so that no sperm are produced, supporting the 
importance of VASA in GC development (Tanaka et al., 2000). 
 
Deleted in Azoospermia like (Dazl) encodes an RNA-binding protein that is also first 
expressed in the cytoplasm of PGCs upon their arrival in the gonad (Seligman and 
Page, 1998). In Dazl -/- mice, adult testis size is reduced because of a loss of GCs, 
which is observable by em19.0 until only sparse spermatogonia and spermatocytes 
are observable in adulthood (Ruggiu et al., 1997; Schrans-Stassen et al., 2001). 
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The Dmrt1 gene, which was previously described in Section 1.2.2.2, is expressed in 
GCs as well as in Sertoli cells where it is driven by different promoters (Lei et al., 
2009). Dmrt1 expression in GCs is initiated by em13.5 and lost by em15.5 whilst 
expression remains in the Sertoli cells (Lei et al., 2007). By birth, Dmrt1 is re-
expressed in the GCs of the testis, where it is required for meiotic progression and 
survival (Kim et al., 2007; Lei et al., 2007). 
 
GCs also proliferate until em13.5, at which time they enter mitotic arrest (Monk and 
McLaren, 1981) and by the end of gestation the GCs migrate from the centre of the 
seminiferous cords to the basement membrane, becoming prespermatogonia. Shortly 
after birth, prespermatogonia resume mitosis and further differentiate into 
spermatogonia. These occupy the spermatogonial stem cell niche, maintained and 
supported by the Sertoli cells. Through the process of spermatogenesis, these 
spermatogonial stem cells produce the GCs that differentiate into other GC types and 
ultimately into spermatozoa, ensuring transmission of genetic information to the next 
generation for the length of the life of the mouse (reviewed in de Rooij (2001) and 
Culty (2009).  
1.3.5.1 Germ cells in the developing human testis  
In stark contrast to the mouse and rat, in which GC development in the testis is 
largely synchronised, human GCs are a heterogeneous population within a 
seminiferous cord (Fukuda et al., 1975; Gaskell et al., 2004). These heterogeneous 
GCs can be sub-divided into 3 groups based on morphology and marker expression; 
gonocytes, prespermatogonia and an intermediate cell type. Gonocytes are mitotic, 
with expression of OCT4 and cKIT but low levels of the protein MAGE-A4. 
Prespermatogonia are no longer mitotic, have lost/losing OCT4 and cKIT expression 
and have high levels of MAGE-A4. And the intermediate cell type is still mitotic but 
losing/lost OCT4 and cKIT, but still do not express MAGE-A4 (Gaskell et al., 2004). 
The relative proportion of these sub-types changes during human gestation, with 
gonocytes predominant in the 1st trimester, all three populations present during the 
2nd and 3rd trimesters with the proportion of prespermatogonia increasing whilst the 
proportion of gonocytes decreasing progressively through to term (Gaskell et al., 
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2004; Honecker et al., 2004). During the course of these thesis studies, understanding 
of human GC development has evolved and is further discussed in Section 3.4.  
 
1.3.6 Germ cells in the developing ovary 
In the developing ovary, the PGCs undergo the same loss of motility and have the 
same morphology as gonocytes, but become organised into nests of syncytial germ 
cells surrounded by stromal granulosa cells, where they become known as oogonia 
(McNatty et al., 2000). Oogonia continue to proliferate before entering meiosis 
between em13.5-15.5 and become classed as oocytes (McLaren and Southee, 1997). 
Oocytes undergo several stages of meiosis including leptotene, zygotene, pachytene 
and start meiotic arrest in diplotene at em17.5 with most oocytes reaching diplotene 
by postnatal D5 (Borum, 1961; Speed, 1982). As the oocytes enter meiotic arrest, 
they become surrounded by the granulosa cells to form ovarian follicles within the 
ovarian cortex (Brennan and Capel, 2004; Hirshfield, 1992). Meiosis is not 
completed until after puberty, just prior to ovulation, completing the role of the 
female germ-line.  
 
Whilst meiotic entry is the major difference between gonocytes and oocytes, there 
are several similarities in the differentiation which will be briefly summarized here. 
Pluripotency genes such as Oct4 and Nanog are also lost during differentiation of 
oocytes. Vasa is expressed in oogonia/oocytes but is not required in the female germ-
line (Tanaka et al., 2000). Dazl is expressed in oogonia/oocytes and has been 
suggested to enable RA to initiate meiosis, because Dazl -/- female mice are infertile 
with few oocytes by em19.0 and no follicles/ova are present in adulthood (Lin et al., 
2008; Ruggiu et al., 1997). Dmrt1 is expressed solely in oocytes/oogonia from 
em13.5-15.5 in the fetal ovary (Lei et al., 2009). Dmrt1 is not re-expressed 
postnatally and may not have an essential role in the female germ-line as Dmrt1 -/- 
female mice are fertile and apparently normal (Raymond et al., 2000). 
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1.4 Epigenetics  
In addition to passing on the correct genetic material, the DNA, to the next 
generation the GCs must also ensure that the correct “epigenetic” instructions are 
passed on. The term “epigenetic” means “above” genetics and refers to the 
mechanisms of inheritable changes in gene expression that do not alter the DNA 
sequence itself (Waddington, 1952). The most basic principle of epigenetics is that it 
is how a totipotent cell (fertilised egg) divides and the resulting cells differentiate, 
losing their totipotency and becoming the various terminally differentiated cell 
lineages that make up the whole organism. This occurs by the selective expression or 
inhibition of specific genes such that every cell retains the same DNA genome but a 
cell-specific complement of “active” genes. These epigenetic mechanisms include, 
but are not exclusively; DNA methylation, histone modification and silencing by 
RNA interference by small non-coding RNA, as summarized in Fig 1.4 (Egger et al., 
2004). The field of “epigenetics” is expansive, so for clarity this section will focus on 
DNA methylation with regard to the germ-line, with some minor consideration of 




Figure 1.4 Summary of interconnection of processes of “epigenetics” on heritable 
gene silencing. RNA refers to small non-coding RNAs that could be involved in 
silencing of heterochromatic chromosome regions or to trigger histone modifications. 
Taken from (Egger et al., 2004). 
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1.4.1 DNA methylation 
In mammals, DNA methylation occurs at the 5’ position of the Cytidine residue 
within Cytidine-Guanosine dinucleotides (CpG) and occurs at 60-80% of the CpGs 
(20-30 million sites) in the genome (Trasler, 2009). DNA becomes methylated after 
DNA replication through the action of DNA methyl transferases (DNMTs) so that 
methylation patterns are retained in daughter DNA strands/cells or can be removed 
without altering the DNA. The acquisition of new DNA methylation patterns is 
termed “de novo methylation”, which must then be maintained in subsequent DNA 
divisions (maintenance methylation), or else lost actively by demethylation or by 
prevention of DNMT action post replication (Klose and Bird, 2006; Trasler, 2009). 
DNA methylation of CpGs in gene promoter regions is associated with silencing of 
that gene through preventing the binding of transcription factors and/or the combined 
action of methyl-CpG binding proteins and DNMTs with histone modifications 
(histone deacetylases and methyltransferases) to cause chromatin remodelling that 
prevents nuclease action and gene transcription. In this way, DNA methylation is 
only one layer of epigenetic control that is readily examined in comparison to 
complex histone modifications that can occur (acetylation, methylation, 
phosphorylation, ubiquitination and sumoylation) (reviewed in Wang et al., 2004). 
 
DNA methylation in gene silencing and regulation has been linked with a variety of 
roles in development and differentiation, genomic imprinting and X-chromosome 
inactivation, whilst altered DNA methylation patterns are associated with cancer and 
developmental abnormalities.  
 
1.4.2 DNA methylation in the germ-line 
Epigenetics in the germ-line has two major roles, which both involve the 
reprogramming of PGCs; the expression of pluripotent and GC-specific genes and 
the establishment of sex-specific genomic imprinting. This epigenetic 
reprogramming begins shortly after PGC specification (around em8.5) and continues 
during migration to the gonad. This initial reprogramming involves the loss of both 
DNA methylation and histone dimethylation (H3K9me2) and the upregulation of 
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histone trimethylation (H3K27me3) (Seki et al., 2005). This change in histone 
methylation results in transcriptional silencing of GCs until arrival in the genital 
ridge and is thought to be driven by PGC-specific repression of GLP, a histone 
methyltransferase (Seki et al., 2007). This transcriptional silencing is thought to 
prevent unwanted gene expression brought on by demethylation whilst 
reprogramming occurs (Seki et al., 2007). During this silenced period, regulation of 
mRNA has been suggested to control the protein expression required in the PGCs 
(Nakamura and Seydoux, 2008). This initial reprogramming requires the expression 
of PGC-specific Prdm14 in order to repress GLP. In addition, Prdm14 and this initial 
epigenetic reprogramming may be required for functional pluripotency (Yamaji et 
al., 2008).  
 
By the time the PGCs arrive at the genital ridge, most DNA sequence methylation 
has been erased resulting in the loss of genomic imprinting and X chromosome 
reactivation in females (Hajkova et al., 2002; Maatouk et al., 2006). This DNA 
demethylation is thought to be a rapid process that leads to the PGCs having a “blank 
epigenetic slate” for the male or female specific methylation patterns to be 
established (Hajkova et al., 2002). This sex-specific difference in DNA methylation 
is known as genomic imprinting and is important in the mono-allelic expression of 
certain genes depending on the parental origin of the allele. The classic example is 
the H19/Igf2 locus, in which H19 is only expressed from the maternal allele and Igf2 
only from the paternal allele, even though both genes are within the same region. If 
an offspring erroneously inherits two copies of the maternally imprinted allele, there 
will be twice as much H19 expressed and no IGF2 (reviewed in Sasaki et al., 2000). 
For such “imprinted” genes, which only make up around 1% of autosomal genes, 
these imprints are retained in somatic cells but must be removed in the germ-line and 
re-established with a new imprint depending on the sex of the developing embryo.  
 
Establishment of male-specific DNA methylation begins in the gonocytes and is not 
complete until after the pachytene stage of meiosis postnatally (Lees-Murdock et al., 
2003; Oakes et al., 2007b), in contrast to the female-specific DNA methylation that 
does not start until after the pachytene stage of meiosis postnatally (Lucifero et al., 
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2004; Obata and Kono, 2002). Post-meiotically, this established sex-specific gametic 
DNA methylation is retained until post-fertilisation of the next generation, when 
another period of rapid global demethylation occurs in the pre-implantation 
blastocyst. Note that not all DNA is demethylated at this stage, for example 
imprinted genes retain the parental methylation pattern. In this way, epigenetic 
programming through DNA methylation is continued every reproductive cycle to 
ensure the correct erasure and reacquisition of DNA methylation (Trasler, 2009). 
These changes in the level of DNA methylation are summarized in Fig 1.5 
 
Figure 1.5 Diagrammatic representation of changing levels of DNA methylation from 
primordial germ cells to fertilization and gonadal differentiation. Taken from 
(Strachan, 2004).  
 
1.4.3 Transgenerational inheritance 
The role of DNA methylation in GC development allows for situations, in which the 
methylation patterns that are established in utero during gonadal development of the 
F1 generation do not have physiological consequences for that generation. Instead 
the methylation patterns of the GCs of the F1 only have consequences in the F2 
generation, providing a non-Mendelian form of inheritance. In this way, novel or 
altered methylation patterns established in utero can be transgenerationally inherited 
and affect only the F2 generation, or possibly becoming permanently fixed in the 
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epigenome by escaping germ-line epigenetic reprogramming into the F3 generation 
and beyond (reviewed in Jirtle and Skinner, 2007).  The possibility of such DNA 
methylation alterations having such long-term effects has become of increasing 
interest as it provides a mechanism via which environmental exposures during 
embryogenesis might influence disease risk down the generations long after that 
exposure is over. Physiologically, this probably represents a mechanism that allows 
relatively rapid adaptation to a changing environment without having to wait for 
(longer-term) genomic selective adaptation.  
 
The ability of environmental exposures in embryogenesis to alter adult disease state 
is of particular interest in this review, discussed with regard to phthalates and 
Testicular Dysgenesis Syndrome in Section 1.5.3, but at this point there should be 
some brief discussion of vinclozolin and transgenerational inheritance. Vinclozolin is 
an anti-androgenic endocrine disruptor that has been reported to produce adult onset 
disorders in the rat up to 4 generations after embryonic exposure (er8-15) (Anway et 
al., 2005; Anway et al., 2006b). These disorders include reduced spermatogenic 
capacity, increased male infertility and cancers of the breast, prostate and kidney of 
variable incidence (Anway et al., 2006a). The transgenerational effect was passed 
only through the male germ-line and the time of exposure to vinclozodin was 
coincident with PGC demethylation and arrival at the genital ridge suggesting a 
precedent of endocrine disruption and altered DNA methylation that is important in 
Chapter 5 (Anway et al., 2006a; Anway et al., 2006b). However no mechanism for 
how vinclozolin alters PGC DNA methylation has been identified and whilst the 
anti-androgenic results of embryonic vinclozolin exposure are well documented 
(Colbert et al., 2005; Hellwig et al., 2000; Yamasaki et al., 2005), the 
transgenerational data (beyond F2) has proven to be controversial and unable to be 
repeated by other research groups (Inawaka et al., 2009; Schneider et al., 2008).   
 
1.4.4 DNA methyl transferases in the germ-line 
The enzymes responsible for DNA methylation are the DNA methyl transferases 
(DNMTs), which have been studied within the prenatal and postnatal germ-line in 
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the mouse. These studies have highlighted the roles of DNMT1 in maintaining DNA 
in the developing GCs and gonad and the DNMT3 group of DMNT3A, 3B and 3L, 
which are seemingly responsible for de novo methylation within the GCs (Jue et al., 
1995; La Salle et al., 2004; La Salle and Trasler, 2006). 
 
In mammals, DNMT1 is the most abundant DNMT and predominantly methylates 
hemi-methylated CpG dinucleotides, hence maintaining methylation patterns on 
newly synthesised DNA strands in both germ-line and somatic cells (Li et al., 1992; 
Yoder et al., 1997). In the fetal testis, it is expressed in the gonocytes from em14.5-
18.5, with decreasing gonocyte expression after em15.5 until it is absent by em18.5 
(La Salle et al., 2004). This expression pattern suggests that DNMT1 expression 
occurs after the initiation of re-methylation (Howell et al., 2001; Sakai et al., 2001). 
A similar expression pattern is reported in fetal oocytes, with DNMT1 being 
downregulated during meiotic prophase (La Salle et al., 2004). Postnatally, DNMT1 
is re-expressed from D3 in GCs until the pachytene stage of spermatogenesis, where 
it is associated with upregulation upon mitotic resumption and down regulated to 
prevent aberrant meiotic methylation (Jue et al., 1995; La Salle et al., 2004). This 
loss of DNMT1 expression at the pachytene stage is also observed in the female 
mouse (La Salle et al., 2004). In addition there is an oocyte specific variant of 
DNMT1 that is necessary only within the pre-implantation embryo to maintain 
imprinted genes (Cirio et al., 2008; Ratnam et al., 2002).  
 
DNMT3 is a family of 3 methyltransferases (DNMT3A, 3B and 3L) that can 
methylate hemi-methylated and unmethylated DNA and are predominantly involved 
in de novo methylation (Okano et al., 1999; Okano et al., 1998). Only DNMT3A and 
3B have been shown to methylate DNA in vivo and the loss of either results in 
neonatal or mid gestation mortality. DNMT3L is restricted to GCs and loss of 
DNMT3L results in infertility and aberrant genomic imprinting (Bourc'his et al., 
2001). DNMT3L has not been shown to have methyltransferase activity itself but has 
been suggested to interact with DNMT3A and 3B (or other factors) to regulate 
genomic imprinting (Bourc'his et al., 2001; Suetake et al., 2004). In vitro co-
expression of DNMT3L with DNMT3A and 3B showed a stimulatory effect on de 
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novo methylation with DNMT3A but not 3B (Chedin et al., 2002). Expression 
analysis of the DNMT3s in the testis and ovary has identified 3A and 3L as highly 
expressed in the fetal testis, and 3L alone increased in the postnatal ovary (La Salle 
et al., 2004). These differences in expression match the differences in de novo 
methylation, supporting that 3A and 3L are crucial for testis de novo gene 
methylation. Additionally, male germ cell loss of DMNT3A results in infertility and 
aberrant imprinting (similar to DNMT3L loss), whilst loss of DNMT3B is not 
required for functional spermatozoa and only one imprinted locus is affected 
(Kaneda et al., 2004; Kato et al., 2007). 
 
1.4.5 DNA methylation and pluripotency 
DNA methylation as a mechanism of gene regulation of pluripotency in embryonic 
stem cells has been extensively studied (reviewed in Spivakov and Fisher, 2007), and 
will only be discussed briefly in relation to GC development.  
 
As discussed previously, upon PGC specification there is an upregulation of 
pluripotency genes Sox2 and Nanog and continued Oct4 expression during GC 
migration to the genital ridge. In both human and mouse, these genes are crucial in 
embryonic stem cells (ES) for maintaining an ES state, where they promote survival 
and proliferation while repressing differentiation genes (Boyer et al., 2006; Loh et 
al., 2006). These “master regulators” are lost as lineage commitment occurs. 
However, ectopic expression of Oct4 and Sox2 (with Klf4 and c-Myc) can “induce” 
differentiated cells from both human and mouse to return to the pluripotent state as 
iPS cells (Takahashi et al., 2007; Takahashi and Yamanaka, 2006)). DNA 
methylation and chromatin remodelling have been suggested as one way via which 
these transcription factors confer pluripotency as in mouse ES cells, as global 
methylation analyses have shown that pluripotency and housekeeping genes are 
relatively unmethylated compared with highly methylated differentiation genes 
(Fouse et al., 2008; Spivakov and Fisher, 2007).  
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1.4.5.1 DNA methylation of the OCT4 promoter 
A particular interest of this thesis is whether promoter DNA methylation is involved 
in the expression of OCT4. In mouse ES cells, DNA methylation of the Oct4 
promoter regulates its expression, and it becomes methylated during cell 
differentiation (Ben-Shushan et al., 1993; Pesce and Scholer, 2000; Yeo et al., 2007). 
In fact Oct4 promoter DNA methylation is often used to assess OCT4 protein 
expression itself, in particular as a register of induced pluripotency in iPS cells 
(Takahashi et al., 2007; Takahashi and Yamanaka, 2006; Wernig et al., 2007). This 
method of Oct4 control appears to be retained in humans, as promoter methylation 
corresponds with gene expression (Cha et al., 2008; Takahashi et al., 2007). In in 
vitro ES cell studies, retinoic acid treatment cause ES cells to lose their OCT4 
expression and it has been suggested that DNMT3A and 3B are involved in de novo 
methylation of Oct4 in these differentiating mouse ES cells (Li et al., 2007; Pikarsky 
et al., 1994).  
 
1.4.6 DNA methylation in cancer 
It should also be noted that DNA methylation is a system that is aberrant in a variety 
of cancers. DNA methylation becomes globally dysregulated with an overall loss of 
DNA methylation coupled with hypermethylation of specific promoters, particularly 
of tumour suppressor genes (reviewed in Esteller, 2007). Naturally this is a huge 
field of research, so will only be briefly discussed with particular regard to human 
testicular germ cell cancer in Section 1.5.1.1.  
1.4.7 Inhibition of DNA methylation 
DNA methylation patterns in development can be altered through maternal dietary 
supplementation, as exemplified by work on the “viable yellow” mutation of the 
agouti gene in mice, in which coat colour is related to the methylation status of the 
agouti gene in development (Cooney et al., 2002). Briefly, maternal dietary 
supplement with methyl donors shifts the coat colour of offspring to the brown 
colour through methylation of the promoter, whilst hypomethylation of the promoter 
region leads to yellow coat colour (Cooney et al., 2002).  
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DNA methylation can also be inhibited through drug treatment, with the most 
common being cytidine analogues 5-azacytidine and 5-aza-2’deoxycytidine (Egger et 
al., 2004). These analogues become incorporated into the DNA during DNA 
replication as a cytidine residue but have a nitrogen at the C5 position and so cannot 
become methylated; they can also bind to DNMTs and inhibit methyl transferase 
action  (Christman, 2002).  
 
The effects of these cytidine analogues on postnatal spermatogenesis has been 
investigated in both the rat and mouse; DNA methylation is reduced and causes a 
reduction in sperm counts and testis weight and subsequent fertilisation and 
implantation are disrupted (Doerksen et al., 2000; Doerksen and Trasler, 1996; Kelly 
et al., 2003). This suggests a link between DNA methylation and infertility (Trasler, 
2009). More detailed examination of the effects of 5-aza-2’deoxycytidine treatment 
on mouse spermatogenesis has suggested that it is de novo methylation that is 
inhibited rather than maintenance methylation (Oakes et al., 2007a). This has clinical 
implications as 5-aza-2’deoxycytidine is used as a chemotherapeutic agent in human 
cancer, particularly in leukaemia, and this treatment could cause persistent faulty 
DNA methylation in the sperm should it be used in adults (Kantarjian et al., 2003).   
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1.5 Testicular Germ Cell Tumours and Testicular Dysgenesis 
Syndrome 
1.5.1 Testicular Germ Cell Tumours 
In humans, abnormal development of GCs in men is linked with testicular germ cell 
cancers, that can arise in childhood (as teratomas and yolk sac tumours), young 
adulthood (seminomas and nonseminomas) or in older men (>50 years old, 
spermatocytic seminoma). The testicular germ cells tumours of young adulthood 
(TGCT) are the most common solid tumour in young men, aged 20-40 (McKiernan 
et al., 1999) and are further subdivided into uniform seminomas and the more 
variable and aggressive non-seminomas. Studies into the origin of TGCT, other than 
spermatocytic seminoma, have identified a non-malignant precursor cell type called 
carcinoma in situ (CIS). CIS cells are often detected in “high-risk” populations, and 
in normal tissue surrounding a tumour (Giwercman et al., 1987; Jacobsen et al., 
1981; Skakkebaek, 1972). These observations were supported by evidence that 
within 5 years of detection of CIS cells in testis biopsies of infertile men, over half of 
patients were diagnosed with TGCT, while subjects without CIS at biopsy did not 
develop TGCT (Skakkebaek, 1978).  
 
CIS cells possess a distinct morphology and express cell markers that other germ 
cells of the adult testis do not. In fact CIS cells more closely resemble fetal GCs 
(Looijenga et al., 2003; Rajpert-De Meyts et al., 2003). Recently, isolation by laser 
microdissection of CIS cells has shown that the gene expression profiles of CIS cells 
and fetal GCs/gonocytes are very similar (Sonne et al., 2009). This has led to the 
current hypothesis that CIS cells are fetal GCs that have failed to undergo correct 
differentiation but remain in the testis until malignant transformation in adulthood, 
probably driven by the same post pubertal signals that drive GC proliferation as part 
of spermatogenesis (Skakkebaek, 1972; Skakkebaek et al., 1982). This hypothesis is 
illustrated in Fig 1.6. The retention of fetal GC markers, such as placental alkaline 
phosphatase, OCT4 and NANOG (Giwercman et al., 1991; Hart et al., 2005; 
Looijenga et al., 2003) are used as diagnostic markers to identify CIS cells in the 
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human testis. This retention of pluripotency may contribute to the variability of 
tumour tissues that can arise in non-seminomas, which are the only known totipotent 
solid cancer (Honecker et al., 2006; van de Geijn et al., 2009). 
 
  
Figure 1.6 Diagrammatic illustration of the proposed fetal GC origin of CIS. This 
highlights the block of GC differentiation that prevents the normal pattern of 
postnatal GC development, causing fetal GC-like cells to persist in the testis as CIS. 
In this Figure: PGC=primordial germ cell, CIS=carcinoma in situ, EC=embryonic 
carcinoma, TER=teratoma, YST=yolk sac tumour and CHC=choriocarcinoma. 
Adapted from (Rajpert-De Meyts, 2006).  
 
After puberty, CIS cells begin to replicate and can result in CIS/Sertoli cell only 
tubules. This increase in CIS replication is believed to be the pre-invasive step that 
causes expansion out of the tubule (Dieckmann and Skakkebaek, 1999; van de Geijn 
et al., 2009). Invasive growth migration may be related to a characteristic gain of 
chromosome 12p material (Ottesen et al., 2003; Rosenberg et al., 2000). Studying the 
origins of CIS/TGCT is obviously limited in the human and there is currently no 
animal model available, possibly due to the careful interplay between Sertoli, Leydig 
and GCs that are probably involved in its aetiology.   
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1.5.1.1 Methylation in TGCT 
As mentioned in Section 1.4.6, incorrect DNA methylation is associated with cancer 
development, and there have been a number of studies into the epigenetics of human 
TGCT (reviewed in Lind et al., 2007). Global methylation patterns are different in 
seminomas and nonseminomas, with seminomas being relatively unmethylated and 
nonseminomas methylated. This difference is hypothesised to be related to whether 
the originating GC has undergone de novo methylation prior to becoming the 
precursor CIS cell (Netto et al., 2008; Smiraglia et al., 2002). Additionally, genomic 
imprinting appears to be lost in both TGCTs and CIS cells, with possible diagnostic 
implications (Kawakami et al., 2006; Kraggerud et al., 2003; Looijenga et al., 1998). 
At a gene specific level, it has been shown that the promoter region of OCT4 in 
TGCTs is predominantly hypomethylated, both in derived tumour cell lines as well 
as in the tumours themselves (De Jong et al., 2007). These DNA methylation patterns 
support the fetal origin of CIS cells and the importance of DNA methylation in 
testicular tumourigenesis. 
 
1.5.2 Testicular Dysgenesis Syndrome 
TGCT is one of a related group of disorders of male reproductive health that are 
thought to have a common fetal origin, in which abnormal fetal development of the 
testis impacts the function of the testis cell types and increases the risk of the 
disorders later in life. This group of related disorders includes; cryptorchidism 
(failure of testis descent), hypospadias (malformation of the penis), low sperm counts 
and TGCT. As these disorders are risk factors for each other in epidemiological 
studies, it has led to the hypothesis of a Testicular Dysgenesis Syndrome (TDS) 
(Sharpe, 2003; Skakkebaek et al., 2001). This proposes that if testicular development 
is perturbed by either genetic and/or environmental factors, one or more somatic cell 
types may function subnormally, leading to one or more of the related disorders, as 





Figure 1.7 Diagrammatic representation of the potential links between disrupted fetal 
testis formation and the TDS disorders. In this Figure: AIS=Androgen Insensitivity 
Syndrome. Taken from (Rajpert-De Meyts, 2006).  
 
 
These male reproductive disorders can manifest at birth (cryptorchidism and 
hypospadias) or in young adulthood (low sperm count and TGCT) and are either 
already common and/or are increasing in incidence in the Western world (Sharpe, 
2003). There is also a variable penetrance of these disorders such that a low sperm 
count is the most common, then cryptorchidism, and hypospadias and TGCT is the 
rarest. 
 
1.5.3 Animal model for TDS 
Due to the high/increasing frequency of TDS disorders and the severity of TGCT, a 
way to study how such dysgenesis occurs has been sought. As TDS probably 
involves complex cell-cell interactions in the fetal testis, transgenic mice are unlikely 
to provide a suitable model for this human disease. However phthalate exposure of 
fetal rats in utero has been shown to result in a TDS-like phenotype in male offspring 
and may therefore offer new insights into TDS origins.  
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Phthalates are ubiquitous environmental chemicals primarily used as plasticizers 
(such as in the production of polyvinyl chloride) and are found in a vast array of 
products used by humans in daily life (personal care products, food containers, 
numerous “fabrics” of modern society and medical devices) (reviewed in Rudel et 
al., 2009). Human biomonitoring studies have detected variable levels and mixtures 
of phthalates in urine samples, illustrating the level of human exposure to phthalate 
esters (Heudorf et al., 2007; Wittassek et al., 2007). The effects of these phthalates 
on human health are still unknown. However, exposure to these phthalates, in 
particular to Di (n-Butyl) Phthalate (DBP) and Di (2-EthylHexyl) Phthalate (DEHP), 
in fetal rats results in males with a TDS-like phenotype. This has led to a variety of 
phthalate studies being performed on rodents, including mixtures of phthalates, 
variable doses and timings, and has raised the question of whether phthalate effects 
might be important in human TDS. This review will focus on in utero exposure to 
DBP, as it is the phthalate treatment that has been optimised for the studies in this 
thesis. 
 
1.5.3.1 In utero DBP exposure  
Exposure of fetal male rats to DBP in utero can induce a range of reproductive 
disorders including cryptorchidism, hypospadias, impaired spermatogenesis and 
reduced fertility and so has provided a useful model to study possible mechanisms of 
human TDS (Barlow et al., 2003; Ema et al., 1998; Ema et al., 2000; Fisher et al., 
2003; Mylchreest et al., 1998; Mylchreest et al., 1999). Crucially, DBP exposure 
does not lead to TGCT in rats, although there are reported acute and long term GC 
effects (Ferrara et al., 2006). The postnatal TDS-like changes resulting from in utero 
DBP exposure are probably not due to a single mechanism but may result from 
effects on Leydig, Sertoli and/or GCs.  
 
In the testes of DBP exposed rats, fetal Leydig cells produce less testosterone and 
INSL3, effects which are probably responsible for the cryptorchidism and 
hypospadias in offspring. In addition, fetal Leydig cells become abnormally 
aggregated resulting in areas of focal dysgenesis postnatally, and postnatally can be 
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found within seminiferous cords (Fisher et al., 2003; Mahood et al., 2005). These 
areas of focal dysgenesis include Sertoli cells and are similar to dysgenetic areas 
found in the testes of human TGCT patients (Hoei-Hansen et al., 2003; Holm et al., 
2003; Skakkebaek et al., 2003).  
 
In addition to being present in focal dysgenetic areas, DBP exposed Sertoli cells are 
reduced in number by around 50% by the end of gestation, though this number 
recovers by adulthood (Hutchison et al., 2008a; Hutchison et al., 2008b; Scott et al., 
2008). DBP exposed animals often exhibit areas in their testes postnatally in which 
seminiferous cords are present that contain Sertoli cells only and these may still 
appear immature (Fisher et al., 2003; Hutchison et al., 2008a), which are again 
similar to what is seen in testes of men with TGCT (Hoei-Hansen et al., 2003; Holm 
et al., 2003; Skakkebaek et al., 2003). 
 
Whilst DBP exposure does not induce TGCT or CIS cells, there are effects on GCs. 
These include induction of abnormal multinucleated gonocytes, delayed entry into 
quiescence and reduction in GC number (Ferrara et al., 2006; Fisher et al., 2003). 
These changes combined with the Sertoli cells effects may explain the reduced sperm 
count and infertility in adulthood. These GC effects and the general similarity of 
abnormal features in DBP exposed rats to these in men with TGCT suggest that the 
effects of DBP exposure on GC development warrants further investigation.  
 
1.5.3.2 In vitro models for phthalate effects 
In order to examine the direct effects of phthalates on testis development, several 
studies have been performed on in vitro cultured testes. The advantage of such in 
vitro techniques is that it removes the maternal and fetal metabolism and 
endocrinology from interfering with investigations of chemical exposures (reviewed 
in Livera et al., 2006). In addition it provides a way to study human fetal testis 
exposure to phthalates (Hallmark et al., 2007; Lambrot et al., 2009). 
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These in vitro manipulations have mainly used DEHP and its active metabolite mono 
(2-EthylHexyl) phthalate (MEHP), with effects in the rat described on mitotically 
active gonocytes (Chauvigne et al., 2009; Li and Kim, 2003), as well as effects on 
Leydig cells but not on Sertoli cells (Chauvigne et al., 2009), as well as differing 
reports on inhibition of testosterone production (Chauvigne et al., 2009; Stroheker et 
al., 2006). Recent work using human testes showed an MEHP induced reduction in 
gonocyte numbers but not on steroidogenesis (Lambrot et al., 2009).  
 
In vitro manipulations using the active metabolite of DBP, monobutyl phthalate 
(MBP) have also been attempted using both rat (er19.5-21.5) and human fetal testis 
explants (Hallmark et al., 2007). In rat fetal testis explants, 48 hours in vitro 
treatment with MBP failed to match in vivo DBP exposure effects on Leydig 
aggregation and testosterone production (Mahood et al., 2005). MBP treatment also 
had no effect on testosterone production in the human fetal testis explants (Hallmark 
et al., 2007). 
 
In vitro manipulation of fetal rat testes at a time point after cord formation (er14.5) 
therefore has potential utility especially for studying early phthalate effects on GCs 
and can be investigated to complement in vivo DBP exposure experiments on GCs. 
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1.6 General Aims of Thesis 
There is currently no accepted animal model for TGCT/CIS and this has severely 
hampered progress in understanding how the disease arises in humans, especially as 
it is impossible to study the origin of CIS cells in the human. More generally there is 
little known about the process of fetal germ cell differentiation, how this is regulated 
and what might perturb these processes and lead to CIS. A more thorough 
understanding of these fetal events is essential if the origin of CIS cells is to be 
elucidated. In the DBP exposed rat model, testes show evidence of altered GC 
differentiation and a somatic cell environment similar to what is reported for TGCT 
and as such may provide a tool to gain some of the insight that is required.  
 
The general aim of this thesis was to obtain new insights into regulation and 
dysregulation of fetal GC development in the rat and the susceptibility of these 
processes to disruption by DBP or other factors. The first step was to characterise 
normal fetal GC development in the rat testis and ovary (Chapter 3), and then to 
investigate how these normal processes are disrupted after DBP exposure in the fetal 
rat testes (Chapter 4). As DNA methylation is one of the key development processes 
that fetal GCs undergo in fetal life, this was investigated further in relation to DBP 
exposure and DNA methylation inhibition (Chapter 5). In vitro studies using testis 
explants were also examined to see if they were useful in providing an additional tool 





2 General Materials and Methods 
2.1 Animal work 
Animal work was performed using Wistar rats and carried out in accordance with the 
UK Home Office Animal Experimentation (Scientific Procedures) Act 1986 under 
project licence 60-3259. Wistar rats, originally purchased from Harlan UK, were 
bred within our own animal facility to generate stock under the supervision of Mark 
Fisken, who provided the day-to-day animal husbandry and performed the majority 
of licensed procedures. Some licensed procedures were performed under my personal 
licence 60-10976.  
2.1.1 Welfare conditions 
Within our animal facility, animals were housed in a room with a fixed 12 hours per 
day light cycle (from 7am-7pm), with the temperature kept between 20-25C and an 
average humidity of 55%. Animals were housed in clear sided, solid bottom cages 
with food (Soy-free, SDS, Dundee, Scotland) and fresh tap water available ad 
libitum. In normal circumstances, male and female rats were housed separately, so 
that females were typically kept in groups of six and stud males housed individually. 
For mating, a single male and female were placed in a cage with a mesh grid bottom, 
so that the copulatory plug could fall to a tray below and be recorded.  
2.1.2 Timed-mating 
Due to the importance of knowing the gestational stage in the present studies, timed-
mating was used to ascertain the date of conception of pregnant rats. Organised by 
Mark Fisken, one male and female were placed together in a mesh grid bottomed 
cage at the end of the working day (approximately 4pm), as mating usually takes 
place at night. The following morning, the tray beneath the cage examined was for 
evidence of mating (the copulatory plug). Should a copulatory plug be found, mating 
was presumed to have occurred and the date was recorded and designated as 
embryonic day (e)0.5. As female rats have a 4-5 day oestrus cycle, mating may not 
occur for up to 5 days. Once a mating is assumed to have happened, the male is 
removed and the pregnant female was usually housed singly. To reduce the risk of 
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non-pregnancy, and wasted animals, whenever possible proven fertile males and 
females were used, that were sexually mature at least over 10 weeks old and usually 
around 3 months of age. 
2.2 In vivo treatments 
The chemicals administered to pregnant female rats for studies in vivo were Di (n-
Butyl) Phthalate (DBP) via oral gavage, and 5-aza-2’deoxycytidine (AZC) via 
intraperitoneal injection, given alongside their respective control vehicles. In 
addition, to label proliferating cells, some pregnant female rats and postnatal males 
were treated with 5-Bromo-2’deoxyuridine-5’-monophosphate (BrdU), via 
intraperitoneal injection 1.5 hours prior to kill. 
2.2.1 Di (n-Butyl) Phthalate (DBP) 
DBP was administered daily by oral gavage using a 10-12cm long 15-16G blunt 
ended steel gavage cannula (Medicut, Sherwood Medical Industries Ltd., UK), 
attached to a disposable plastic 1 ml syringe (B-D Plastipak), usually between 9.00-
10.30am. Pregnant dams were weighed prior to dosing to calculate the correct 
volume of chemical to be administered. Post-treatment, animals were regularly 
checked for signs of discomfort or toxicity. 
 
The dose of DBP (Sigma) used for the present studies was 500mg/kg bodyweight per 
day, as this dose has been optimised in this research group to induce a high incidence 
of TDS-like disorders. This in utero DBP500 exposure results in Leydig cell 
aggregation and multinucleated gonocytes in the fetal testes and focal dysgenetic 
areas in adulthood (Fisher et al., 2003; Mahood et al., 2005; Mylchreest et al., 1998). 
The treatment window used most commonly involved starting dosing at e13.5 until 
either birth or killing, although in some experiments other treatment windows were 
used. An early window of treatment from e13.5 to e15.5 only (EW), a middle 
window of treatment was from e15.5 to e17.5 (MW) and an extended window 
involved starting treatment at e11.5 instead of e13.5 (Ext). These treatments are 
summarised in Table 2.1. As with the previous in vivo DBP studies, DBP was diluted 
with corn oil (supermarket bought) to the 500mg/kg bodyweight dose. It was 
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assumed that DBP and corn oil had similar densities (1g/ml), so that making up a 
dose to be given at 1ml/kg bodyweight, involved adding 5ml DBP to 5ml corn oil. 
Fresh DBP/corn oil mixes were made for each study and kept in glass airtight 
containers (to prevent additional phthalate leaching from a plastic container) and kept 
at room temperature. Upon completion of a DBP study, any remaining DBP/corn oil 
was disposed of. In DBP studies, control animals received 1ml/kg bodyweight corn 
oil per day.  
 
Table 2.1 Summary of maternal DBP treatments and collection ages used in the 














e14.5, e15.5, e17.5, e19.5, 
e21.5, D4, D6, D8, D10, D15, 
D25, Adult 
500 e11.5-e20.5 Ext e21.5, D6 
500 e13.5-e15.5 EW e17.5, e19.5, e21.5, D6 
500 e15.5-e17.5 MW e17.5, e21.5 
 
2.2.2 5-aza-2’deoxycytidine (AZC) 
AZC is an analogue of the DNA nucleotide cytidine, that cannot become methylated 
and can inhibit DNA methylation by two mechanisms; either it can substitute 
cytidine during DNA replication and then that nucleotide cannot be methylated, or it 
can bind to DNA methyl transferases and directly inhibit their action (Christman, 
2002). AZC (Sigma) was administered in 2ml/kg saline (0.9% NaCl, w/v) on e16.5 
via intraperitoneal injection, with the aim that one dose of AZC towards the end of 
germ cell (GC) proliferation (Section 3.3.5) would cause AZC to become 
incorporated into the GC genome prior to Oct4 gene silencing (~e17.5), while 
minimizing the side-effects of global methylation inhibition in the developing rat 
fetus. Two doses of AZC alone were used, 5mg/kg bodyweight and 10mg/kg 
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bodyweight. The 10mg/kg dose of AZC was also combined with DBP treatment 
from e13.5 until collection, as summarised in Table 2.2. The AZC doses of 5mg/kg 
bodyweight and 10mg/kg bodyweight were chosen as having had been used 
previously in Wistar rats to inhibit methylation and produced acceptable levels of 
fetal mortality (Lu, 1998).   
 
Table 2.2 Summary of maternal AZC±DBP treatment and collection ages used in 


















5 e16.5 - - AZC5 e17.5, 
e19.5 
10 e16.5 - - AZC10 e17.5, 
e19.5 
10 e16.5 500 e13.5-e20.5 AZC+DBP e17.5, 
e19.5 
 
2.2.3 5-Bromo-2’deoxyuridine-5’-monophosphate (BrdU) 
BrdU is an analogue of the DNA nucleotide thymidine. If BrdU is present during 
DNA replication, it can substitute thymidine and become incorporated into newly 
synthesised DNA strands. The incorporation of BrdU can be detected by BrdU 
specific antibodies and allows the identification of proliferating cells. By counting 
BrdU labelled and unlabelled nuclei of identified cell types allows the proliferation 
index to be calculated, by expressing the number of proliferating cells as a 
percentage of the total number of that cell type (Section 2.8.3). 
BrdU (Sigma) was administered via intraperitoneal injection at approximately 1.5 
hours prior to kill. The BrdU dose used was 100mg/kg bodyweight in 2ml/kg saline 
(0.9% NaCl, w/v). To aid solubilisation of BrdU, the saline is first heated to boiling 
point in the microwave before the BrdU was added, the mixture was then left to cool 
to room temperature before being injected into animals. 
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2.3 Necropsy procedure 
Pregnant dams and postnatal males were killed by inhalation of carbon dioxide 
followed by cervical dislocation under Schedule 1 of the Animal (Scientific 
Procedures) Act 1986. Fetuses were then removed from pregnant dams and placed in 
ice-cold phosphate buffered saline (PBS, Section 2.13), while older fetuses (e19.5 
and e21.5) were decapitated before being placed in ice-cold PBS.  
2.3.1 Gross dissection 
In pregnant dams, after cervical dislocation the rat was placed on her back, and the 
abdomen cut open to reveal the uterine horns. The uterus was then removed, and 
each fetus removed from its amniotic sac and the umbilical cord severed. Fetal 
bodyweight and anogenital distance (at e19.5 and e21.5 ages) were then recorded and 
the fetuses stored and transported in PBS on ice to the dissection area, to avoid 
degeneration of the fetal tissue. In postnatal males, after cervical dislocation the 
bodyweight and anogenital distance were recorded, as described in Section 2.3.2, and 
a thorough examination was made for hypospadias and cryptorchidism. Postnatal 
males were then cut open to examine and weigh the testes and other internal male 
reproductive tissues. Tissues collected from postnatal males at this point were 
preserved as described in Section 2.3.5.  
2.3.2 Fetal bodyweight and testis weight 
Pups taken at e19.5 and e21.5 were wiped clean to remove excess tissue and labelled 
using permanent marker, so that the bodyweight and testis weight for each individual 
animal could be recorded. Fetuses were then weighed, using an electronic analytical 
balance (Handy H110, Sartorius), before being decapitated and placed in PBS.   
2.3.3 Fine dissection 
Testes or ovaries were removed from fetuses under a binocular dissecting 
microscope (Leica, MZ6). Illumination of tissue during dissection was provided 
using a transilluminated stage and lighting from external cold lights (Leica CLS 
150x). Fetuses collected at e14.5 were immersed in PBS during dissection, while 
older ages were placed on their backs on a moistened paper towel bed to allow stable 
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dissection. The fetal abdomen was cut open just below the umbilical cord, and the 
abdominal cavity examined to find the gonads, which were generally located 
between the kidneys and bladder, depending on the gestational age. Gonads and 
attached mesonephros or ducts were then carefully removed and placed in chilled 
PBS in a separate petri dish for microdissection. By e14.5, cord structures are visible 
in the fetal testis using the transilluminated stage, this made identification of testes at 
e14.5 and e15.5 easier. At later ages the testis is much larger than the fetal ovary and 
was located lower in the abdomen. Fetuses collected at e13.5 were fixed in Bouin’s 
for 30 minutes, discussed in Section 2.3.5, prior to fine dissection to strengthen the 
tissue so that gonads could be removed. 
2.3.4 Microdissection 
Gonads from fetuses at e13.5, e14.5 and e15.5 were collected with the mesonephros 
attached for in vitro experiments or for fixation, whilst the mesonephros was 
removed for frozen samples. In testes and ovaries from older animals, the fetal 
‘epididymis’ and efferent ducts were removed using disposable plastic 1ml syringes 
fitted with 25G needles (Monoject, sterile needles, 0.5mm x 25mm) attached as 
scalpels. 
2.3.5 Tissue preservation 
Generally, one gonad from each fetus was frozen and the other fixed using Bouin’s 
solution. The frozen gonads, trimmed of ducts/mesonephros, were placed in 
individually labelled 1.5ml Eppendorf tubes and frozen on dry ice, before being 
stored at -80C. The fixed gonads were individually fixed by immersion in Bouin’s 
solution (Section 2.13) in at least 10 times their own volume for a time dependent on 
the collection age; 30 minutes for e14.5 and e15.5, and 1 hour for older fetal ages. 
Bouin’s solution is a formaldehyde based fixative that works by forming cross-links 
between proteins and aldehydes that produces a stable structure without losing or 
damaging antigenic sites. Bouin’s is well established for preserving both embryonic 
and endocrine tissues. After a suitable fixation time, gonads were then transferred to 
70% ethanol, and weighed using an electronic analytical balance (Handy H110, 
Sartorius).  
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Testes from postnatal males were preserved in a similar manner, with some slight 
differences. Testes to be frozen were de-capsulated and macerated to allow more 
efficient freezing. The length of time testes were fixed in Bouin’s solution was 
dependent on the postnatal age at collection; 6 hours for testes from adult animals, 
and 3 hours for testes from younger animals. Generally halfway through fixation 
time, testes would be cut in half with a razorblade to aid fixation.   
2.3.6 Fixed tissue processing 
Once Bouin’s fixed tissue had been transferred to 70% ethanol, it was processed by 
the histology department of the MRC Human Reproductive Sciences Unit, 
Edinburgh. Briefly, the tissue was processed through a series of graded alcohols 
using the 18 hour automated cycle on a Leica TP-1050 (Leica UK Limited, UK) 
tissue processor, and then embedded into molten paraffin wax by hand. These wax 
blocks were then allowed to cool and then stored at room temperature prior to 
sectioning (Section 2.6.2). 
 
2.4 GC sorting from whole testis 
In an attempt to isolate GC DNA from whole testis DNA (Section 5.3.3), a protocol 
was developed to isolate GCs from the whole testis. Previously, this has been done 
successfully in the postnatal testis of mice and primates (von Schonfeldt et al., 1999). 
The chosen method for cell sorting was to use Magnetic-activated cell sorting 
(MACS), which required only two stages; making a single cell suspension from 
whole testis and then using magnetic beads and antibodies to isolate GCs from that 
cell suspension. 
2.4.1 Single cell suspension 
To develop this protocol (adapted from in-house protocols from L. O’Hara and G. 
Cowan), excess rats from postnatal day 0 (birth) were used. These animals were 
killed and their testes dissected out, as described in Sections 2.3.1-2.3.4, except filter 
sterilised PBS (FS-PBS, Section 2.13) was used to reduce bacterial contamination of 
cell sorting. Testes from 4-5 rats were decapsulated and extensively macerated in 
4.5ml of FS-PBS to break up the tissue using disposable plastic 1 ml syringes fitted 
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with 25G needles (Monoject, sterile needles, 0.5mm x 25mm). 500μl of 1mg/ml 
collagenase (Roche) was then added to the testes to help break cellular adhesion. The 
resulting 5ml solution was transferred into a flat-bottomed glass tube, and incubated 
at 32C in a shaking waterbath for 15 minutes. 200μl of 1mg/ml DNase (Roche) was 
then added to the suspension, which was returned to the waterbath for a further 15 
minutes. The resulting cellular solution was transferred to a 15ml Falcon tube and 
centrifuged for 5 minutes at 3000 rpm, and the supernatant was replaced with 1ml 
FS-PBS and the pellet resuspended. This washing of the pellet was repeated twice 
more. The cellular pellet was then resuspended in 500μl trypsin (0.5mg/ml trypsin in 
0.2mg/ml EDTA, Roche), 4.5mls FS-PBS and 200μl DNase, and incubated at 32C 
in a shaking waterbath for 5 minutes, to further break down cellular adhesion. The 
cell mixture was then dispersed using a 1ml pipette and filtered through a 70μm 
mesh filter (Millipore), to remove any remaining clumps of tissue. This cell mixture 
was then centrifuged for 5 minutes at 3000 rpm and washed in FS-PBS, twice more, 
before being finally resuspended in 1ml FS-PBS+0.1%BSA+10% normal sheep 
serum. At this point the cell suspension was counted using a haemocytometer 
(usually ~5 million cells/ml were present) and examined to make sure it consisted of 
single cells. Cells were left to rest/recover at 32C in a lightly shaking waterbath for 
1 hour prior to cell sorting.    
2.4.2 Magnetic bead preparation 
Whilst the single cell suspension was resting, the sheep anti-mouse antibody 
conjugated magnetic Dynabeads (Invitrogen) were prepared for cell sorting. 
Dynabeads were mixed within their container and 30μl was removed into an 
autoclaved 1.5ml Eppendorf tube. This tube was placed in a magnetic rack for two 
minutes, so that Dynabeads would separate from the storage solution, which was 
then removed. The beads were then removed from the magnet and resuspended in 
1ml FS-PBS, before being returned to the magnet for a further two minutes to wash 
the beads. This wash was repeated again, until finally the beads were resuspended in 
30μl FS-PBS. This prepared approximately 10 million Dynabeads for MACS, a 
slight excess beyond the target 4 beads per GC.  
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2.4.3 Magnetic-activated cell sorting (MACS) 
From the 1ml single cell suspension, 500μl was removed and stored at -80C as the 
Unsorted (US) fraction. The remaining 500μl solution was incubated with 2μg anti-
SSEA1 antibody (Abcam, ab16285) for 1 hour at 4C. Anti-SSEA1 proved to be the 
most efficient for MACS, though other GC surface antigens were attempted (e.g. 
cKIT, CD9, CD44). A GC surface antigen had to be used as whole, unlysed cells 
were present in the solution. After incubation with the antibody, the cell solution was 
washed by gently centrifuging at 1000rpm for 10 minutes and discarding the 
supernatant, before resuspending in 500μl FS-PBS. This wash was repeated twice 
more to remove any unbound antibody, leaving only the antibody bound to the GCs. 
30μl of the prepared Dynabeads were then added to the cell solution, which was 
incubated for 30 minutes at 4C on a gentle rocker, to allow the anti-mouse 
Dynabeads to mix throughout the solution and bind to the antibody labelled GCs. 
The cell solution was then placed in a magnetic rack for 2 minutes to separate the 
Dynabeads (and attached cells) from the cell solution. The cell solution was then 
removed and stored at -80C as the Unbound (UB) fraction. The Dynabeads were 
then removed from the magnetic rack and resuspended in FS-PBS and stored at -
80C as the Bound (B) fraction. These cell fractions were then used for RNA 
analysis (Section 2.11). 
 
2.5 In vitro culture 
2.5.1 Testis explant preparation for in vitro culture  
Testes with attached mesonephros were dissected out of e14.5 aged fetuses from 
untreated dams, as described in Section 2.3.3. Care was taken to remove testes and 
mesonephros without damage to ensure more successful in vitro culture. These testis 
explants were then cultured for between 48-72 hours with either no treatment or 
treatments designed to disrupt fetal testis development. The culture media and 
equipment used for these testis explants were optimised in this laboratory by Nina 
Hallmark (Hallmark et al., 2007).   
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2.5.2 Tissue culture conditions 
Once testis explants were isolated from fetuses, experiments were performed in a 
sterile class 2 microbiological safety cabinet (BioMAT-2, MAT, Lancashire, UK), 
using standard aseptic techniques. Culture media was prepared as detailed below: 
Stock Media:   500ml DMEM/F12 (Gibco Invitrogen Ltd.) 
   5ml Penicillin/Streptomycin (Sigma) 
   2.5ml Amphotericin (Sigma) 
 
Culture Media: 48.5ml Stock Media (above) 
   1ml Sodium Pyruvate (Sigma) 
   0.5ml ITS liquid media supplement (Sigma) 
   1.5mg Bovine serum albumin (Sigma) 
 
Once culture experiments were prepared, they were kept humidified and incubated 
using a HERACell 150 CO2 incubator, for 48-72 hours in 95% air, 5% CO2 and 37C 
conditions (the temperature of in situ fetal testes).  
2.5.3 Culture contamination 
Testis explant in vitro cultures were at risk of contamination from a variety of 
microorganisms during dissection and culture preparation, so in addition to aseptic 
techniques being used wherever possible, anti-microbial agents were added to the 
media. The anti-microbials used were Penicillin/Streptomycin (Sigma; antibiotics) 
and Amphotericin (Sigma; antifungal), these were chosen as having been routinely 
used in cultures in-house and had not shown any adverse affects on cultured tissues. 
2.5.4 Culture set up 
Culture well inserts (Millicell 0.4 µm, Millipore, UK) were placed in 24 well culture 
plates (Corning, NY), 400µl of culture media (pre-warmed to 37C) was then added 
to each well, 200µl within the insert and 200µl outside the insert. Testis explants 
were then placed onto the porous membranes of the culture well insert, with a 
maximum of 4 explants per insert. If testis explants were to be treated, chemical 
treatments would then be added to the culture well, in volumes/concentrations 
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described in Section 2.5.2, with half the volume within the insert and the other half 
outside the insert.  
Every 24 hours, 200µl of culture media (and treatment) in the insert was replaced 
with fresh pre-warmed culture media (and treatment). 45 minutes to 1 hour prior to 
the end of the culture period,  200µl of culture media was removed and replaced with 
pre-warmed culture media containing an excess of BrdU (approximately 10µg/ml), 
and in vitro cultures were then returned to the incubator. At the end of the culture 
period, testis explants were carefully removed from inserts and either fixed in 
Bouin’s for 30 minutes or snap frozen on dry ice, before being archived at -80C. 
After 30 minutes of Bouin’s fixation, testis explants were transferred to 70% ethanol 
and were processed into paraffin wax blocks, as described in Section 2.3.6.  
2.5.5 Culture treatments 
If testis explants were treated in vitro, the concentrations of treatment compounds in 
the culture media that were used are summarized in Table 2.3. For monobutyl 
phthalate and cyclopamine treatment, solvents were necessary and equivalent 
volumes of these were added to the media of the corresponding controls. These doses 
had previously been optimised within the laboratory.  
 






Vol in 400 μl 
culture media 
MBP TCI, Europe DMSO 1 x 10-3M 10μl 
DMSO Sigma - - 
10μl 
Cyclopamine 
In-house gift from 
Dr Axel Thomson 
Ethanol 25µM 
8μl 
Ethanol VWR International - - 8μl 
2.5.5.1 Monobutyl phthalate (MBP) 
MBP is the active metabolite of DBP, and has been used on both human and rat fetal 
testis explants to examine the effects of phthalate treatment directly (Hallmark et al., 
2007). In that study, MBP treatment in vitro on e19.5 aged rat testis explants failed to 
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match observations in vivo of DBP exposure on Leydig cells and steroidogenesis. 
The present studies were more focussed on GC development and it was hoped that 
use of earlier aged testis explants treated with MBP would match in vivo effects. A 
high dose of 10-3M MBP was used to maximise potential treatment effects. MBP was 
dissolved in dimethyl sulfoxide (DMSO, Sigma) as a solvent, so that an equivalent 
volume of DMSO was used as a control treatment.   
2.5.5.2 Cyclopamine (Cyc) 
Cyc is a steroidal alkaloid that inhibits the Hedgehog signalling pathway. Briefly, 
Hedgehog ligand inhibits the PTCH1 receptor, which removes the repression of 
SMO, which then stimulates transcription factors to induce the expression of certain 
genes. Cyc inhibits Hedgehog signalling by binding and blocking the SMO protein 
and so prevents the Hedgehog signal being transduced. In the mouse testis, DHH is 
thought to be produced by the Sertoli cell and acts through the PTCH1 receptor on 
the Leydig cell surface and other interstitial cells (Bitgood et al., 1996). In Dhh 
knock-out mice, fetal Leydig cells fail to differentiate and postnatally adult Leydig 
cells are lacking (Clark et al., 2000; Yao et al., 2002). In vitro mouse gonad organ 
culture using Cyc has showed that blocking DHH signalling in early testis 
development prevented Leydig cell differentiation (Yao et al., 2002). 
Cyc was used in these experiments to investigate a chemical treatment that has many 
effects in vivo beyond the testis which limits utility in in vivo testis investigations, 
and one that could disrupt signalling between Sertoli cells and Leydig cells. Cyc 
treatment in vitro was performed at 25μM concentration with ethanol (EtOH) as a 












2.6 Protein investigations 
2.6.1 Immunohistochemical (IHC) analysis 
The major method to investigate protein expression in this thesis was through the use 
of specific antibodies on individual sections of Bouin’s fixed tissue, in order to 
visualize both the localization and level of protein expression.  The basic system 
used to perform this antibody detection is described below: 
 Tissue sections were dewaxed and re-hydrated 
 Antigen retrieval, if required for specific primary antibody 
 Blocking of non-specific antigens and detection enzymes 
 Primary antibody incubation  
 Primary antibody detection using an amplification system 
 Primary antibody visualization using colour reaction 
 Counterstaining of non-stained tissue 
During each IHC analysis, control slides were generated by incubating slides with 
normal serum instead of primary antibody to ensure IHC staining was succesful.  
2.6.2 Sectioning 
Tissue collected and fixed (Section 2.3.5) was embedded in wax blocks (Section 
2.3.6) for sectioning. Wax blocks were chilled on ice for 30 minutes prior to 
sectioning; to harden the wax and aid cutting.  Using a hand operated microtome 
(RM 2135, Leica), 5m thick sections were then cut and floated onto warm (45-
50C) water. This enabled smooth unwrinkled wax sections to be placed on slides. If 
needed, sections were floated on 30% industrial methylated spirit (IMS, Fischer 
Scientific) prior to the water. Charged glass slides (SuperFrost Plus, Menzel GmbH 
& Co.) that were pre-labelled with animal codes and ages (automated slide labeller, 
Leica IP S) were used to ensure that tissue data was recorded on each slide. Once 
wax sections were placed on the individual slide, they were allowed to dry overnight 
in a metal rack in a 50C oven. 
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2.6.3 Dewaxing and re-hydration 
Slides were initially dewaxed by submerging them in Xylene for 5 minutes (twice), 
before being re-hydrated by being passed through a series of alcohols. These alcohols 
were: absolute alcohol (twice), 95% alcohol, 80% alcohol and finally 70% alcohol, 
spending 20 seconds in each. After 70% alcohol, slides were rinsed in tap water, 
prior to either antigen retrieval or blocking. 
2.6.4 Antigen retrieval 
In most cases, to allow antibody recognition in fixed tissue, antigen retrieval was 
performed. This is necessary as fixation with Bouin’s, a formaldehyde based fixative, 
causes protein cross-links that can hide antigenic sites from antibody detection. 
Antigen retrieval breaks these cross-links, revealing the antigen sites (Shi et al., 
1993). If antigen retrieval was required, dewaxed and re-hydrated slides were 
immersed in 2L of boiling citrate retrieval buffer, (0.01M citrate buffer, pH 6.0, 
Section 2.13), within a Tefal Clipso pressure cooker. The pressure cooker was then 
sealed and pressure set to the highest setting. Slides were pressure cooked for 5 
minutes at maximum pressure, as evidenced by a continuous jet of steam from the 
cooker lid. Then the pressure was released and the entire pressure cooker removed 
from the heat. Slides and buffer were left to cool for 15-20 minutes, then additional 
tap water was added to cool slides to room temperature, before being blocked.  
2.6.5 Blocking 
After dewaxing, re-hydration and optional antigen retrieval, slides were incubated in 
3% (vol/vol) hydrogen peroxide (VWR) in methanol for 30 minutes to block any 
endogenous peroxidase activity within the tissue; this prevents any non-specific 
background staining. Slides were then rinsed for 5 minutes in tap water followed by 
two 5 minute washes in Tris buffered saline (TBS, Section 2.13). Once the 
methanol/hydrogen peroxide was washed off, serum blocking was performed. Using 
an ImmEdge pen (Vector Laboratories, Inc. Burlingame, CA), a circle was drawn 
around the tissue section on each slide. This produced a hydrophobic barrier that 
ensured maximum coverage of sections with reagents, as well as aiding visualization 
of smaller sections.  
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Serum blocking was performed using normal serum (Diagnostics Scotland) diluted 
1:5 in TBS with 5% bovine serum albumin (BSA, Sigma), this was done to block any  
non-specific binding sites and so reduce background staining. The serum used for 
blocking was dependent on the species the secondary antibody was raised in, such 
that rabbit serum would be used for blocking if a rabbit raised anti-mouse secondary 
antibody was used for detection.  
2.6.6 Primary antibodies 
After 30 minutes of blocking, serum was replaced with the primary antibody/serum 
solution for the IHC detection. Primary antibodies were diluted in normal 
serum/TBS/BSA, as described in Table 2.4 and then incubated overnight at 4C in a 
humidity chamber.  
Table 2.4 Details of primary antibodies used, and dilution used in single IHC. 
Antibody Source Retrieval Species Dilution 
AMH  Santa Cruz, CA No Goat 1:1000 
BrdU Fitzgerald industries, 
MA 
Yes Sheep 1:1000 
cKIT Santa Cruz, CA Yes Rabbit 1:50 
CYP11A Chemicon No Rabbit 1:300 
DAZL AbD Serotec Yes Mouse 1:300 
DMRT1 
Gift from David 
Zarkower, MN 
Yes Rabbit 1:2000 
DNMT1 Abcam, Cambridge Yes Rabbit 1:50 
DNMT3A Abcam, Cambridge Yes Rabbit 1:250 
DNMT3L Abcam, Cambridge Yes Rabbit 1:100 
OCT4 Santa Cruz, CA Yes Goat 1:100 
PTCH1 Abcam, Cambridge Yes Rabbit 1:250 
PTCH1 Santa Cruz, CA Yes Goat 1:200 
SMA Novocastra No Mouse 1:1000 
SOX9 Santa Cruz Yes Goat 1:1000 
VASA Abcam, Cambridge Yes Rabbit 1:200 
3β HSD Gift from Ian Mason, 
Edinburgh 
No Rabbit 1:2000 
5MeC 
 





2.6.6.1 5-methyl cytidine (5MeC) 
IHC staining for 5MeC required a slightly altered protocol to allow the methylated 
cytidine residues to be detected by the antibody. Slides for 5MeC staining were 
dewaxed, rehydrated and blocked in methanol/hydrogen peroxide as normal. Then 
slides underwent a digest using 1mg/ml pepsin (Sigma) solution with 3% acetic acid 
(vol/vol) (BDH), for 15 minutes at 37C using a water bath. After the pepsin digest, 
slides were incubated in 2M hydrochloric acid (VWR) for 20 minutes at 37C. Slides 
were then serum blocked and the protocol continued as described in Section 2.6.7. 
2.6.7 Secondary antibodies  
After incubation overnight with the primary antibody at 4C, the primary antibody 
was removed and the slides underwent two 5 minute washes in TBS to remove any 
of the unbound primary antibody from the slide. A biotinylated secondary antibody 
to the species the primary antibody was raised in, was diluted in the same type of 
serum used in the serum blocking step, as described in Table 2.5. The 
antibody/serum mix was then added to the slides, which were incubated at room 
temperature for 30 minutes. After this incubation time, the antibody/serum mix was 
removed from the slides which then underwent two 5 minute washes in TBS.  
Table 2.5 Details of secondary antibodies and dilutions used for both single and 
double IHC. 
Secondary Antibody Source Dilution 
Rabbit anti-mouse biotinylated DAKO, Cambridge 1:500 
Rabbit anti-sheep biotinylated Vector Labs, CA 1:500 
Rabbit anti-goat biotinylated Vector Labs, CA 1:500 
Swine anti-rabbit biotinylated DAKO, Cambridge 1:500 
Goat anti rabbit biotinylated Vector Labs, CA 1:500 
To amplify the biotinylated secondary antibody signal, a streptavidin-horseradish 
peroxide (HRP) enzyme conjugate was used, where the streptavidin binds to the 
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biotin on the antibody and the HRP causes detection. Streptavidin-HRP was prepared 
by adding 1l solution (Vector Labs) to 1ml TBS (1:1000 dilution). The final step in 
antibody detection was to expose the slides to a chromogenic substrate (DAB) 
(Section 2.6.9) that undergoes a colour change reaction in the region where the 
primary antibody had bound. 
2.6.8 Double IHC 
In order to perform GC proliferation index analysis (Section 2.8.3), and to calculate 
the percentage of GCs expressing OCT4 or DMRT1 (Section 2.8.4), or simply to 
examine two proteins in the same section, double IHC was performed requiring two 
different detection systems. To perform double IHC, primary antibody 
concentrations were adjusted, as described in Table 2.6. 
Table 2.6 Details of primary antibodies used, and dilution used in double IHC. 
Antibody Source Retrieval Species Dilution 
AMH  Santa Cruz, CA No Goat 1:500 
BrdU Fitzgerald industries, 
MA 
Yes Sheep 1:500 
DAZL AbD Serotec Yes Mouse 1:100 
DMRT1 
Gift from David 
Zarkower, MN 
Yes Rabbit 1:1000 
OCT4 Santa Cruz, CA Yes Goat 1:50 
SMA Novocastra No Mouse 1:500 
VASA Abcam, Cambridge Yes Rabbit 1:200 
To perform double IHC, after chromogen detection of streptavidin-HRP the slides 
were not counterstained and mounted (Sections 2.6.10-2.6.11) but underwent two 
further 5 minute washes in TBS. After these washes, slides underwent a second 
serum blocking step as described (Section 2.6.5) for 30 minutes, before incubation 
overnight at 4C with the second primary antibody to be used. 
After overnight incubation with the second primary antibody, slides underwent two 5 
minute washes in TBS before being incubated for 30 minutes with a second 
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antibody/serum mix, in the same manner as for single IHC. After another two 5 
minute washes in TBS, slides were exposed to a different detection method, avidin 
conjugated alkaline phosphatase enzyme (DAKO). Avidin-alkaline phosphatase was 
diluted 1l in 200l TBS and incubated on the slides for 30 minutes at room 
temperature. Following two further 5 minute washes in TBS, slides were exposed to 
the Fast Blue chromogenic detection system (Section 2.6.9), such that brown DAB 
staining would visualize the first antibody and blue/purple Fast Blue staining would 
visualize the second antibody on the same tissue section.  
2.6.9 Chromogen detection  
Chromogen detection using either 3,3 DiAminoBenzidine (DAB) or Fast Blue was 
used to visualise the location within a tissue section at which the primary antibody 
had bound to its specific protein.  
DAB was diluted from its concentrated form using a kit from DAKO, just prior to 
use. Upon application to slides, HRP action on DAB causes brown staining of tissue 
within 30 seconds to 5 minutes, depending on the primary antibody. After colour 
development, DAB was removed and the slides were washed in tap water for 5 
minutes to prevent further development.  
Fast Blue was made just prior to use by adding 1mg Fast Blue salt (Sigma), stored at 
-20C to 1ml Fast Blue buffer (Section 2.13), stored at 4C. This solution was then 
thoroughly mixed and filtered through a 0.2m filter before being applied to the 
slides. Upon application to the slide, alkaline phosphatase action on Fast Blue 
solution causes blue/purple staining in tissue after around 20-30 minutes of 
development, which required the slides were kept in the dark. After colour 
development, Fast Blue solution was removed and slides were washed in PBS 
(Section 2.13) to prevent further development. If Fast Blue staining was performed, 
slides were not dehydrated or counterstained with haematoxylin, as Fast Blue is 
soluble in alcohol and staining would be lost. Instead, after washing in PBS, slides 
were mounted using glass coverslips (VWR International) and Permafluor aqueous 
mounting fluid (Beckham Coulter).  
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2.6.10 Counterstaining 
Slides were counterstained using haematoxylin (Section 2.13) for 5 minutes, to 
ensure saturation of binding sites. Excess haematoxylin was then rinsed off by 
submerging slides in tap water, before being transferred to 1% acid alcohol (Section 
2.13) for 10-20 seconds, to remove any non-specific background staining. Acid 
alcohol was then rinsed off by tap water and slides then transferred to Scott’s tap 
water (Section 2.13), an alkaline solution, for 20 seconds. In this alkaline 
environment, haematoxylin staining of nuclei turned blue. Scott’s tap water was then 
rinsed off by transferring slides to tap water again. 
2.6.11 Dehydration and mounting 
After counterstaining with haematoxylin, slides were dehydrated by passing them 
through a series of increasing concentrations of alcohol for 20 seconds at a time, 
going from 70% to absolute alcohol. Slides were then cleared by two 5 minute 
washes in Xylene, before being mounted using glass coverslips (VWR International) 
and Pertex mounting medium (Cell Path, Hemel Hampstead, UK), a solvent based 
glue. Once slides were mounted, the sections could be imaged (Section 2.6.13) and 
analysed (Section 2.8).  
2.6.12 Terminal deoxynucleotidyl transferase dUTP nick end labelling 
(TUNEL) 
In the last phase of apoptosis there is massive DNA fragmentation, which the 
TUNEL assay detects by labelling the terminal ends of nucleic acids (Negoescu et 
al., 1998). By using IHC to detect the labelled DNA strands, it is possible to visualize 
apoptotic cells in a tissue section. The TUNEL assay required a modified IHC 
protocol. Slides for TUNEL IHC were dewaxed, rehydrated and blocked in methanol 
as normal (Sections 2.6.3-2.6.5), but after methanol blocking slides underwent two 5 
minute washes in PBS (Section 2.13). At this point slides were placed on ice and 
exposed to the TUNEL reaction solution of 1μl TdT (Roche), 5μl Dig-11-dUTP 
(Roche) in 1ml TUNEL reaction buffer (Section 2.13). Temporary coverslips 
(GelBond Film) were then placed on slides to prevent dehydration whilst slides were 
incubated at 37C for 30 minutes to allow the TUNEL reaction to occur. After 30 
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minutes, slides underwent two 5 minute washes in PBS, before serum blocking 
(using normal rabbit serum (NRS)/BSA/PBS) for 10 minutes at room temp. Slides 
were then incubated with anti-Dig primary antibody (raised in Sheep, from Roche) 
diluted 1:100 in NRS/BSA/PBS, for 90 minutes at room temperature. After primary 
antibody incubation, slides underwent two 5 minute washes in PBS, before 
incubation with the secondary antibody, rabbit anti-sheep biotinylated, diluted in 
NRS/BSA/PBS as described in Table 2.5). From this point, IHC detection continued 
as described for DAB staining in Sections 2.6.7-2.6.9.       
2.6.13 Imaging 
Images were taken of mounted slides stained with IHC by using a Provis microscope 
(Olympus Optical AX70, London, UK) fitted with a DCS330 digital camera 
(Eastman Kodak, NY). Images were then edited using PhotoshopCS2 9.0 (Adobe 
Systems Inc, CA).  
 
2.7 Immunofluorescent IHC 
In order to investigate colocalization of GC proteins DAZL and VASA, and early 
testis proteins SOX9 and DMRT1 in Chapter 3, immunofluorescent IHC detection 
was used in a similar manner to standard IHC. Slides to be examined by 
immunofluorescence were prepared as described (Sections 2.6.3-2.6.5) until the 
serum blocking stage, where normal serums were diluted in 1:5 in PBS instead of 
TBS, and all washes in TBS washes were replaced with PBS. 
2.7.1 First primary antibodies 
After serum blocking, slides were incubated overnight at 4C with the primary 
antibodies for either VASA diluted in swine serum/PBS (1:200), or DMRT1 diluted 
in swine serum/PBS (1:1000). After incubation overnight with the primary antibody, 
slides underwent two 5 minute washes in PBS to remove any of the unbound primary 
antibody from the slide. A swine anti-rabbit biotinylated secondary antibody was 
diluted in the swine serum/PBS 1:500. This secondary antibody/serum mix was then 
added to the slides, which were then incubated at room temperature for 30 minutes. 
After this incubation time, the antibody/serum mix was removed from the slides and 
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they underwent two 5 minute washes in PBS. From this point onwards, slides were 
kept in the dark to prevent bleaching of fluorescent signal.  
2.7.2 Detection of first primary antibody 
After PBS washes, slides were incubated with streptavidin conjugated to a fluorescent 
label that emits signal at a wavelength of 546 nm (Molecular Probes, Leiden, 
Netherlands), diluted 1:200 in PBS, for 60 minutes. Slides then had two 5 minute 
washes in PBS, before blocking in rabbit serum/PBS for 30 minutes.  
2.7.3 Second primary antibodies 
After the second serum blocking step, slides were incubated overnight with the 
second primary antibody, either DAZL diluted in rabbit serum/PBS (1:100), or SOX9 
diluted in rabbit serum/PBS (1:500). After overnight incubation, slides were washed 
twice in PBS for 5 minutes, before being incubated for 30 minutes at room 
temperature with either a rabbit anti-goat HRP conjugated antibody (to detect SOX9) 
diluted 1:500 in rabbit serum/PBS, or rabbit anti-mouse HRP conjugated antibody (to 
detect DAZL) diluted 1:500 in rabbit serum/PBS. Slides then underwent two 5 minute 
washes in PBS.  
2.7.4 Detection of second primary antibody 
To detect the HRP conjugated secondary antibody, the tyramide signal amplification 
system (TSA, Perkin Elmer) was used, where the HRP catalyzes the deposition and 
binding of a labelled tyramide adjacent to the location of the HRP conjugated 
secondary antibody.  Slides were incubated for 10 minutes with Tyramide-Cy5 
diluted 1:50 with the supplied buffer. This resulted in VASA or DMRT fluorescing 
green, and DAZL or SOX9 fluorescing red. To remove any excess background 
tyramide staining, slides underwent two final 5 minute washes in PBS.  
2.7.5 Counterstaining and imaging 
To counterstain the immunofluorscent slides, the nuclear stain 4',6-diamidino-2-
phenylindole (DAPI; Sigma) was used. Slides were incubated with DAPI diluted 
1:1000 in PBS for 10 minutes, before being mounted using Permafluor (Section 
2.6.8). These mounted slides were stored at 4C in the dark to prevent loss of 
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fluorescence. Images were captured using an LSM 510 Meta Confocal microscope 
(Carl Zeiss).  
2.8 Image analysis 
To quantify GC number in a testis and to calculate the GC proliferation index and the 
percentage of GCs expressing either OCT4 or DMRT1, specialised stereological 
image analysis of IHC stained slides was performed. These investigations were 
achieved using a microscope fitted with a camera and motorised stage (Prior 
Scientific Instruments Ltd., Cambridge, UK), and ImagePro 6.2 computer software 
(Media Cybernetics, Wokingham, Berkshire, UK). 
2.8.1 Calculation of GC number per testis 
Sections of testis were IHC stained for either DAZL or VASA protein to label GC 
cytoplasm and then used to calculate GC number per testis using standard 
stereological techniques. This was of particular interest in relation to determining 
how in utero DBP exposure may be reducing GC number.  IHC stained sections were 
examined under oil immersion using a Zeiss ×63 EC Plan objective fitted to a Zeiss 
Imager A1 microscope. The number of fields that were counted depended on the size 
of the testis section, but was usually between 30-60 random fields to ensure a 
percentage standard counting error below 5%. Fields were counted by recording 
points falling over GC nuclei, which was then expressed as a percentage of the total 
points counted, giving the percentage nuclear volume occupancy. This measurement 
of percentage nuclear volume was converted to absolute nuclear volume (of GCs) per 
testis by multiplying by testis weight, determined at collection (Section 2.3.2), or 
derived for testes collected at e14.5, e15.5 and e17.5 (Section 2.8.2). The testis 
weight (mg) is assumed to be equivalent to total testis volume (mm3), as shrinkage 
was assumed to be minimal and the specific gravity of tissue is close to 1. 
Absolute volume (mm3) = (% volume occupancy/100) x testis weight (mg) 
GC absolute nuclear volume per testis can be converted into the GC number per 
testis, if mean nuclear volume of GC is calculated. The same IHC stained slides were 
again examined under oil immersion using a Zeiss ×63 EC Plan objective, and using 
the Stereology tool of ImagePro 6.2 (Media Cybernetics, Wokingham, Berkshire, 
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UK) the centre of a GC nucleus was selected, and then three lines from this centre 
were used to generate three diameter measurements (m). From these diameter 
measurements the nuclear volume was calculated by the software, which assumed 
nuclei were spherical. As GC nuclei were broadly spherical, this was a good estimate 
of GC nuclear volume. At least 90 GC nuclei per testis section were measured in this 
manner, and the mean nuclear volume was then calculated. The number of GCs was 
then calculated by dividing the GC absolute volume by the mean GC nuclear 
volume:   
Number of cells =      Absolute volume (mm3)          x1000 (to account for mg to m3) 
     (millions)           mean nuclear volume (m3) 
In this way, GC number of the whole testis was calculated from a single testis 
section. It should be noted that the Sertoli cell counts performed by H. Scott and S. 
Auharek, discussed in Section 4.3.1, were generated using the same method except 
using staining for WT-1 to identify Sertoli cells. 
2.8.2 Calculating volume/weights of fetal testes 
Testes taken from pups younger than e19.5 were too small to be weighed accurately 
using the electronic analytical balance (Handy H110, Sartorius). Therefore, in order 
to generate an approximate testis weight to compare control and DBP exposure for 
GC number, two different methods were used. 
2.8.2.1 Calculating volume/weights of e17.5 testes 
The weights of e17.5 testes used in this thesis were calculated by H. Scott during her 
thesis studies using the following method based upon Cavalieri’s Principle. Briefly, 
an average weight/volume for control and DBP exposed testes was calculated by 
using three control and three DBP exposed testes that were each serially sectioned 
(Section 2.6.2). Then the first section, every fifth section and the final section were 
stained with haematoxylin to visualize the section. Each serial section was then 
measured for area, using Image-Pro Plus 4.5.1 software (Media Cybernetics, 
Wokingham, Berkshire, UK) at x10 magnification. As illustrated in Fig 2.1, the areas 
of adjacent sections (Section A and B,) were averaged and then multiplied by the 
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distance between them (Distance C), to give the volume. This was calculated for all 
serial sections to get an overall volume (m3), equal to weight (mg).   
 
Figure 2.1 Representation of how testis volume at e17.5 was calculated. Taken from 
(Scott, 2007).    
2.8.2.2 Calculating volume/weights of e14.5 and e15.5 testes 
The H. Scott method for calculating testis weight was deemed unsuitable for testes 
taken from pups at e14.5 and e15.5, as serial sectioning is not as efficient at younger 
ages with smaller testes and haematoxylin staining of every fifth slide was viewed as 
too wasteful for the limited sections available from these ages. Instead, to calculate 
an average weight/volume for control and DBP exposed testes, three control and 
three DBP exposed litters at each age were used. During collection (prior to 
processing), images were taken of dissected testes from each male of these litters 
using Leica FireCam. These images were then analysed using ImagePro 6.2, to 
measure the dimensions of the each testes in each litter, as shown in Fig 2.2.  
 
Figure 2.2 Photograph illustrating how e14.5 and e15.5 testes were measured to 
calculate testis weight. 
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At e14.5 and e15.5, the testis is broadly cylindrical so that the equation for 
calculating the volume of a cylinder was used to calculate testis volume (m3), equal 
to weight (mg). With testis width as an approximation of cylinder diameter.     
Volume of a cylinder (m3) =      π x radius2 (m2) x length (m) 
 
In this way, average testis weight at e14.5 and e15.5 was calculated and used to 
generate GC number data (Section 2.8.1) for these ages.   
2.8.3 GC proliferation index 
The proliferation index was calculated as the percentage of GCs that were positively 
stained for the proliferation marker BrdU (Section 2.2.3). This was calculated by 
double IHC staining for both a cytoplasmic GC marker (VASA or DAZL) and BrdU, 
before image analysis using a microscope with camera and motorised stage (Prior 
Scientific Instruments Ltd., Cambridge, UK), and ImagePro 6.2 computer software 
(Media Cybernetics, Wokingham, Berkshire, UK) as above. Between 30-60 random 
fields were counted, depending on the size of the testis, to generate a percentage 
standard error below 5% for counting. In each field, the number of BrdU-positive 
and BrdU-negative GCs were counted. From this data the GC proliferation index was 
calculated as follows: 
GC Proliferation Index = Number GCs expressing BrdU      x100 
                 Total number GCs 
 
 
2.8.4 Percentage of OCT4 or DMRT1 expressing GCs 
To calculate the percentage of OCT4 expressing GCs at e17.5 in Section 4.3.1.3, or 
DMRT1 expressing GCs at e19.5 in Section 4.3.1.6, a similar method was used for 
determining the proliferation index, except using OCT4 or DMRT1 expression 
instead of BrdU.  
2.8.5 GC position at postnatal day 6 
At postnatal day 6, the position of GCs within the seminiferous cords was 
investigated as discussed in Section 4.3.3.4. By using double IHC for SMA to 
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identify the PTMCs and the GC marker VASA (Section 2.6.8), GC position was 
classed as centrally located, if no GC cytoplasm was touching the basal lamina, or 
basally located, if the whole GC was located at the basal lamina, or some of the 
cytoplasm was touching the basal lamina. This position was then calculated as a 
percentage, in a similar manner to the proliferation index (Section 2.8.3). 
 
2.9 Western immunoblotting 
Western immunoblotting was attempted during the course of these thesis studies, but 
failed to be an efficient use of animal material and few antibodies worked 
sufficiently well, therefore no Western blots are presented in the results Chapters. In 
brief, protein was extracted from frozen testis tissue by homogenization in RIPA 
buffer and then quantified using the Biorad assay (Bio-Rad, California, US). From 
this quantification, the sample volume needed to contain 10g protein was 
determined which would then be loaded into sample wells after NuPAGE 
(Invitrogen, California, US) preparation. Samples were be loaded into a 10% 
NuPAGE Bis-Tris gel (Invitrogen), and fitted loaded into a gel tank containing 1x 
NuPAGE MOPS SDS running buffer (Invitrogen). The gel was run at 200V for 50 
minutes, before being removed and transferred to a nitrocellulose Immobilon FP 
membrane (Millipore). After transferring, the membrane was washed and blocked to 
prevent non-specific protein binding using Odyssey blocking buffer (Li-Cor 
Biosciences, Cambridge, UK). The membrane would then be incubated with the 
primary antibody of interest and a loading control. These antibodies would be 
detected by fluorescently labelled secondary antibodies that were visualized using 
the Li-Cor Odyssey system and software (Li-Cor Biosciences). 
 
2.10 DNA investigations 
To investigate the methylation status of the Oct4 gene in the fetal testis (Section 
5.3.3), a series of DNA investigations were undertaken. This involved extraction of 
DNA from whole testes, quantification of the DNA extracted followed by bisulphite 
treatment of the DNA, before a standard PCR amplification of three regions of the 
Oct4 promoter. These three regions were then sequenced and analysed.    
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2.10.1 DNA extraction  
DNA was extracted from frozen whole testes from e19.5 and pooled (3-4) whole 
testes from e15.5 using a QIAamp DNA Micro extraction kit (Qiagen, Crawley, 
UK), utilising the manufacturer’s solutions and the protocol for isolation of genomic 
DNA from tissue. Briefly, 180μl ATL buffer was added to frozen testes in 1.5ml 
tubes, and equilibrated to room temperature before 20μl Proteinase K was added and 
the mixture pulse vortexed. Samples were incubated overnight at 56C to ensure 
complete lysis. After incubation, 200μl AL buffer was added and the solution pulse 
vortexed. Then 200μl of 96-100% EtOH was added and the tube thoroughly vortexed 
again. The entire solution was then transferred to a QIAamp MinElute column, and 
centrifuged for 1 minute at 8,000 rpm. The column was moved to a fresh 2ml 
collection tube, and 500μl of AW1 buffer was used to wash the column by 
centrifuging for 1 minute at 8,000 rpm. The column was again moved to a fresh 2ml 
collection tube, and 500μl of AW2 buffer was used to wash the column by 
centrifuging for 1 minute at 8000 rpm. The column was then transferred to another 
fresh 2ml collection tube and centrifuged for 3 minutes at full speed (14000 rpm) to 
dry the membrane. DNA was eluted from the column by adding 20μl nuclease free 
water, and then incubated for 2 minutes at room temperature, before centrifugation 
for 1 minute at full speed to collect the extracted DNA solution. DNA concentrations 
were measured using the Nanodrop spectrophotometer (Section 2.10.2). DNA was 
stored at -20C before use.  
2.10.2 DNA quantification 
To quantify the extracted DNA, the Nanodrop-1000 spectrophotometer (Nanodrop 
Technologies, Delaware, USA) was used. 1.5l sample was pipetted directly onto the 
measurement pedestal and the amount of 260nM UV light absorbed by the sample 
was measured and the Beer-Lambert law was used to calculate the concentration of 
the light absorbing molecule (DNA or RNA). To examine the purity of the sample, 
the Nanodrop also measured the amount of 280nM UV light absorbed, as this was 
absorbed by impurities such as proteins, salts and solvents. By using the ratio of 
260nM:280nM, the purity of the DNA sample can be ascertained and values between 
1.9-2.1 were acceptable for further use.  
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2.10.3 Bisulphite treatment of DNA 
Bisulphite treatment of testis DNA was performed using the EZ DNA Methylation-
Gold kit (Zymo Research Corp.). Bisulphite treatment causes the conversion of 
unmethylated cytidine to uracil, whilst methylated cytidine residues are unaltered. 
This converts methylation status into changes in the DNA sequence that can be 
identified by subsequent sequencing. The protocol and reagents used were provided 
by Zymo Research Corp. Briefly, 200ng DNA extracted and quantified as in Sections 
2.10.1-2.10.2, was added to 130μl CT Conversion Reagent in a 0.2ml PCR tube. 
Samples were placed in a thermal-cycler for 10 minutes at 98C, and then incubated 
for 2.5 hours at 64C, before storage at 4C. Samples were loaded into a Zymo-Spin 
IC column, containing 600μl M-Binding buffer and the resulting solution mixed by 
gentle inverting. The column was then centrifuged for 30 seconds at full speed 
(14,000 rpm). The column was then washed by adding 100μl M-Wash buffer and 
centrifuged for 30 seconds at full speed. Then 200μl M-Desulphonation buffer was 
incubated in the column at room temperature for 15 minutes. After incubation, the 
column was centrifuged for 30 seconds at full speed, followed by two washes using 
200μl M-Wash buffer and centrifugation for 30 seconds at full speed. Finally, 10μl 
M-Elution buffer was directly added to the column matrix, and the column was 
added to a 1.5ml collection tube, and centrifuged briefly at full speed to elute the 
converted DNA. DNA was stored at -20C before use.       
2.10.4 PCR amplification of converted DNA 
Bisulphite converted DNA was amplified for three regions of the rat Oct4 gene 
promoter and proximal enhancer that contained several possibly methylated CpG 
dinucleotides. These regions were chosen based on the importance of methylation of 
the promoter and proximal enhancer regions in silencing of Oct4 gene in both mice 
and human (Deb-Rinker et al., 2005; Freberg et al., 2007; Hattori et al., 2004). The 
primers were designed using MethPrimer 
(http://www.urogene.org/methprimer/index1.html), based on the Primer3 system that 
takes into account the conversion of cytidine residues by bisulphite treatment. The 
details of the primers used to amplify the three regions are shown in Table 2.7. 
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Table 2.7 Details of primers used to amplify bisulphite converted whole testis DNA. 
Region of 
Oct4 gene 
Forward Primer  
5’  3’ 
Reverse Primer 



















The DNA was amplified using the Platinum PCR SuperMix (Invitrogen), using 45μl 
Platinum PCR SuperMix, 2μl forward primer (200nM), 2μl reverse primer (200nM) 
and 1μl of converted DNA, so that the final PCR reaction was 50μl. This solution 
was mixed together in 0.2ml sterile thin walled PCR tubes (VWR International) and 
placed in a thermo-cycler with the following cycle times: 
94C for 2 minutes 
Then 35 cycles of  94C for 30 seconds 
55C for 30 seconds 
72C for 1 minute 
 
The amplified DNA product was then stored at 4C prior to purification using the 
QIAquant PCR purification kit (Qiagen, Crawley, UK) and ran on a standard 1% 
agarose gel to check the success of the amplification.  
2.10.5 Sequencing of converted DNA 
Purified PCR product and PCR region primers were sent to the MRC Human 
Genetics Unit, Edinburgh for sequencing to be performed. The resulting sequence 
data was analysed using Vector NTI Version 10 software (Invitrogen), and the 
methylation status of CpG dinucleotides recorded.  
 
2.11 RNA investigations 
To investigate the relative mRNA expression levels of genes in the fetal rat testis, 
both during normal development and after DBP exposure, Q-RT-PCR was performed 
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using the Taqman system. This involved extraction of RNA from whole testes, 
quantification of the RNA extracted, followed by conversion to cDNA, before the Q-
RT-PCR reaction and analysis.     
2.11.1 RNA extraction  
RNA was extracted from frozen whole testes using the RNeasy Micro kit (Qiagen, 
Crawley, UK), using the manufacturer’s solutions and the protocol for purification of 
total RNA from animal tissue. Briefly, 350l RLT lysis buffer was added to frozen 
testes that were then homogenized using a hand homogenizer (Kontes Pellet Pestle) 
on ice. After homogenization 350l EtOH was added, and the lysate was then 
transferred into RNeasy mini columns and centrifuged for 15 seconds at 10,000 rpm. 
The flow through was then reloaded onto the column to maximise yield, before being 
centrifuged again for 15 seconds at 10,000 rpm. The resulting flow through was then 
discarded. The columns were then washed to remove impurities by adding 350μl 
RW1 buffer and centrifuged for 15 seconds at 10,000 rpm. On column DNase 
digestion was performed by incubating DNase (10μl DNase 1 stock and 70μl RDD 
buffer) for 15 minutes at room temperature. After incubation, 350μl RW1 buffer was 
added and the column was centrifuged for 15 seconds at 10,000 rpm. The column 
was then transferred to a new collection tube and 500l RPE buffer was added before 
the column was centrifuged for 15 seconds at 10,000 rpm. 500l 80% EtOH was 
then added to the column, which was centrifuged for 2 minutes at 10,000 rpm. The 
column was then transferred to a fresh collection tube and spun for 2 minutes at full 
speed to allow the membrane to dry. The RNA was then eluted by adding 20l 
RNase-free water directly onto the membrane and then incubating at room 
temperature, followed by centrifugation for 1 minute at 10,000 rpm to collect the 
RNA. RNA concentrations were measured using the Nanodrop spectrophotometer, as 
described in Section 2.10.2 for RNA instead of DNA, and then stored at -80C.  
2.11.2 Preparation of cDNA for Taqman analysis 
Due to the limited amount of RNA extracted from fetal tissues (~100ng/μl), the 
VILO cDNA synthesis kit (Invitrogen) was used to maximise the number of cDNA 
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preparations that could be made. This reaction system converted total RNA, 
including ribosomal RNA, as in the Taqman assay 18S (ribosomal RNA) is used as 
the internal positive control. Each cDNA synthesis 20μl reaction mixture was 
performed in 0.2ml sterile thin walled PCR tubes (VWR International), set up as 
follows:  
5x VILO reaction Mix   4l 
10x Superscript Enzyme Mix  0.25l 
RNA (100ng/l)   1l 
Nuclease free H2O    14.75l 
The reagents were mixed together and placed in a thermo-cycler with the following 
cycle times: 
25C for 10 minutes 
42C for 60 minutes 
85C for 5 minutes 
2.11.3 Quantitative RT-PCR 
To asses the relative levels of RNA expression, Q-RT-PCR was carried out using the 
Taqman system devised by Applied Biosystems, using primers and probes designed 
using the Universal Probe library system (Roche). The principle of the Taqman 
system is that a probe was assigned for each reaction, so that it anneals to the cDNA 
between the forward and reverse primers of the gene of interest. Each probe consists 
of a reporter dye at the 5’ end, 6-carboxyfluorescein (FAM), and a quencher dye at 
the 3’end, 6-carboxy-tetramethyl-rhodamine (TAMRA). The proximity of the 
quencher suppresses the fluorescence of the reporter. So whilst the probe is intact, no 
fluorescence occurs. During the Taqman amplification, the probe becomes cleaved 
through the action of the Taq polymerases moving in a 5’ to 3’ direction, this 
releases FAM dye and the fluorescent activity is recorded. This is repeated for every 
cycle, so that fluorescent activity increases every time the probe is cleaved, which is 
proportional to the amount of PCR product created. With each cycle the fluorescent 
activity is measured quantitatively by the sequence detection system. 
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2.11.4 Primer Design 
Primers were designed for each gene of interest using the free Universal 
ProbeLibrary assay design centre at http://www.roche-applied-
science.com/sis/rtpcr/upl/ezhome.html. For each gene of interest, this enabled design 
of the primer sequences and provided the number of the probe compatible from the 
Universal ProbeLibrary (Roche). The primers were then purchased from MWG 
Biotech, London, UK, which were then diluted to 20M with nuclease free water. 
Table 2.8 summarizes the primer sequences and Universal Probe Library probes used 
in these present studies. 
Table 2.8 Taqman primer sequences and Universal ProbeLibrary probe number. 
Gene  
Forward Primer  
5’  3’ 
Reverse Primer 















Dmnt1 CGATGACGATGAAAAGGACA GTCTCCGTTTGGTGGCTAGA 26 
Dmnt3A AACGGAAGCGGGATGAGT TGCAATCACCTTGGCTTTCT 75 


















2.11.5 Q-RT-PCR reaction 
Samples to be analysed using the Taqman system were run in triplicate on a 96 well 
MicroAmp optical reaction plate (Applied Biosystems). For each sample, a tube 
containing the following was prepared, totalling 45μl:  
2x Express Supermix    22.5l 
Forward primer (20M)   0.45l 
Reverse primer (20M)   0.45l 
Universal Probe (10M)   0.45l 
18s (primers 1.33M, probe 5.3M)  0.3375l 
cDNA (Section 2.11.2)   4.5l 
Nuclease free H2O    16.3125l 
 
Each Taqman reaction mixture was vortexed and then divided into three wells, with 
15l in each. When each sample was loaded, the entire plate was sealed with a 
MicroAmp optical adhesive cover (Applied Biosystems) and then loaded onto the 
ABI 7900 sequence detection system. 
2.11.6 Analysis of results – comparative Ct method 
The Taqman RT-PCR system provided the results as an amplification plot, which 
showed the amount of reporter dye/fluorescence generated during amplification and 
that is proportional to the amount of PCR product formed. The FAM Ct value was 
the cycle number at which the fluorescence rises above the threshold level, 
representing when the amount of amplified DNA becomes significant above the 
background level. This threshold level was determined at a point during the 
exponential increase of the PCR product. The FAM Ct value was dependent on the 
original amount of target mRNA in the reaction mixture, such that a difference in Ct 
value by one compared to a reference sample equated to a two-fold difference in 
RNA in the initial reaction mixture. 18S ribosomal RNA was used as an internal 
control, to adjust for mRNA variation between samples. 
By analysing the differences in FAM Ct value compared to a reference control 
(usually adult rat testis or ovary), relative changes in RNA expression of the target 
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gene were calculated using the comparative Ct method. This required the calculation 
of the Ct value, which was the difference between the FAM Ct and the 18S Ct 
value for each of the three 15μl reaction wells for each sample. From these 
triplicates, the mean Ct for that sample was calculated. Using the mean Ct, the 
Ct was then calculated, which was the difference between the mean Ct of each 
sample compared to the mean Ct of the reference sample. In most cases, the 
reference sample was either adult rat testis total RNA or adult rat ovary total RNA, 
purchased from Applied Biosystems. However for some analyses, where the gene 
could not be detected in adult RNA, a fetal sample collected and processed in-house 
was used as the reference sample.  
The amount of amplified target was calculated as 2-Ct, which was based on the 
mathematical equation for the exponential amplification of the PCR reaction Xn = X0 
 (1+Ex)n, where Xn is the number of target molecules at the threshold at cycle n, X0 
is the initial number of target molecules, (1+Ex) is the efficiency of the target 
amplification and n is the number of cycles. If the efficiencies of the target and 
internal control reactions are equal, the 2-Ct value provided a measure of relative 
quantification, showing the fold increase or decrease in mRNA expression in 
samples, in relation to the reference sample, which always has a 2-Ct value of one. 
2.11.7 Primer validation 
Use of the Universal Probe Library assay design centre to design primers ensures that 
primers meet the necessary criteria for Taqman assay use. However if further 
validation was required for use with the comparative CT method, a five-fold series of 
diluted cDNA (made from rat testis total RNA) was run in triplicate whilst 
maintaining the concentrations of the other reagents. From the triplicate of each 
sample, the mean Ct was calculated. This value should be the same for each 
concentration, reflecting the dilution of both gene of interest and 18S (internal 
control). Plotting of mean Ct against log transformed initial cDNA concentrations 




2.12 Statistical analysis 
Values are expressed as means ±SEM, and data were analysed using Student’s 
unpaired t test, comparing between ages, between testis and ovary or between control 
and treated, using GraphPad Prism (version 5, GraphPad software Inc., San Diego, 
CA). In Figures 3.7 and 4.18, analysis of variance was performed using ANOVA 
followed by Bonferroni’s multiple comparison test between each set of results using 
GraphPad Prism (version 5, GraphPad software Inc., San Diego, CA). Asterisks were 
used to denote any statistically significant differences, using the following criteria: * 
P<0.05, ** P<0.01 and *** P<0.001. 
 
2.13 Commonly used solutions 
Acid alcohol:   70% EtOH  
1% concentrated HCl 
Bouin’s solution: Purchased from Triangle Biomedical Sciences Ltd, 
Lancashire, UK. 
Citrate buffer:   42.02g Citric acid monohydrate; Sigma) 
    1.9L distilled H2O 
    Make up to 2L and pH to 6, using concentrated NaOH 
    Use at 0.01M, diluting 1:10 in distilled H2O 
Harris’s Haematoxylin: 2.5g Haematoxylin + 25ml absolute alcohol 
50g aluminium potassium sulphate + 500ml distilled H2O  
Combine solutions and boil 
Add 1.25g mercury oxide  
Cool solution on ice then filter  
Add 4ml glacial acetic acid/100ml Haematoxylin 
Fast blue buffer:  12.1g Tris (VWR International) 
    950ml distilled H2O 
    Make up to 1L and pH to 8.2 using concentrated HCl  
    Take 98ml of this solution and add 
    20mg Napthol AS-MX phosphate  
    2ml Dimethyl formamide  
PBS:     1 tablet of PBS concentrate (Medicago, Sweden) 
    1L distilled H2O 
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Scott’s Tap water:   10g Potassium chloride  
100g Magnesium sulphate  
Dissolved in 5L tap water 
TBS:    60.5g Tris (Sigma)  
    87.6g NaCl (Sigma) 
    300ml Hydrochloric acid (BDH) 300ml 
    Adjust to pH 7.4 using concentrated HCl 
TUNEL buffer:   6ml of 0.5M Tris/HCl pH7.2  
100ml distilled H2O 
2.99g Na Cacodylate 
0.195g CoCl 
Store at 4C 
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3 Germ cell development during the last week of fetal life 
in the rat 
 
3.1 Introduction 
Studies of germ cells (GC) and gonad formation in the mouse, as reviewed in Section 
1.3, have identified the series of events that GCs undergo during embryogenesis. In 
summary, specification as primordial GCs occurs around em7.25 (Ginsburg et al., 
1990), long before the gonads are formed at em11 (Capel, 2000), GCs then migrate 
through the hindgut and arrive at the gonad around em11 (Molyneaux et al., 2001). 
As GCs migrate, they undergo several rounds of proliferation and express genes 
associated with pluripotency, which continues in the early gonad. Depending on the 
somatic environment of the gonad, GCs will begin differentiation into a gonocyte in 
the testis or an oocyte in an ovary. Proliferation stops as GCs either become arrested 
in mitosis or meiosis between em12.5 and em13.5, and enter a quiescent state until 
postnatal resumption of gametogenesis (McLaren, 2003). During this same time 
period, GCs undergo global demethylation and begin the epigenetic reprogramming 
required in postnatal life. Each of these varied processes can become dysregulated 
which would be expected to have serious postnatal consequences. In the human 
testis, such dysregulation of fetal GC function is suggested to alter GCs 
differentiation and result in the carcinoma in situ (CIS) cell, the pre-malignant 
precursor to testicular germ cell tumours (TGCT). 
 
To investigate the processes of early GC proliferation and differentiation in the rat 
and their susceptibility to disruption with the aim of giving insights that might be 
relevant to CIS, a thorough investigation into GC development in the fetal rat gonad 
was undertaken. Using the processes identified from mouse studies, the timings and 
specifics of fetal GC development in the gonad were described in detail for both the 
testis and ovary in the rat. As dysregulated GC differentiation is thought to be the 
major factor in CIS origin, a particular focus on GC differentiation formed the basis 
of these investigations.  
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3.2 Materials and Methods 
3.2.1 Animals 
Briefly, control animals were collected at e13.5, e14.5, e15.5, e17.5, e19.5 and e21.5 
and gonads dissected out (Section 2.3-2.3.4). Gonads were either fixed in Bouin’s 
and processed for immunohistochemical analysis, or stored at -80C for RNA 
analysis.   
3.2.2 Immunohistochemical (IHC) analysis 
Briefly, IHC staining (Section 2.6) was performed on processed and sectioned fetal 
testes and ovaries as summarised in Table 3.1. The number of fetal testes and ovaries 
used for IHC was a minimum of 5 testes or ovaries in each age group and came from 
a minimum of three different litters. 
 
Table 3.1 Details of antibodies used in Chapter 3. 
Antibody Source Retrieval Species 
AMH  Santa Cruz, CA No Goat 
BrdU Fitzgerald industries, 
MA 
Yes Sheep 
DAZL AbD Serotec Yes Mouse 
DMRT1 
Gift from David 
Zarkower, MN 
Yes Rabbit 
OCT4 Santa Cruz, CA Yes Goat 
SOX9 Santa Cruz Yes Goat 
VASA Abcam, Cambridge Yes Rabbit 
 
 
Additional IHC analyses were performed to calculate the GC number in fetal testes 
(Sections 2.8.1-2.8.2.2) and GC proliferation index (Section 2.8.3).   
3.2.3 Immunofluorescent IHC 
Briefly, immunofluorescent IHC staining (Section 2.7) was performed on processed 
and sectioned testes for colocalization of GC proteins DAZL and VASA, and for 
early testis proteins SOX9 and DMRT1. Images were taken using a LSM 510 Meta 
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Confocal microscope and settings were maintained between sections examined to 
produce comparable images (Section 2.7.5). The number of testes used for 
immunofluorescent IHC was a minimum of 5 testes in each age group and came 
from a minimum of three different litters. 
3.2.4 RNA analysis 
Briefly, RNA isolated from frozen testes or ovaries was converted into cDNA 
(Section 2.11.2) and Taqman quantitative RT-PCR performed (Section 2.11.5), to 
establish quantitative mRNA expression levels. The genes investigated, and primers 
used, are listed in Table 3.2. 




3.3.1 Primordial germ cell migration 
In the fetal rat, the earliest age that gonads could be visually identified and 
successfully removed during micro-dissection was embryonic day (e)13.5. At this 
age, there were no gross morphological differences between the sexes. To identify if 
sexual differentiation had initiated by e13.5, immunohistochemical (IHC) staining 
for SOX9 was performed as it is upregulated in pre-Sertoli cells and is a primary 
event in testis formation. It was used to establish the sex of the e13.5 gonad (Fig 
3.1A and B). To determine if GC migration into the gonad had occurred by e13.5, 
Gene  
Forward Primer  
5’  3’ 
Reverse Primer 























double IHC staining for the pluripotency factor OCT4 and the GC specific marker 
DAZL was performed (Fig 3.1C and D). 
 
 
Figure 3.1 Panels A and B show representative photomicrographs of 
immunostaining for SOX9 in e13.5 fetal rat gonads (Dab = brown). Panels C and D 
show representative photomicrographs of DAZL (Fast blue = blue) and OCT4 (Dab 
= brown) in the same e13.5 fetal rat gonads as shown in A and B. White arrow 
depicts an isolated SOX9 cell in a presumptive ovary. In Panels A and B, G=gonad 
and M=mesonephros. Black arrow depicts isolated mesonephric GC. Insert in panel 
B shows a negative control for SOX9. Scale bar in panel A represents 100µm. 
 
 
By e13.5, GC migration into the gonad is nearly completed in the fetal rat, with only 
isolated single GCs remaining in the mesonephros (Fig 3.1D) and by e14.5 GCs were 
only detected in the gonad (data not shown).  
 
Expression of the GC protein VASA was also investigated at e13.5 and was barely 
detectable by IHC (data not shown). Similarly, the Sertoli cell protein Anti Müllerian 
Hormone (AMH) was also undetectable by IHC at e13.5, identifying this time point 
as around the time of sexual differentiation in the fetal rat. Due to the difficulty in 
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obtaining tissue from fetuses younger than e13.5 and the observation that GC 
migration into the gonad is more or less completed by e13.5, younger ages were not 
investigated.  
3.3.2 Sexual differentiation and seminiferous cord formation 
By e14.5, in contrast to e13.5, there was a clear sexual dimorphism of the gonads. 
This was evident during microdissection as an increased gonad size and conspicuous 
cord formation which gave the testes a “striped” appearance in contrast to ovaries. 
To examine this further, IHC for AMH was performed on e14.5 fetal rat testis 
sections and showed that AMH was detectable at this age, as the Sertoli cells become 
organised around GCs into seminiferous cords, as shown in Fig 3.2. Fetal rat ovaries 
showed no AMH staining in fetal life, as demonstrated by the insert in Fig 3.2B. 
 
Figure 3.2 Representative photomicrographs of immunostaining for AMH in e14.5 
fetal rat testis in panel A and, e15.5 fetal rat testis in panel B (Dab = brown). Panels 
C and D show representative photomicrographs of VASA (Fast blue = blue) and 
OCT4 (Dab = brown) in the e14.5 fetal rat testis (C) and e15.5 fetal rat testis (D). 
Insert in panel B shows negative staining for AMH in the e15.5 fetal rat ovary. Scale 
bar in panel C represents 50µm. 
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3.3.3 Germ cell distribution and protein expression 
In the e14.5 fetal rat testes, the GC specific markers OCT4, VASA and DAZL were 
expressed (Fig 3.2 and data not shown) in the all GCs. In the fetal rat ovary at e14.5, 
similar GC protein expression was seen (data not shown). Between the ages of e14.5 
and e15.5, the arrangement of GCs in the early seminiferous cords changed from a 
more ‘single cell’ distribution (Fig 3.2C) to central aggregation (Fig 3.2D). GC 
aggregations remain in the fetal rat testis until e21.5, and will be discussed in greater 
detail in Section 4.3.1.8. For the clarity of figures in the rest of this chapter, e14.5 
gonads show the same GC protein expression patterns as e15.5 gonads unless 
otherwise stated. 
3.3.4 Germ cell increase in the developing gonad  
Having examined the early events of GC migration and seminiferous cord formation 
in the fetal rat, GC number in the developing gonad was investigated using IHC 
staining for VASA or DAZL to label GCs for counting, as shown in Figs 3.3 and 3.4. 
Due to the small size of the rat ovary throughout fetal life, reliable measurements of 
ovarian weight could not be obtained. As gonad weights are crucial for the 
determination of GC number (Section 2.8.1), GC counts were only performed on 
fetal testes, shown in Fig 3.3. The overall change in GC number in the developing 
gonad is illustrated in Fig 3.4, contrasting the difference between rat testes and 
ovaries.  
























Figure 3.3 Number of germ cells in testes of animals between e14.5 and e21.5 (n=8 
for e17.5, n=5 for others). Values are means ± SEM. Student’s unpaired t test was 




Figure 3.4 Representative photomicrographs of immunostaining for VASA (Dab = 
brown) in fetal testis (left) and ovary (right) from e15.5 (top) through to e21.5 
(bottom). Scale bar in panel A represents 100µm. 
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Fig 3.3 shows how the number of GCs increased in the fetal rat testis over time, with 
a significant increase between e14.5 and e15.5, and again between e19.5 and e21.5. 
This increase in GC number was visualised (Fig 3.4), by VASA IHC and also 
illustrates the morphological changes that occur in the last week of fetal life in the 
rat. The fetal testis becomes much larger, especially in comparison to the ovary after 
e15.5. This increase in testis size has been studied with respect to the contribution of 
increasing number of the different somatic cell types of the testis (as quantified in 
(Hutchison et al., 2008; Scott et al., 2008) for Wistar rats that were kept, collected 
and analysed in the same manner as this thesis. In addition, Fig 3.4 shows that VASA 
IHC staining of GCs remained relatively constant during e15.5-21.5, in comparison 
to both OCT4 (Fig 3.6) and DAZL (Fig 3.9). 
3.3.5 Germ cell proliferation index  
To further examine the increase in GC number, GC proliferation was examined in 
the fetal rat gonads by performing double IHC staining for Bromo deoxyuridine 
(BrdU) and DAZL. As described in Section 2.2.3, BrdU labels proliferating cells in 
the developing fetus and when combined with the GC marker DAZL allowed 
proliferating and non-proliferating GCs to be identified and the determination of the 

























Figure 3.5 Germ cell proliferation index of fetal rat testes (blue bars) and ovaries 
(pink). n=5 for each age and sex, except for e15.5 ovary where n=6. Student’s 
unpaired t test was performed, *** P<0.001 between testis and ovary. 
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GC proliferation was high in both the ovary and testis at e15.5, but at e17.5 GC 
proliferation in the testis had dropped to near zero whereas it remained high in the 
ovary. In both testis and ovary, no proliferating GCs were observed after e19.5, 
showing a difference in timing of cessation of GC proliferation (entry into 
quiescence) between testis and ovary.  
 
However as described in Fig 3.3, GC number continued to increase after e17.5 when 
proliferation was completed. This is most likely due to differential errors in 
determining testis weights/volumes (Section 2.8.2) at the different fetal ages. This 
will be discussed in greater detail in Section 4.3.1, with respect to DBP exposure. 
 
3.3.6 OCT4 expression in the developing gonad 
As discussed in Sections 1.3.3, the pluripotency gene Octamer-binding transcription 
factor 3/4 (Oct4) is an early PGC marker in the mouse that is lost as GCs 
differentiate. To examine Oct4 expression in the fetal rat, double IHC for OCT4 and 
VASA was performed (Fig 3.6).  
 
Previously in this Chapter, IHC staining of OCT4 was shown to be present in GCs of 
both sexes at e13.5 (Fig 3.1C and D) and e14.5 (Fig 3.2) and remained in all GCs at 
e15.5 but declined thereafter. By e17.5 there was a mix of OCT4+ and OCT4- GCs 
(Fig 3.6C and D) and by e19.5, OCT4 expression was undetectable in all GCs, 
indicating loss of pluripotency (Fig 3.6E and F and data not shown for e21.5). In the 
e17.5 fetal rat ovary, there was relatively fewer OCT4+ GCs compared to the testis, 




Figure 3.6 Representative photomicrographs of immunostaining for OCT4 (Dab = 
brown) and VASA (Fast blue = blue) in fetal testis (left) and ovary (right) from e15.5 
(top) to e19.5 (bottom). White arrow depicts an OCT4 positive, VASA positive 
ovarian GC. Scale bar in panel A represents 50µm. 
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To complement IHC analysis of OCT4, Oct4 mRNA levels were quantified over the 
same time period using Taqman (Section 2.11) for the testis (Fig 3.7) and ovary (Fig 
3.8). As different control values were used to generate the following graphs, care 
should be taken when comparing these two figures. It should also be noted that 
whole testes or ovary were used for RNA extraction, not isolated cell types. 
  







































Figure 3.7 Quantitative analysis of Oct4 mRNA levels in fetal rat testis at e15.5, 
e17.5, e19.5 and e21.5, (n=6 for each age). Values are means  SEM. ANOVA 
followed by Bonferroni’s multiple comparison test was performed. a= *** P<0.001 
between e15.5 and e19.5, b= *** P<0.001 between e15.5 and e21.5, c= ** P<0.01 
between e17.5 and e19.5 and d= ** P<0.01 between e17.5 and e21.5.  
 
In the fetal rat testis, relative Oct4 expression decreased over time, reducing 
significantly between e15.5-e17.5 and e19.5-e21.5 (Fig 3.6). Interestingly, Oct4 
mRNA was still detectable in e19.5 and e21.5 testes when OCT4 was no longer 
detectable by IHC. This may indicate that transcriptional mechanisms do not regulate 
OCT4 protein levels alone in the rat testis. In this Taqman assay, Oct4 mRNA was 
also detectable in adult rat control testes in which OCT4+ cells are also undetectable 
by IHC (adult RNA purchased from Applied Biosciences, data not shown).     
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Figure 3.8 Quantitative analysis of Oct4 mRNA levels in fetal rat ovary at e15.5, 
e17.5, e19.5 and e21.5, (n=6 for e15.5 and e17.5, n=5 for e19.5 and n=3 for e21.5). 
Values are means  SEM. Student’s unpaired t test performed on log transformed 
values, *** P<0.001 between e15.5 and e17.5.  
 
In the fetal rat ovary, Oct4 mRNA reduced between e15.5 and e17.5 and became 
undetectable at and beyond e19.5 in this assay, closely mirroring the OCT4 IHC 
results in Fig 3.6. In addition Oct4 mRNA was not detected in the adult rat ovary 
(purchased from Applied Biosciences). Whilst it is important not to over-analyse, 
this sex-specific difference in Oct4 expression profile over time may indicate both 
that different Oct4 gene regulation occurs between the sexes in the rat.  
 
3.3.7 DAZL expression in the developing gonad 
Deleted in Azoospermia Like (Dazl) is a GC-specific gene, which is important in 
both male and female fertility, described in more detail in Sections 1.3.5-1.3.6. IHC 
analysis of DAZL during the last week of fetal life in the fetal rat gonad was 




Figure 3.9 Representative photomicrographs of immunostaining for DAZL (Dab = 
brown) in fetal testis (left) and ovary (right) from e15.5 (top) through to e21.5 
(bottom). Scale bar in panel A represents 50µm. 
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DAZL staining was intense in GCs at e15.5 and e17.5 but became weaker (but still 
detectable) at e19.5 and e21.5 for both ovary and testis. A similar reduction in DAZL 
in GCs has not been previously reported in other species, so this may be a rat-
specific change. Attempts to quantify this reduction level of DAZL protein by 
Western blot proved unsuccessful, meaning that this potentially interesting aspect of 
DAZL expression cannot be confirmed.  
 
Dazl gene expression was also examined using mRNA analyses by Taqman in the 
testis (Fig 3.10) and ovary (Fig 3.11). As with all Taqman analyses in this Chapter, 
whole gonads were used to extract RNA and different controls (adult gonads) were 
used for ovarian and testicular samples. 




































Figure 3.10 Quantitative analysis of Dazl mRNA levels in fetal rat testis at e15.5, 
e17.5, e19.5 and e21.5, (n=6 for each age). Values are means  SEM. No 
statistically significant differences.  



































Figure 3.11 Quantitative analysis of Dazl mRNA levels in fetal rat ovary at e15.5, 
e17.5, e19.5 and e21.5, (n=6 for e15.5 and e19.5, n=5 for e17.5 and e21.5). Values 
are means  SEM. No statistical significant differences. 
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Relative Dazl mRNA expression for both fetal testis and ovary shared a similar 
profile, with a slight increase between e15.5-e17.5 and then a decrease from e19.5 
onwards, which supports the DAZL IHC results. Of note is that relative Dazl 
expression in the fetal rat ovary (Fig 3.11) is much higher than in the adult rat ovary 
(reference control), especially in comparison to the fetal versus adult testis 
comparison (Fig 3.10).  
3.3.8 VASA expression in the developing gonad 
Mouse Vasa Homologue (Vasa) is a GC-specific gene that is necessary for postnatal 
spermatogenesis. IHC analysis of VASA in the fetal rat gonad showed that it is 
barely detectable at e13.5 (data not shown), but from e14.5 until adulthood it 
remained a GC-marker that was not lost during differentiation (e.g. OCT4) and did 
not show variable expression over time (e.g. DAZL), as illustrated earlier in Fig 3.4. 
This makes it an important GC-specific gene to analyse as a relative “constant” in 
relation to these other genes, especially in regard to relative mRNA expression 
studies. Vasa mRNA expression was examined in the fetal testis (Fig 3.12 A and B) 
and ovary (Fig 3.13). Further analysis at each age to adjust for GC content of whole 
testis was performed by dividing by estimated GC number (Fig 3.3) and testis weight 
(Section 2.8.2) to determine how individual GC Vasa mRNA expression changed 
over time, and are shown in Fig 3.12B. 







































Figure 3.12 A: Quantitative analysis of Vasa mRNA levels in fetal rat testis at e15.5, 
e17.5, e19.5 and e21.5, (n=6 for each age). Values are means  SEM. Student’s 
unpaired t test was performed, * P<0.05 between e17.5 and e19.5.  
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Figure 3.12 B: Quantitative analysis of Vasa mRNA levels in fetal rat testis at e15.5, 
e17.5, e19.5 and e21.5, (n=6 for each age) adjusted for GC number and testis 
weight. Values are means  SEM. Student’s unpaired t test was performed, * P<0.05 
between e17.5 and e19.5.  




































Figure 3.13 Quantitative analysis of Vasa mRNA levels in fetal rat ovary at e15.5, 
e17.5, e19.5 and e21.5, (n=6 for e17.5 and e21.5, n=5 for e15.5 and n=4 for e19.5). 
Values are means  SEM. No statistically significant differences. 
 
Relative Vasa mRNA levels in both sexes shared a similar pattern to Dazl, with an 
insignificant increase at e17.5 followed by a reduction afterwards. Adjusting for GC 
number supported the reduction of Vasa mRNA per GC from e15.5 to e21.5. 
3.3.9 DAZL and VASA co-expression in the testis 
To identify if DAZL and VASA stain different sub-populations of GCs in the fetal 
testis with IHC, co-localization immunofluorescent IHC for DAZL and VASA 
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protein was performed (Section 2.7) and visualized by confocal microscropy (Fig 
3.14).  
 
Figure 3.14 Representative confocal photomicrographs of immunostaining for VASA 
(green) and DAZL (red) in fetal rat testis at e15.5 (A and B), e17.5 (C and D), e19.5 
(E and F) and e21.5 (G and H). Panels on the left side show individual staining for 




Throughout the last week of fetal life in the testis DAZL and VASA protein co-
localized, even both exhibiting the slightly punctate expression at e19.5 and e21.5. 
As with DAZL IHC analysis alone (Fig 3.9), there was a reduction in DAZL protein 
visualized at e19.5 and e21.5 compared to the younger ages. Whilst it is possible this 
observation could be a result of differences in acquisition during the confocal 
imaging, the maintenance of settings between slides and ages make this unlikely.  
 
DAZL and VASA co-localization was also examined during postnatal testis 
development, as shown in Fig 3.15. In early postnatal testis development, DAZL and 
VASA protein continued to co-localize. However in the adult rat, defined as over 3 
months old in these studies, a difference in DAZL and VASA localization can be 
seen as DAZL expression is only expressed in spermatogonia and spermatocytes at 
the base of the tubule, and is lost as GCs proceed into spermatogenesis. 
 
From these co-localization studies, DAZL and VASA can be used as interchangeable 


















Figure 3.15 Representative confocal photomicrographs of immunostaining for VASA 
(green), DAZL (red) and DAPI (blue) in rat testis at postnatal day(D) 6 (A and B), 
D10 (C and D), D15 (E and F) and adulthood (G and H). Panels on the left side 
show individual staining for VASA and DAZL, and the panel on the right shows the 
merged image to highlight co-localization and DAPI (blue) nuclei staining. Note 
DAPI staining has been turned off in the two lefthand panels. 
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3.3.10 DMRT1 expression in the developing gonad 
Doublesex- and mab-3 related transcription factor 1 (Dmrt1), a gene that is important 
in postnatal testis differentiation. As described in Section 1.2.2.2, Dmrt1 is expressed 
in both Sertoli and GCs of the fetal mouse testis and remains expressed in the testis 
into adulthood (Raymond et al., 2000). In contrast in the fetal mouse ovary Dmrt1 
expression was absent after em15.5 and undetectable in the adult mouse ovary 
(Raymond et al., 1999a). This suggests an importance for Dmrt1 in both fetal GC 
development and in the postnatal testis. In the fetal rat gonads, DMRT1 expression 
was examined by IHC during the last week of fetal life in both testes in ovary as 
shown in Fig 3.16.   
 
In the fetal rat ovary, DMRT1 expression was GC-specific at e15.5-e17.5 but became 
undetectable after e19.5. In the fetal rat testis, a more complex pattern of DMRT1 
protein expression was evident, with both Sertoli and GCs staining strongly until 
e19.5, when DMRT1 expression was switched off in GCs, similar to the ovary (Fig 
3.16 E and F). These findings agree with the mouse studies, in which it has been 
shown that expression in Sertoli cells and in GCs may be driven by different 





Figure 3.16 Representative photomicrographs of immunostaining for DMRT1 (Dab = 
brown) in fetal rat testis (left) and ovary from e15.5 (top) through to e21.5 (bottom). 
Scale bar in panel A represents 50µm for the testes panels. Scale bar in panel B 
represents 50µm for the ovarian panels. 
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Dmrt1 mRNA analysis was performed in fetal rat testis and ovary, in Figs 3.17 and 
3.18 below. As with all Taqman analyses, whole gonads were used to extract RNA 
and different controls were used for ovarian and testicular samples.  
 





































Figure 3.17 Quantitative analysis of Dmrt1 mRNA levels in fetal rat testis at e15.5, 
e17.5, e19.5 and e21.5, (n=6 for each age). Values are means  SEM. Student’s 
unpaired t test was performed, ** P<0.01 between e19.5 and e21.5.  
 
In the fetal rat testis, Dmrt1 expression changes were confounded by both Sertoli and 
GC expression being detected at e15.5-e17.5. Nevertheless, the reduction at e19.5 is 
likely due to silencing of GC-specific Dmrt1, and the significant rise at e21.5 may be 
due to the substantial increase in Sertoli cell number by the end of gestation (Scott et 
al., 2008).  




































Figure 3.18 Quantitative analysis of Dmrt1 mRNA levels in fetal rat ovary at e15.5, 
e17.5, e19.5 and e21.5, (n=6 for each age). Values are means  SEM. No 
statistically significant differences. 
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In the fetal rat ovary, without somatic cell Dmrt1 expression, GC specific Dmrt1 was 
still detectable (background noise) after e19.5 and even showed some evidence of an 
increase at e21.5. As with several other GC genes in the ovary, there was a much 
higher level of relative expression compared to the (control) adult rat ovary (Fig 
3.18). 
 
To identify if DMRT1 expression was differentially expressed in Sertoli and GCs in 
the early fetal testis, confocal microscopy of e13.5 testes was performed with double 
IHC staining for SOX9 and DMRT1 as shown in Fig 3.19.  
 
Figure 3.19 Representative confocal photomicrographs of immunostaining for 
DMRT1 (green) and SOX9 (red) in e13.5 fetal rat gonad (A and B). Panel A shows 
individual staining for DMRT1 and SOX9, and panel B shows the merged image to 
highlight the lack of co-localization. 
 
At e13.5 in the rat fetal testis (SOX9+), DMRT1 was detected in presumptive GCs 
and not in the SOX9+ pre-Sertoli cells. This suggests that initial GC expression of 
DMRT1 is not induced in the same way as in Sertoli cells and follows the pattern 
observed in the fetal rat ovary where GCs alone expressed DMRT1. At present, it is 
unknown if GCs express DMRT1 earlier in development or if it is induced upon 
entry into the gonad. 
3.3.11 Germ cell/pluripotency associated genes 
During the course of this thesis, several other GC or pluripotency genes were also 
investigated, particularly in the fetal rat testis in relation to DBP exposure (Chapter 
4). These genes were suggested by the literature, conferences or from personal 
discussions with other researchers. Many of these genes and/or their encoded 
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proteins were unable to be investigated in the fetal rat due to failure of antibodies to 
work or showed a vastly differing expression pattern from what has been reported in 
the mouse or human. Some genes showed no difference in expression during the last 
week of fetal life and/or with DBP exposure, and were therefore of less interest for 
the studies in this thesis. Table 3.3 below provides a brief summary of these attempts.  
 
Table 3.3 Summary of germ cell and pluripotency associated genes investigated. 
Gene Function 
Tech 
tried Result Selected References 
Klf4 
Pluripotency factor, also 
expressed in TGCT 
IHC and 
Taqman Did not work 
Godmann et al 2009, 
Takahashi et al 2007 
Dppa2 
Pluripotency factor, expressed 
then lost in PGCs 
IHC and 
Taqman Did not work 
Maldonado-Saldivia et al 
2007 
Ssea1 
Early stem cell marker, 
expressed in PGCs of human 
fetal gonad then lost  
IHC and 
Confocal Did not work Kerr et al 2008 
Ssea3 Early stem cell marker IHC Did not work Brimble et al 2007 
Ssea4 Early stem cell marker IHC Did not work Brimble et al 2007 
Plap PGC marker retained in TGCT IHC 
Leydig cell 
expression 
Molyneaux et al 2001, 
Koshida et al 1996 
Cd9 
GC surface marker and 
spermatogonial stem cell niche 
IHC and 
Confocal Did not work 
Kanatsu-Shinohara et al 
2004  
Gcna 
GC marker after arrival in 
gonad until meiosis 
IHC and 
Confocal Did not work Enders and May 1994 
Tex14 
Maintains male GC intercellular 
bridges Confocal 
GC specific but 
unaltered with DBP 
Greenbaum et al 2006, 
Greenbaum et al 2009 
Fgf2 
Growth factor that signals in 
Sertoli cells and in 
spermatogenesis IHC 
GC specific but 
unaltered with DBP 
Gomzalez-Herrara et al 
2006 
Fgfr2 
Growth factor receptor involved 




Schmahl et al 2004, Kim 
et al 2007 
E-cad 
Adhesion protein, involved in 
TGCT IHC 
Leydig cell 
expression Batistatou et al 2005 
p53 
Apoptotic protein, involved in 
several cancers IHC 
Leydig cell 
expression  Renaud et al 2007 
p63 
Apoptotic protein, involved in 
TGCT and normal ovary IHC 
Postnatal GC 
expression, 
unaltered with DBP 
Suh et al 2006, Emanuel 
et al 2006 
Cxcl12 
Chemokine involved in GC 




Molyneaux et al 2003, 
Gilbert et al 2009 
Cxcr4 
Chemokine receptor involved 




Molyneaux et al 2003, 






The aim of this chapter was to characterise GC development in the fetal rat gonad 
using the variety of studies previously published for the mouse as a basis for 
comparison (as reviewed in Section 1.3). This was to provide understanding of how 
fetal GC development occurs, how it is regulated and to identify targets for 
dysregulation that could be investigated with regard to fetal DBP exposure and 
Testicular Dysgenesis Syndrome in Chapter 4. 
 
In the fetal rat, the majority of GC migration into the developing gonad was 
completed at e13.5 and finished by e14.5. At e13.5 the gonads are in the beginnings 
of sexual differentiation, as no seminiferous cords were visible and only increased 
SOX9 expression was detected. SOX9 is upregulated in pre-Sertoli cell nuclei by 
testis specific SRY expression and is one of the earliest markers of sex 
differentiation. 24 hours later at e14.5 in a fetal rat testis, AMH was expressed in the 
Sertoli cells which have become organised around the GCs to form the seminiferous 
cords. In the e14.5 fetal ovary, the GCs were comparatively disorganised.  
 
By e15.5 in the fetal rat gonad, GCs show very little developmental change since 
e14.5, with the exception of their central aggregation within the seminiferous cords. 
This aggregation could be an active feature or could simply reflect clonal expansion 
of the proliferating GCs. GCs within the fetal rat ovary do not show any strong 
aggregation until around e19.5. In both fetal testis and ovary, GC proliferation was 
high during early gonad formation (at both e14.5 and e15.5 ~50%). The early events 
of GC migration, cord formation and GC proliferation in the fetal rat testis are 
similar to that described for the mouse, just on a different time scale.   
 
The proliferation index of GCs in the fetal gonads was reducing at e17.5 and by 
e19.5 and e21.5 no proliferating GCs were found in either the testis or ovary. 
Interestingly, the GC proliferation index was significantly different between the 
sexes at e17.5, with ~40% of ovarian GCs still proliferating, compared to ~2% of 
GCs in the testis. As GC proliferation initiates during migration (in the mouse) and is 
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independent of the sex of the GC, this sex dependent difference at e17.5 must be due 
to the somatic environment regulating GC proliferation.  
 
One other possibility for the observed difference at e17.5, is that a proliferation index 
does not calculate the actual number of proliferating GCs but instead labels the 
percentage of GCs that are in S phase during the time between BrdU injection and 
collection (1.5hours) and not the actual number of GCs that are proliferating. This 
leaves the option that there might be the same number of proliferating GCs in an 
ovary and testis if there are fewer GCs in an e17.5 rat ovary. However, such a 
significant difference in proliferation index and visual comparison of GC number in 
e17.5 testes and ovaries makes this possibility highly unlikely. A more likely 
explanation is that this difference in proliferation index is a reflection of the 
difference in the timing of commitment to spermatogenesis in the testis that occurs 
earlier than commitment to oogenesis (meiotic arrest) in the ovary. If GCs require a 
somatic signal to end their proliferation, the later initiation of meiotic control, 
possibly through retinoic acid exposure (reviewed in Section 1.3.4), would explain 
this sex specific difference in GC proliferation index at e17.5.  
 
The disparity between the end of GC proliferation and the observed increase in GC 
number in the fetal testis is hard to reconcile and is most likely due to an error in 
calculating GC number, because of differences in determining testis weight/volume. 
This will be discussed in more detail, and with regard to DBP exposure in Section 
4.3.1 and Section 4.4.  
 
Investigation of fetal GC differentiation was performed by examining several key 
GC genes and how both protein and mRNA expression changed over time, as early 
GC markers are lost and markers of more mature GCs are initiated. The early GC 
marker OCT4 was investigated and found to be expressed in all fetal rat GCs from 
e13.5 until e17.5 at which point some GCs had lost OCT4 expression. After e19.5 
OCT4 was lost in all GCs and was not detected postnatally. This pattern of OCT4 
expression was similar in GCs of both fetal testes and ovaries, except at e17.5 when 
fewer OCT4 positive GCs were observed the fetal ovary, which matches a sex 
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difference in OCT4 expression reported in the fetal mouse ovary. In the fetal mouse 
ovary, once Stra8 is expressed Oct4 expression becomes down regulated (Menke et 
al., 2003), possibly induced by retinoic acid (RA) exposure (Bowles and Koopman, 
2007). mRNA analysis of Oct4 matched the protein expression pattern, but showed 
an interesting difference between the ovary and testis. In both the adult and fetal rat 
testis, Oct4 mRNA was detectable in the absence of OCT4 protein, whereas Oct4 
mRNA was not detected in the fetal ovary after e19.5 or in the adult rat ovary. Whilst 
it is important not to over-interpret such results, this observed difference in Oct4 
expression profile over time may indicate that different gene regulation occurs 
between the sexes in the rat. The reduced but continued detection of Oct4 mRNA in 
the male rat suggests that both post transcriptional control and promoter silencing are 
involved in OCT4 protein expression. If it is RA that induces Oct4 down regulation, 
as in in vitro ES studies (Li et al., 2007; Pikarsky et al., 1994), then this difference in 
Oct4 expression regulation would be needed as RA may be degraded in the fetal 
testis by CYP26B1 enzyme action (Bowles et al., 2006). If there is indeed a 
difference (possibly due to differing RA levels) in how Oct4 expression is regulated 
between the testis and ovary, this may also occur in the human testis, where it could 
play a role in how Oct4 expression is retained into CIS and TGCT.  
 
DMRT1 is another GC gene for which protein expression is switched off in the GCs 
during fetal life at ~e19.5, although it remains expressed in the Sertoli cells. Analysis 
of Dmrt1 mRNA in the testis was complicated by its Sertoli cell expression, but there 
was a reduction in mRNA coincident with loss of GC protein expression and the 
significant increase in mRNA at e21.5 is likely due to the increase in Sertoli cell 
numbers at this age (Scott et al., 2008). In the fetal rat ovary, in which DMRT1 was 
only detected in GCs, Dmrt1 mRNA expression was reduced at e19.5 but showed a 
slight increase at e21.5 and was also detectable in the adult rat ovary. This is 
interesting as mice knockouts for Dmrt1 suggest that its expression is not required 
for normal ovarian function, but otherwise the present results in the rat match reports 
of Dmrt1 in the mouse (Lei et al., 2007; Raymond et al., 1999). 
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Markers of more mature GCs such as VASA and DAZL were found to be expressed 
in all GCs during the last week of fetal life in both the testis and ovary, with VASA 
initiating later than DAZL and remaining relatively constant. DAZL expression 
showed a possible reduction at e19.5 and e21.5 in both testis and ovary, a change 
which has not been described in the mouse. However, postnatally DAZL expression 
increased and co-localized with VASA until adulthood. mRNA analysis for both 
Vasa and Dazl showed a similar pattern of expression levels in fetal rat testes and 
ovaries, with highest expression at e17.5 followed by a sharp reduction at e19.5.  
 
As with all the Taqman analyses of mRNA levels, the whole gonad is used for RNA 
isolation, resulting in a mix of cellular origins for the mRNA pool relative to both the 
expression from each cell and the ratio of cell types in the gonad. This means that the 
high level of Vasa and Dazl expression at e17.5 could be due to an increase in GC 
expression of these genes or due to the relatively high GC contribution to the whole 
gonad at this age (as visible in Fig 3.3C and D). Whilst the fetal rat testis increased in 
size over time due to increase in number of Sertoli, Leydig and other cell types, the 
fetal rat ovary did not. As the relative mRNA expression pattern was the same in the 
fetal testis and ovary, the similar reduction in expression at e19.5 is more likely due 
to reduced GC mRNA expression. The continued levels of VASA protein expression 
observed after e19.5, when mRNA levels were reduced, indicates that VASA protein 
is not being actively degraded and is relatively stable at these ages.    
 
During the mRNA analyses of the fetal rat ovary, some genes were undetectable in 
the adult ovary or showed highly increased expression in fetal life relative to the 
adult ovary (e.g. Dazl Fig 3.10 and Dmrt1 Fig 3.17). This could be due to the high 
level of GC activity for these genes in the fetal ovary when compared to the adult 
ovary, or is due to the relatively small GC contribution to the adult ovary. In contrast, 
the adult rat testis contains a high number of GCs, in a variety of steps of 
development through spermatogenesis, and highlights that many of the GC genes 
investigated in fetal life are still expressed in the adult testis.    
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In summary, GC development is similar in both fetal rat testis and ovary, with some 
small differences (OCT4 expression at e17.5) and some major (meiotic/mitotic 
arrest). These similarities highlight the importance of the somatic environment of the 
gonad in fetal life in both determining the sex-specific development of the GC and 
supporting their subsequent development into a gonocyte or oocyte. By examining 
the events of fetal GC development in the rat, we have identified several processes 
that could become dysregulated with DBP exposure, and these events are 
summarised in Fig 3.20 (note that GC apoptosis is discussed in Chapter 4 and 
methylation in Chapter 5).  
 
 
Figure 3.20 Summary of the different events of fetal GC development investigated in 




Since the start of the studies comprising this thesis, new understanding about fetal 
and early postnatal GC development in the human has been published and has 
highlighted some important and fundamental differences between rat and human 
fetal GC organization and development. As described in Section 1.3.5.1, human GCs 
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show sub populations of GCs (e.g. differentiated and non-differentiated) within any 
individual seminiferous cord, in comparison with the largely synchronised GC 
populations observed within an individual seminiferous cord in the rat (Gaskell et al., 
2004). Further examination has identified separate OCT4+, VASA+ and DAZL+ GC 
sub populations within seminiferous cords in the fetal human testis (Anderson et al., 
2007). In the fetal rat testis, it is only at e13.5 that GCs do not express DAZL and 
VASA proteins (barely detectable) at the same time, and sub populations of germ 
cells that only expressed OCT4 were never observed. These species differences have 
further been highlighted by comparison to the marmoset (Mitchell et al., 2008), 
which shows a similar “unsynchronised” pattern of GC development to the human, 
with GCs only expressing OCT4 persisting into neonatal life and the existence of 
distinct sub populations of GCs within individual seminiferous cords. Based on these 
comparisons, GC development in the fetal rat may have limited usefulness as a 
model for GC development in the human, but these differences may account for the 
absence of CIS cells and TGCT in the rat.   
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4 The effect of exposure in utero to Di (n-Butyl) Phthalate 
on fetal germ cell development 
 
4.1 Introduction 
Having established the normal process of germ cell (GC) development during the last 
week of fetal life in the rat in Chapter 3, the effects of in utero Di (n-Butyl) Phthalate 
(DBP) exposure on this pattern was investigated. DBP exposure during fetal life of 
the rat produces several reproductive defects in the male, including cryptorchidism, 
hypospadias, impaired spermatogenesis and reduced fertility and is used as an animal 
model for human Testicular Dysgenesis Syndrome (TDS, discussed in more detail in 
Section 1.5) (Fisher et al., 2003). Whilst DBP exposure does not induce the most 
severe aspect of TDS, Carcinoma in Situ (CIS) cells or testicular germ cell tumours 
(TGCT), a previous study showed that DBP exposure can alter fetal rat GC 
development, resulting in significantly reduced GC number prior to birth and 
postnatal consequences (Ferrara et al., 2006). In addition, in utero DBP exposure 
causes areas of focal dysgenesis and seminiferous cords containing only immature 
Sertoli cells in the postnatal rat testis, which are features similar to those found in 
human testes with TGCT (Hoei-Hansen et al., 2003; Mahood et al., 2005; 
Skakkebaek et al., 2003; Hutchison et al., 2008a). 
 
The aim of this chapter was first to examine in detail how DBP exposure in utero 
altered GC development in the fetal rat testis, by investigating GC number, 
proliferation, apoptosis, differentiation (observed through changes in protein 
expression) and aggregation/migration in testes from control and DBP exposed 
animals. Then, different time windows of in utero DBP exposure were examined to 
gain more insight into when and how DBP exposure caused its effects on GC 
development. Finally, early postnatal testes were examined to determine the 
consequences of in utero DBP effects on fetal GC development for postnatal GC 




4.2 Materials and methods 
4.2.1 Animals and in vivo treatments 
Briefly, pregnant Wistar rats were treated with DBP or corn oil and collected at fetal 
and postnatal ages, as described in Section 2.2 and summarized in Table 4.1.  
 
Table 4.1 Summary of maternal DBP treatments and collection ages used in 














e14.5, e15.5, e17.5, e19.5, 
e21.5, D4, D6, D8, D10, D15, 
D25, Adult 
500 e11.5-e20.5 Ext e21.5, D6 
500 e13.5-e15.5 EW e17.5, e19.5, e21.5, D6 
500 e15.5-e17.5 MW e17.5, e21.5 
 
Testes from control and DBP exposed animals were dissected out (Section 2.3-2.3.4) 
and were either fixed in Bouin’s and processed for immunohistochemical analysis, or 
stored at -80C for RNA analysis.   
4.2.2 Immunohistochemical (IHC) analysis 
Briefly, IHC staining (Section 2.6) was performed on processed and sectioned fetal 
testes as summarised in Table 4.2. The number of fetal testes used for IHC was a 
minimum of 5 testes in each age and treatment group and came from a minimum of 
three different litters. 
 
In addition to standard single and double IHC, TUNEL IHC for apoptotic cells was 
performed as described in Section 2.6.12. Several IHC analyses were performed to 
calculate the GC number in fetal testes (Sections 2.8.1-2.8.2.2), GC proliferation 
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index (Section 2.8.3), the percentage of OCT4 or DMRT1 expressing GCs (Section 
2.8.4) and GC position at postnatal day (D)6 (Section 2.8.5). 
 
Table 4.2 Details of antibodies used in Chapter 4. 
Antibody Source Retrieval Species 
BrdU Fitzgerald industries, 
MA 
Yes Sheep 
cKIT Santa Cruz, CA Yes Rabbit 
DAZL AbD Serotec Yes Mouse 
DMRT1 
Gift from David 
Zarkower, MN 
Yes Rabbit 
OCT4 Santa Cruz, CA Yes Goat 
SMA Novocastra No Mouse 
VASA Abcam, Cambridge Yes Rabbit 
 
4.2.3 RNA analysis 
Briefly, RNA isolated from frozen testes was converted into cDNA (Section 2.11.2) 
and Taqman quantitative RT-PCR performed (Section 2.11.5), to establish 
quantitative mRNA expression levels. The genes investigated, and primers used, are 
listed in Table 4.3. 





Forward Primer  
5’  3’ 
Reverse Primer 

























4.3.1 Germ cell counts after DBP exposure 
As described above, previous studies of the effects of DBP exposure on fetal rat 
germ cell (GC) development had identified that DBP induced a significant reduction 
in GC number at embryonic day (e)21.5 (Ferrara et al., 2006). To examine in detail 
when this reduction occurs, GC counts at e14.5, e15.5, e17.5, e19.5 and e21.5 were 
performed on sections of control and standard DBP exposed fetal rat testes (as 
outlined in Table 4.1) by immunohistochemical (IHC) staining for VASA or DAZL, 




























Figure 4.1 Number of germ cells in testes of control and DBP exposed animals 
between e14.5 and e21.5 (n=8 for control e17.5, n=5 for others). Values are means 
± SEM. Student’s unpaired t test was performed, * P<0.05, ** P<0.01 between 
control and DBP exposed. 
 
 
The previously reported significant reduction in GC number at e21.5 was confirmed, 
and a pattern of consistently reduced GC number with DBP exposure was observed 
at every age investigated. There was also a significant early reduction in GC number 
with DBP exposure at e14.5 and e15.5, suggesting an early origin for this consistent 




In testes from both control and DBP exposed animals, GC number increased during 
the last week of fetal life, even though GC proliferation no longer occurs in the fetal 
rat testis after e17.5 (Fig 3.5). The increase in GC number after GC proliferation has 
ceased may therefore be artificial and result from errors in the accuracy of using 
three different methods to determine testis weight (Section 2.8.2). Beyond e17.5, 
there is a large increase in numbers of somatic cells, in particular Sertoli cells, which 
can clearly be seen in the left panels of Fig 3.4. Whilst stereology is an accurate way 
to calculate cell number it is possible that as the testis weight increased so much 
between e17.5 and e19.5 and is used as a multiplier to generate GC number, an over-
estimation of GC number may have occurred. This is discussed in more detail in 
Section 4.4. To illustrate this increase in other testicular cell types and to examine if 
DBP exposure altered the ratio of Sertoli cells to GCs, Sertoli cell counts (performed 
by S. Auharek and H. Scott) were combined with GC counts at e17.5, e19.5 and 
e21.5 to generate Fig 4.2.  
 





















Figure 4.2 Number of Sertoli cells (SC) and germ cells (GC) in testes from control 
and DBP exposed animals at e17.5, e19.5 and e21.5 (n=5-19). Values are means ± 
SEM. Student’s unpaired t test was performed, * P<0.05, *** P<0.001 between 





At e17.5, Sertoli cell number and GC number were relatively similar but as Sertoli 
cell number increased from e19.5 onwards, relatively speaking GC number did not. 
DBP exposure significantly decreased both Sertoli cell number and GC number at 
e21.5, but did not significantly alter the ratio of GC to Sertoli cells (data not shown).  
4.3.1.1 GC proliferation after DBP exposure 
Having established that GC number was consistently reduced at each age with DBP 
exposure, it was suspected that altered GC proliferation by DBP exposure may 
explain this reduction. This was investigated by double IHC staining for Bromo 
deoxyuridine (BrdU) and DAZL. As described in Section 2.2.3, BrdU labels 
proliferating cells and when combined with GC marker DAZL, allowed a GC 
proliferation index to be generated, as shown in Fig 4.3. 
























Figure 4.3 Germ cell proliferation index in testes of control and DBP exposed 
animals at e15.5, e17.5, e19.5 and e21.5 (n=5). Values are means ± SEM. No 
statistically significant differences.  
 
 
GC proliferation index was high in both control and DBP exposed testes at e15.5, 
and then reduced markedly at e17.5 to zero levels at e19.5-e21.5 in controls. At 
e17.5, DBP exposure increased average GC proliferation compared to controls, but 
not significantly, and rare single proliferating GCs were also identified at e19.5 in 
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DBP exposed animals. This suggested that DBP exposure was prolonging GC 
proliferation. 
 
To reconcile this observed increase in GC proliferation over time with the observed 
decrease in GC number with DBP exposure, the number of proliferating GCs was 
calculated for testes from control and DBP exposed animals at e15.5, e17.5, e19.5 

































Figure 4.4 Total proliferating germ cell number in testes from control and DBP 
exposed animals at e15.5, e17.5, e19.5 and e21.5 (n=5). Values are means ± SEM. 




By calculating the number of proliferating GCs in the fetal rat testis it became clear 
that even though GC proliferation was prolonged, the significant reduction in 
proliferating GC number at e15.5 means that GC number cannot recover to control 
levels. This result implied that the consistent reduction observed in Fig 4.1 is due to 
an initial effect/reduction in GC number that occurred prior to e14.5 or e15.5, and 




During the process of generating the GC counts, it was observed that GC nuclear 
volume increased as the GCs were developing during the last week of fetal life. To 
investigate if DBP exposure altered this aspect of GC development, mean nuclear 
GC volumes were calculated for testes from control and DBP exposed animals 
































Figure 4.5 Germ cell mean nuclear volume in testes from control and DBP exposed 
animals between e14.5 and e21.5 (n=5). Values are means ± SEM. Student’s 
unpaired t test was performed, * P<0.05 between control and DBP exposed.  
 
 
GC mean nuclear volume increased between e14.5 and e21.5, and especially beyond 
e19.5 and was not affected by DBP exposure until e21.5, when a significant 
reduction was found. This may be due to DBP exposure delaying an increase in 
nuclear size during GC development, or that DBP exposure is directly preventing GC 
nuclear expansion at e21.5. 
 
4.3.1.2 Apoptosis analysis after DBP exposure 
To investigate if the reduction in GC number resulting from DBP exposure was due 
to an increase in GC apoptosis, the apoptosis assay TUNEL was performed on fetal 
rat testes from control and DBP exposed animals, as described in Section 2.6.12. The 

































Figure 4.6 Number of apoptotic germ cells in testes from control and DBP exposed 
animals at e15.5, e17.5, e19.5 and e21.6 (n=6). Values are means ± SEM. No 
statistically significant differences. 
 
 
GC apoptosis in the fetal testis was low at e15.5 and e17.5 with only around 5 
TUNEL positive GCs in a complete testis cross-section, and by e19.5 and e21.5 no 
TUNEL positive GCs were detected. Examination of e13.5 control and DBP exposed 
testes (8 hours after oral gavage) showed no greater increase in TUNEL+ GCs (data 
not shown). Therefore DBP exposure had no significant effect on the number of 
apoptotic GCs, suggesting that DBP does not cause an increase in GC apoptosis, at 
least not at the ages examined.  
 
4.3.1.3 OCT4 expression after DBP exposure 
As discussed in Section 1.3.3, the pluripotency factor Octamer-binding transcription 
factor 3/4 (OCT4) is an early PGC marker in the mouse, whose expression is reduced 
as fetal GCs differentiate. In previous studies using the DBP rat model, OCT4 
expression was reported to be affected by DBP exposure (Ferrara et al., 2006). To 
confirm this and to quantify this DBP effect, IHC for OCT4 and VASA was 
performed (Fig 4.7) and the percentage of OCT4 positive GCs determined, as shown 





Figure 4.7 Representative photomicrographs of immunostaining for OCT4 (Dab = 
brown) and VASA (Fast blue = blue) in fetal rat testes from control (left) and 
DBP500 exposed animals (right) from e15.5 (top) through to e19.5 (bottom). Scale 




























Figure 4.8 Percentage of OCT4 expressing germ cells in e17.5 fetal rat testes from 
control and DBP exposed animals (n=6). Values are means ± SEM. Student’s 
unpaired t test was performed, ** P<0.01 between control and DBP exposed.  
 
At e17.5 there was a significant increase in the percentage of GCs expressing OCT4 
after DBP exposure. As OCT4 expression is lost during the last week of fetal life, 
this result suggested that DBP exposure delayed but did not prevent the loss of OCT4 
protein expression. To examine how Oct4 mRNA expression was altered by DBP 
exposure, Taqman analysis was performed on testes from control and DBP exposed 
animals at e15.5, e17.5, e19.5 and e21.5 are shown in Fig 4.9A. Further analysis at 
e17.5 to adjust for GC content of whole testis was performed by dividing by 










































Figure 4.9 A: Quantitative analysis of Oct4 mRNA levels at e15.5, e17.5, e19.5 and 
e21.5 in fetal rat testes from control and DBP exposed animals (n=6). Values are 


































































Figure 4.9 B: Quantitative analysis of Oct4 mRNA levels at e17.5 in control and 
DBP exposed animals (n=6) adjusted for GC number and testis weight. Values are 
means  SEM. No statistically significant differences.  
 
Oct4 mRNA expression diminished over time in the fetal testis and, unlike the IHC 
result in Figs 4.7 and 4.8, was not altered by DBP exposure at e17.5. As GC number 
is reduced after DBP exposure, the similar Oct4 mRNA levels observed at e17.5 in 
control and DBP exposed animals could be due to the fewer GCs individually 
expressing higher levels of Oct4 mRNA than in controls. When Oct4 mRNA levels 
at e17.5 were adjusted for GC number and testis weight, an increase in mRNA 
expression between control and DBP exposed testes was observable but not 
significant. 
4.3.1.4 DAZL expression after DBP exposure 
Deleted in Azoospermia Like (Dazl) is a GC-specific gene, which is described in 
more detail in Sections 1.3.5-1.3.6. During normal GC development in the fetal rat, 
DAZL expression is reduced in GCs after e17.5, discussed in Section 3.3.7. To 
examine if DBP exposure altered the expression of DAZL, IHC analysis of DAZL 
expression was performed during the last week of fetal life in the testes from control 
and DBP exposed animals (Fig 4.10). 
 
As described in Section 3.3.7 and Fig 4.10, DAZL protein was expressed throughout 
the last week of fetal life, and appeared to be reduced at e19.5 and e21.5. In contrast, 
DBP exposure resulted in a persistence of stronger DAZL expression at e19.5 
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compared with control testes, although this was less evident at e21.5. Attempts to 
quantify these differences in level of DAZL protein by Western blot proved 
unsuccessful.   
 
Figure 4.10 Representative photomicrographs of immunostaining for DAZL (Dab = 
brown) in fetal rat testes from control (left) and DBP500 exposed (right) animals 
from e15.5 (top) through to e21.5 (bottom). Scale bar in panel A represents 50µm. 
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Dazl gene expression was also examined after DBP exposure using mRNA analyses 
by Taqman on testes from control and DBP exposed animals at e15.5, e17.5, e19.5 









































Figure 4.11 Quantitative analysis of Dazl mRNA levels at e15.5, e17.5, e19.5 and 
e21.5 in fetal rat testes from control and DBP exposed animals (n=6). Values are 
means  SEM. * P<0.05 between control and DBP exposed. 
 
Dazl mRNA levels showed a slight increase at e15.5 after DBP exposure, and at 
e17.5, e19.5 and e21.5 DBP exposure produced a reduction in Dazl mRNA 
expression, although this was only significant at e21.5. This decrease in Dazl mRNA 
may be due to the reduction in GC number at these ages.  
 
4.3.1.5 VASA expression after DBP exposure 
Mouse Vasa Homologue (Vasa) is a GC-specific gene that is necessary for postnatal 
spermatogenesis. In normal fetal rat testes, as described in Section 3.3.4, VASA was 
expressed in all GCs from e14.5 onwards. To examine if DBP exposure altered this 
expression, IHC analysis of VASA was undertaken in the fetal testes from control 
and DBP exposed animals during the last week of fetal life. DBP exposure had no 
effect on VASA protein expression (data not shown). Vasa mRNA expression was 













































Figure 4.12 Quantitative analysis of Vasa mRNA levels at e15.5, e17.5, e19.5 and 
e21.5 in fetal rat testes from control and DBP exposed animals (n=6). Values are 
means  SEM. ** P<0.01 between control and DBP exposed. 
 
Vasa mRNA expression was unaltered by DBP exposure until e21.5, when there was 
a significant reduction. As with Dazl mRNA expression, this could be due to each 
GC expressing less Vasa or as a consequence of fewer GCs at e21.5 after DBP 
exposure. However, GC number is consistently reduced at each age examined (Fig 
4.1) whilst Vasa expression is only reduced at e21.5, so it is possible DBP exposure 
is only effecting Vasa expression at e21.5 or that a significant reduction in GC 
number (at e21.5) is required for a significant reduction in Vasa expression levels to 
be detected. 
  
4.3.1.6 DMRT1 expression after DBP exposure 
Dmrt1 is a gene that is essential for postnatal testis function in the mouse, as 
described in Sections 1.2.2.2 and 1.3.5. In the fetal rat testis, as discussed in Section 
3.3.10, DMRT1 protein is expressed in both Sertoli cells and GCs during the last 
week of fetal life. DMRT1 expression is diminished in GCs at e19.5 and is no longer 
detectable by e21.5. To examine if DMRT1 expression is altered by DBP exposure, 
IHC for DMRT1 was performed on testes from control and DBP exposed animals 




Figure 4.13 Representative photomicrographs of immunostaining for DMRT1 (Dab = 
brown) in fetal rat testes from control (left) and DBP500 exposed (right) animals 
from e17.5 (top) through to e21.5 (bottom). Scale bar in panel A represents 100µm. 
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DMRT1 GC expression in controls was pronounced at e17.5 but was virtually absent 
at later ages. In DBP exposed animals, this pattern was altered as many GCs still 
expressed DMRT1 at e19.5 and even at e21.5 there were still occasional GCs 
positively staining for DMRT1. To quantify the proportion amount of GCs 
expressing DMRT1 at e19.5, double IHC for VASA and DMRT1 was undertaken to 
ensure that DMRT1 expressing cells could be identified as GC or Sertoli cell. The 































Figure 4.14 Percentage of DMRT1 expressing germ cells in e17.5 fetal rat testes 
from control and DBP exposed animals (n=4). Values are means ± SEM. Student’s 
unpaired t test was performed, * P<0.05 between control and DBP exposed.  
 
 
There was a significantly higher percentage of GCs expressing DMRT1 at e19.5 in 
DBP exposed animals, suggesting that, as with OCT4, DBP exposure delayed the 
loss of GC-specific DMRT1 expression but did not prevent it. To examine if this is 
delay in Dmrt1 loss was observable at the mRNA level, Taqman mRNA analysis was 












































Figure 4.15 Quantitative analysis of Dmrt1 mRNA levels at e15.5, e17.5, e19.5 and 
e21.5 in fetal rat testes from control and DBP exposed animals (n=6). Values are 
means  SEM. * P<0.01 between control and DBP exposed. 
 
 
As DMRT1 is also expressed in Sertoli cells as well as in GCs, Dmrt1 mRNA levels 
per testis will not accurately reflect just GC expression. There was no significant 
increase in Dmrt1 mRNA expression induced by DBP exposure at e19.5, which 
could be due to the combined effect of fewer GCs and Sertoli cells at this age. At 
e21.5, Dmrt1 mRNA expression levels was significantly reduced in DBP exposed 
animals, most likely due to the reduction in both GC and Sertoli number (Fig 4.2) 
that was observed with DBP exposure at this age. 
 
4.3.1.7 cKIT expression after DBP exposure 
cKIT is the cell surface receptor for the KIT ligand, which is essential for GC 
migration into the gonad in the mouse, as well as for GC survival and proliferation, 
as discussed in Section 1.3.2. To examine the pattern of cKIT expression in fetal rat 
testes, and whether DBP exposure altered this pattern, IHC for cKIT was performed 
on testes from control and DBP exposed animals at e15.5, e17.5 and e19.5, as shown 




Figure 4.16 Representative photomicrographs of immunostaining for cKIT (Dab = 
brown) in fetal rat testes from control (left) and DBP500 exposed (right) animals 
from e17.5 (top) through to e19.5 (bottom). Scale bar in panel A represents 50µm. 
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According to the IHC, there was a change in cKIT localisation during GC 
development, changing from predominantly nuclear at e15.5 to more 
cytoplasmic/cell membrane localisation at e19.5. DBP expression did not prevent 
this change in localisation, but seemed to delay the change, most noticeable at e17.5 
where there were more GCs with nuclear cKIT staining compared to controls. As 
cKIT is normally described as a cell membrane associated protein, working as a 
receptor for KIT ligand, the observation of nuclear expression at some ages was 
unexpected (Matsui et al., 1990). A different antibody for cKIT (from DAKO, 
A4502) was also used for IHC and produced a perinuclear pattern of expression that 
was unaltered by DBP exposure. Based on these results, the localisation of 
expression of cKIT remains uncertain in the fetal rat testis. However, if cKIT is not 
detected in Fig 4.16, the antibody is clearly binding to an antigen with a GC-specific 
expression pattern that is altered/delayed by DBP exposure.  
 
 
4.3.1.8 Prenatal germ cell aggregation/migration 
As described in Section 3.3.3, GCs in the testis show an aggregation centrally in the 
seminiferous cords that begins at e15.5 until e19.5 when the GCs disaggregate and 
begin to migrate down to the basal lamina. To identify if this process of GC 
disaggregation was affected by DBP exposure, double IHC for SMA (to identify the 
basal lamina) and VASA was performed and is shown in Fig 4.17. 
 
In e21.5 DBP exposed animals, the GCs did not disaggregate and remained centrally 
located in the seminiferous cords. In addition, as previously described in detail 
(Ferrara et al., 2006), DBP exposure increased the occurrence of multinucleated 





Figure 4.17 Representative photomicrographs of immunostaining for SMA (Dab = 
brown) and VASA (Fast blue = blue) in fetal rat testes from control (left) and 
DBP500 exposed animals (right) from e19.5 and e21.5. Scale bar in panel A 
represents 50µm. Black arrow depicts a MNG. 
 
 
In summary, DBP exposure from e13.5-e21.5 delayed fetal GC development when 
compared to controls, as exhibited by prolonged proliferation, delayed increase in 
GC nuclear size, prolonged OCT4, DMRT1 and possibly DAZL expression and 
delayed GC disaggregation at e21.5. That GC development is delayed but not 
stopped may explain why CIS like cells are not produced by DBP exposure in the rat 




4.3.2 Effect of different time windows of DBP exposure on GC 
development 
Having established how in utero DBP exposure from e13.5-e20.5 altered several 
aspects of GC development in the fetal rat testis, several different time windows of 
DBP exposure were investigated with the aim of elucidating the crucial time points 
when DBP exposure affects GCs. These different treatment windows are discussed in 
Section 4.2 above, but in brief they were: an extended exposure window of e11.5-
20.5 (Ext), an early exposure window of e13.5-e15.5 (EW) and a middle exposure 
window of e15.5-e17.5 (MW). For the rest of this chapter the exposure window of 
e13.5-e20.5 is termed as the standard DBP exposure window (Std). 
 
As GC number in the fetal rat testis at e21.5 was significantly reduced with the 
standard DBP exposure, the effect of DBP exposure windows on GC number was 
investigated at e21.5. This is shown in Fig 4.18.  
 























Figure 4.18 Number of germ cells at e21.5 in testes from control and DBP exposed 
animals after different DBP exposure time windows (n=5-8). Values are means ± 
SEM. ANOVA followed by Bonferroni’s multiple comparison test was performed, * 
P<0.05 between control and Ext DBP exposure, ** P<0.01 between control and Std 
DBP exposure. 
 
The extended exposure window (Ext) caused a significant reduction in GC number 
by e21.5, but was not significantly different than that induced by the standard DBP 
exposure, suggesting that earlier DBP exposure than e13.5 had no greater effect on 
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GC number. The early exposure window (EW) also reduced GC number by e21.5, 
but not to the same extent as did the standard DBP exposure window. The middle 
exposure window did not have a significant effect on GC number at e21.5.     
 
As size of the GC nuclei was also reduced at e21.5 with the standard DBP exposure 
window (Fig 4.5), the effects of the other exposure windows on GC nuclear volume 
was also investigated, as shown in Fig 4.19. 
 





























Figure 4.19 Germ cell mean nuclear volume at e21.5 in testes from control and DBP 
exposed animals in different exposure time windows (n=5-6). Values are means ± 




The mean nuclear volume of GCs at e21.5 in the extended and middle DBP exposure 
time windows showed the same significant reduction in GC nuclear volume as seen 
with the standard DBP exposure window. The early exposure window did not 
produce a significant reduction in GC nuclear volume at e21.5. This result suggested 
that the altered GC endpoints described require DBP exposure at different times, 
instead of one time period of DBP exposure being responsible for all of the DBP 




4.3.2.1 OCT4 expression after DBP exposure in different time windows 
As previously described in Section 4.3.1.3, OCT4 protein expression was prolonged 
with standard DBP exposure, such that at e17.5 significantly more GCs expressed 
OCT4 in testes from DBP exposed animals. To examine if this DBP effect was due 
to exposure within a certain time window, the percentage of OCT4+ GCs at e17.5 
was calculated for animals exposed to DBP in the EW and MW using double IHC for 
OCT4 and VASA. This analysis is shown in Fig 4.20.  


























Figure 4.20 Percentage of OCT4 expressing germ cells in e17.5 fetal rat testes from 
control and DBP exposed animals after DBP exposure in different time windows 
(n=6). Values are means ± SEM. Student’s unpaired t test was performed, * P<0.05, 
** P<0.01 between control and DBP exposed.  
 
 
The early exposure window produced a significant increase in the number of OCT4+ 
GCs at e17.5, although this was not as large an increase as found with the standard 
DBP exposure. The middle DBP exposure time window had no effect on numbers of 
OCT4 expressing GCs. This suggested that DBP exposure during e13.5-e15.5 is 
crucial to alter OCT4 expression whereas continued DBP exposure between e15.5-






4.3.2.2 DMRT1 expression after DBP exposure in the early time window 
Having established that the early exposure window was the more important exposure 
time to induce a GC differentiation delay; based on OCT4 expression, the effect of 
DBP exposure in the early time window on DMRT1 expression at e19.5 was 
investigated. As described above in Section 4.3.1.6, standard DBP exposure 
prolonged DMRT1 expression in GCs at e19.5 resulting in a significant increase in 
the percentage of GCs expressing DMRT1. The same analysis was performed for the 
EW as well, as shown in Fig 4.21. Exposure to DBP only in the early window 
(e13.5-e15.5) increased the percentage of GCs expressing DMRT1, but not to the 






























Figure 4.21 Percentage of DMRT1 expressing germ cells at e19.5 in fetal rat testes 
from control and DBP exposed animals from different exposure time windows (n=4-
6). Values are means ± SEM. Student’s unpaired t test was performed, * P<0.05 
between control and DBP exposed. 
 
 
These results using different DBP exposure time windows have identified that 
shorter exposure windows can alter GCs as in the standard DBP exposure time 
window, although the magnitude of effect tended to be smaller. It also suggested that 
DBP exposure prior to e13.5 had no greater effect than did the standard DBP 
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exposure and that exposure e13.5-e15.5 is the crucial exposure time for GC number 
reduction and delay in GC differentiation (OCT4 and DMRT1 expression).  
 
 
4.3.3 Early Postnatal Consequences of DBP exposure 
Having identified that DBP exposure induced a delay in fetal GC development, and 
the effects of different fetal DBP exposure windows on that delay, the postnatal 
development of GCs after fetal DBP exposure was examined. As previous studies 
(Ferrara et al., 2006) of fetal DBP exposure on rat GCs had identified significant 
reductions in GC number at postnatal day (D)6 and D15 that recovered by adulthood 
(over 3 months of age), the early events of postnatal GC development were focussed 
upon as most likely to show effects of the DBP induced GC delay.     
 
4.3.3.1 DMRT1 expression in the postnatal testis 
DMRT1 is essential for postnatal development in the mouse testis, where it is 
expressed in both Sertoli and GCs (Raymond et al., 2000). Having established that 
DMRT1 expression is absent in GCs at around e19.5 and is altered by DBP exposure 
in the fetal rat testis, several postnatal ages were examined to identify the GC re-
expression pattern of DMRT1 in the rat. At D4, GCs did not express DMRT1 in 
controls (data not shown) but by D6 GCs begin to express DMRT1, this can be seen 




Figure 4.22 Representative photomicrographs of immunostaining for DMRT1 (Dab = 
brown) in postnatal rat testes from control (left) and DBP exposed (right) animals 
from D6 (top) through to d25 (bottom). Scale bar in panel A represents 50µm. Black 
arrow depicts a dysgenic area, white arrow depicts a GC in Panel B. 
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At D6 in controls, the GCs began to re-express DMRT1 and to migrate from the 
centre of the cords, discussed further in Section 4.3.3.4. DMRT1 then remained 
expressed in all GCs until D25, when expression was confined to the spermatogonia 
(as well as Sertoli cells). Fetal DBP exposure appeared to result in fewer GCs 
expressing DMRT1 at D6. To clarify this impression double IHC for DMRT1 and 
VASA was performed, as shown in Fig 4.23.  
 
 
Figure 4.23 Representative photomicrographs of immunostaining for DMRT1 (Dab = 
brown) and VASA (Fast blue = blue) in postnatal rat testes from control (left) and 
DBP500 exposed animals (right) at D6. Scale bar in panel A represents 100µm. 
 
 
Fetal DBP exposure did not prevent the re-expression of DMRT1in GCs postnatally 
at D6, but did seem to reduce the number of GCs expressing DMRT1. To quantify 
this possible DBP effect, the percentage of DMRT1 expressing GCs at D6 was 
calculated and the results shown in Fig 4.24. Fetal DBP exposure did significantly 
reduced the percentage of GCs expressing DMRT1 at postnatal D6, showing that the 

































Figure 4.24 Percentage of DMRT1 expressing germ cells at D6 in postnatal rat 
testes from control and DBP exposed animals (n=4). Values are means ± SEM. 




To investigate if the different exposure windows of DBP could produce the same 
postnatal GC effect, D6 testes from early time window DBP exposed animals (EW, 
e13.5-e15.5) and extended window exposed animals (Ext, e11.5-e21.5) were also 
quantified for DMRT1 expression in GCs in Fig 4.25.   
 




























Figure 4.25 Percentage of DMRT1 expressing germ cells at D6 in postnatal rat 
testes from control and DBP exposed animals from different exposure time windows 
(n=4). Values are means ± SEM. Student’s unpaired t test was performed, * P<0.05, 





The different DBP exposure time windows all resulted in a significant reduction in 
the percentage of GCs expressing DMRT1 at D6, but the effect was largest for the 
standard DBP exposure window. The less significant reduction observed with the 
extended exposure window is most likely due to the variability of DBP effects and 
the relatively low “n” number.  
 
4.3.3.2 Postnatal germ cell number 
As previously reported,  DBP exposure reduced GC number at D6 (Ferrara et al., 
2006), so to examine if the different DBP exposure windows could reproduce this 
effect, GC counts were performed on D6 testes from control and standard, early and 
extended time window DBP exposed animals, and results are shown in Fig 4.26. 
 






















Figure 4.26 Number of germ cells at D6 in testes from control and DBP exposed 
animals from different DBP exposure time windows (n=4). Values are means ± 




The extended exposure window reduced GC number to a similar level as did the 
standard DBP exposure window, whilst DBP exposure in the early window did not. 
This may be a reflection of the fact that the EW exposed testes used for this analysis 
did not show the same severe reduction in testis size at D6 as the Std or Ext DBP 
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treatment windows. Whilst this may be due to EW DBP exposed testes somehow 
recovering from the significant reduction in GC number with EW DBP exposure at 
e21.5 (Fig 4.18), it is more likely due to the variability of in vivo tissue and the 
relatively low “n” number used to calculate GC number. 
 
4.3.3.3 Postnatal resumption of germ cell proliferation 
As postnatal GC numbers are reduced after fetal DBP exposure, changes in their 
proliferation were investigated as a possible cause of this reduction. GC Proliferation 
indices were calculated for postnatal D6, D8 and D10 testes in control and standard 
























Figure 4.27 Germ cell proliferation index in testes from control and DBP exposed 
animals at D6, D8 and D10 (n=4-5). Values are means ± SEM. Student’s unpaired t 
test was performed, * P<0.05 between control and DBP exposed. 
 
 
DBP exposure only significantly reduced the GC proliferation index at D6, possibly 
indicating that the postnatal initiation of proliferation has been delayed by DBP 
exposure, providing another postnatal GC effect for which development is delayed 





4.3.3.4 Postnatal germ cell migration 
As fetal GCs in DBP exposed animals showed a delayed disaggregation/migration at 
e21.5, the postnatal GC migration to the basal lamina was investigated for a possible 
DBP exposure effect. Double IHC for VASA and SMA, used to identify the basal 
lamina, was performed on D6 testes and is shown in Fig 4.28  
 
Figure 4.28 Representative photomicrographs of immunostaining for SMA (Dab = 
brown) and VASA (Fast blue = blue) in postnatal rat testes from control (left) and 





In addition to an increased incidence of multinucleated gonocytes (MNG) in testes of 
DBP exposed animals, the position of GCs within the seminiferous cords seemed to 
be more centrally located than in controls at D6. To quantify this, the percentage of 
GCs in either basal or central positions within the cords was evaluated, as described 

























Figure 4.29 Percentage of germ cells in basal or central seminiferous cord positions 
at D6 in testes from control and DBP exposed animals (n=3). Values are means ± 




In testes from DBP exposed animals at D6, there is a significant increase in the 
percentage of GCs located centrally within the seminiferous cords compared to 
controls, once again indicating a delay in GC migration. As mouse studies have 
identified that DMRT1 is essential in GCs for postnatal GC migration to the basal 
lamina, the delay in re-expression of DMRT1 may be involved in this delay (Kim et 
al., 2007). However, there were DMRT1- GCs at the basal lamina and DMRT1+ 
GCs centrally located (Fig 4.22), suggesting no consistent relationship between 




4.3.3.5 Later postnatal consequences of DBP exposure 
As previously reported (Ferrara et al., 2006), fetal DBP exposure significantly 
reduced GC number at D15. This was examined in the present study using VASA 
IHC to identify GCs for enumeration in D15 testes from control and DBP exposed 























Figure 4.30 Number of germ cells at D15 in testes from control and DBP exposed 
animals (n=6). Values are means ± SEM. Student’s unpaired t test was performed, 
*** P<0.001 between control and DBP exposed. 
 
In analysing the D15 testes there was an observable difference in the position of GC 
in the seminiferous cords, as visualized by VASA IHC on testes from control and 
DBP exposed animals (Fig 4.31). 
 
Figure 4.31 Representative photomicrographs of immunostaining for VASA (Dab = 
brown) in postnatal rat testes from control (left) and DBP exposed (right) animals at 
D15. Scale bar in panel A represents 50µm. 
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At D15, the reduction in number of GCs in testes of DBP exposed animals was 
clearly visible and GCs were located sparsely around the base of the seminiferous 
cords. In D15 control testes, GCs were beginning to enter meiosis (differentiate), 
and, in doing so, to move to the centre of the cords.  This showed again that the fetal 
DBP exposure continued to delay GC development at least 15 days after DBP 
exposure had ended. 
 
4.4 Discussion 
The aim of this chapter was to determine how DBP exposure in utero could alter the 
process of germ cell (GC) development in the fetal rat testis, as described in Chapter 
3. To that end GC number, proliferation, apoptosis, differentiation (observed through 
changes in protein expression) and aggregation/migration were examined in testes 
from control and DBP exposed animals. In addition, the effect of different DBP 
exposure time windows on GC development was examined to gain more insight into 
when DBP exposure causes its effect(s). Finally, early postnatal GC development 
was investigated to determine if altered GC development continued after DBP 
exposure was over. 
 
Having established the normal pattern of GC development within the fetal rat testis 
in Chapter 3, the first aspect of this investigation was to thoroughly examine how 
these GC events were altered by in utero DBP exposure. Using previous work on the 
effects of DBP exposure on GCs as a starting point (Ferrara et al., 2006), which 
showed that GC number was significantly reduced by e21.5, GC number was 
calculated throughout fetal testis development for control and DBP exposed animals 
to identify when the significant reduction in GC numbers induced by DBP at e21.5 
occurs. At every fetal age investigated, GC number was consistently reduced in the 
testes of DBP exposed animals, but this reduction was only significant in early testis 
development (e14.5 and e15.5) and just prior to birth (e21.5).  
 
Problematically, GC number was shown to also increase after the established end of 
GC proliferation around e17.5 (Fig 3.5) in both control and DBP exposed animals. 
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This apparent increase after e19.5 is most likely due to differential errors in 
determining GC number at different ages. Whilst stereology is a well established 
technique to accurately determine cell numbers, in this case the huge increase in 
testis size/weight between e17.5 and e19.5 (which is a multiplier to calculate cell 
number per testis, Section 2.8.1) is a key factor in determining final GC number. In 
this regard, 3 different methods of determining testis weight were used according to 
age, with directly determined individual testis weights only being undertaken at 
e19.5 and e21.5, making GC number at e19.5 and e21.5 probably the most accurate. 
It seems likely that differential errors in determining testis weight/volume at the 
different ages explains the apparent increase in GC numbers beyond e17.5. However 
this chapter is focussed on DBP exposure effects and not on how GC number 
increases over time. Therefore, at each age comparison of GC number between testes 
from control and DBP exposed animals is valid and this showed a consistent 
reduction in GC numbers due to DBP exposure, which is the most important aspect 
of Fig 4.1.  
 
Other factors that may be involved in errors in determining GC number are that there 
is inherently high variability with in vivo animal work and that, as shown in Fig 4.5, 
the mean nuclear volume of GCs changes substantially during testis development, 
which is also a potential source of error when comparing GC number at different 
ages. In fact DBP exposure seemed to cause a significant reduction in mean nuclear 
volume at e21.5 compared to control GCs, suggesting either delayed GC 
development or that DBP exposure is directly preventing GC nuclear expansion. 
Despite these technical reservations, there is no doubt that DBP exposure reduces GC 
number, in agreement with previously published data on GC number at e21.5 
(Ferrara et al., 2006). This reduction in GC number is supported by similar reported 
reductions in GC number after in vitro phthalate exposure (MEHP) in neonatal 
mouse testes (Li and Kim, 2003) and in fetal human testes (Lambrot et al., 2009).  
 
To try and determine how DBP induced a reduction in GC number, both GC 
proliferation and apoptosis were examined. The GC proliferation index was not 
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significantly altered by DBP exposure, but in testes from DBP exposed animals there 
was a noticeable increase in proliferating GCs at e17.5 and even isolated rare 
proliferating GCs at e19.5, neither of which were observed in controls. This 
suggested that instead of reducing GC proliferation as might have been suspected, 
GC proliferation was continuing for longer in DBP exposed animals. By combining 
GC number and the proliferation index data, the total number of proliferating GCs 
was calculated and this showed a significant reduction in testes from DBP exposed 
animals at e15.5. Therefore, even though GC proliferation was prolonged, GC 
number could not recover to control levels following the early reduction in their 
numbers. This suggested that the entry of GC into quiescence was being delayed by 
DBP exposure. This may be the result of a delay in time taken to complete each GC 
division, or a delay in the change from primordial GC division to regulation by the 
somatic environment, or a delay in the somatic signalling that regulates the entry into 
mitotic arrest (Monk and McLaren, 1981). 
 
When GC apoptosis was examined by TUNEL staining, there was no significant 
difference between testes of control and DBP exposed animals, with only a few cells 
on each section staining TUNEL+. The lack of DBP effect and the general low level 
of GC apoptosis suggested that the consistent reduction in GC number observed with 
DBP exposure is not due to increased apoptosis, at least not at the ages investigated. 
However it is possible that, as collection of tissue occurred generally 24 hours after 
DBP dosing, any increase in GC apoptosis that might have occurred soon after 
treatment would no longer be evident at the time of collection. In vitro studies of 
MEHP treatment on fetal human testes has shown increased GC apoptosis (by 
cleaved caspase-3 detection) compared to controls (Lambrot et al., 2009). However, 
fetal mouse testes collected at em18 and cultured in vitro for 3 days with MEHP did 
not show an increase in GC apoptosis, whilst neonatal mouse testes collected at D3 
and cultured in the same manner with MEHP did show a significant increase in 
apoptosis (Li and Kim, 2003). This may indicate that GCs are only susceptible to 
phthalate induced apoptosis at certain points in their development. This would fit 
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with the absence of evidence for any accumulative loss of GC as treatment 
progressed in the present studies.  
 
There are several possible explanations for the consistent reduction in GC number 
after DBP exposure. As GC number is significantly reduced at e14.5, only 24 hours 
after the initial DBP dosing, this suggests that some early event of testis development 
is being disrupted. This is supported by findings involving DBP treatment in only an 
early time window, as discussed below. Unfortunately, no insights into what is 
causing this early effect have been identified in this thesis. But it is possible this 
early disruption could cause direct loss of GCs through phthalate induced apoptosis, 
as in vitro (Lambrot et al., 2009; Li and Kim, 2003), or through some indirect way 
that results in a reduction in GC number by e14.5, such as delaying the organisation 
of Sertoli cell and GC into cords, such that the program of GC development is 
initially delayed. As described above, it is also possible that DBP induced GC 
apoptosis may be being missed, or that it occurs at an early point in testis 
development (e.g. e13.5), when a relatively minor effect of DBP exposure may get 
multiplied by each subsequent round of GC proliferation and would lead to the 
observed major reduction in GC numbers by e21.5. In view of the observed reduction 
in GC number at e14.5 in DBP exposed animals, this sort of explanation seems most 
likely.  
 
Having further investigated the reported reduction in GC number, the process of GC 
differentiation was examined for DBP exposure effects. For the purpose of this 
thesis, GC differentiation was viewed as the change in protein expression over time. 
Previous work on effects of DBP exposure on GCs in the fetal rat testis discovered 
that the pluripotency factor OCT4 appeared to be more highly expressed at e17.5 in 
the GCs of testes from DBP exposed animals compared to controls (Ferrara et al., 
2006). This was confirmed in the present studies and the effect quantified. This 
showed that significantly more GCs expressed OCT4 at e17.5 in testes from DBP 
exposed animals, compared with controls, without a significant change in mRNA 
level in whole testes. This may be due to the fact that DBP exposure is having no 
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effect on mRNA expression at e17.5, or may reflect that there are fewer GCs in DBP 
exposed animals at e17.5 that are each expressing a higher level of Oct4 mRNA than 
are individual GCs in control testes. As OCT4 expression in GCs in DBP exposed 
animals was absent by e19.5, as in controls, this suggested that DBP exposure was 
simply delaying the switching off of OCT4 expression, rather than preventing its 
switch off. 
 
As described in Section 3.3.7, the expression of DAZL protein appeared to diminish 
in GCs after e19.5 but was still detectable at e21.5. In the testes of DBP exposed 
animals at e19.5 and e21.5, DAZL expression still diminished, as in controls, but 
possibly to a lesser extent than in control testes. Regrettably this could not be 
quantified by Western blot, so remains observational. When Dazl mRNA expression 
was examined there was no significant reduction in DBP exposed animals versus 
controls until e21.5, possibly reflecting the significant reduction in GC number at 
e21.5 in testes of DBP exposed animals. The possibly stronger expression of DAZL 
protein in GCs of testes from DBP exposed animals as compared to controls is most 
likely due to a DBP-induced delay in the silencing of DAZL.  
 
Another GC marker investigated was VASA, which showed no change in protein 
localization or strength of expression (by IHC) between control and DBP exposed 
animals at any age. However, when Vasa mRNA was examined in control and DBP 
exposed animals it was significantly reduced in DBP exposed animals at e21.5, once 
again possibly reflecting the significant reduction in GC number at this time. 
However, GC number was consistently reduced in DBP exposed animals at each age 
investigated, but Vasa mRNA expression was only reduced at e21.5. This suggests 
that either DBP exposure reduced the individual GC expression of Vasa at e21.5, and 
by inference Dazl too, or that for a significant reduction in Vasa expression to be 
detected, a significant reduction in GC number must also be present.   
 
In the fetal rat testis, DMRT1 was expressed in both GCs and Sertoli cells, but at 
around e19.5 most GCs have switched off DMRT1 expression until it resumes in 
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postnatal life. In the testes of DBP exposed animals at e19.5, there was a significant 
increase in the number of GCs that were continuing to express DMRT1, similar to 
the earlier delay in switching off of OCT4 expression. When Dmrt1 mRNA 
expression levels were examined, they were complicated by mRNA expression from 
both GCs and Sertoli cells. At e21.5 there was a significant reduction in Dmrt1 
expression, but this is likely due to the significant reduction in both Sertoli and GCs 
at this age. At e19.5, when GCs are normally switching off DMRT1 protein 
expression, mRNA expression levels were similar in testes from control and DBP 
exposed animals, which may be due to individual GCs expressing more Dmrt1 
mRNA even though there are fewer GC in number in DBP exposed animals. In this 
way, GC-specific expression of DMRT1 is another aspect of GC development that 
showed a delay after DBP exposure.      
 
When expression of cKIT protein was examined, a change in localization was 
discovered over time as expression went from predominantly nuclear to a more 
cytoplasmic/cell membrane staining. In the testes of DBP exposed animals there 
seemed to be a delay in the change in cKIT re-localization, so that at e17.5 cKIT 
expression remained nuclear in GCs from DBP exposed animals and cytoplasmic in 
GCs from controls. However, as cKIT protein is generally considered to be localized 
to the cell membrane the nuclear staining observed at earlier ages is puzzling and is 
potentially artifactual. Irrespective of this, the antibody to cKIT once again indicated 
that GC differentiation is delayed after DBP exposure. 
 
Towards the end of fetal life in the rat, GCs begin to disaggregate from their central 
location in the cords and move gradually towards the basal lamina by e21.5. In testes 
from DBP exposed animals, GCs remained centrally aggregated at e21.5 although by 
postnatal life disaggregation has occurred, suggesting that DBP exposure is delaying 
this aspect of GC development. Related to this disaggregation is the appearance of 
multinucleated gonocytes (MNG) in the testes of DBP exposed animals at e19.5 and 
e21.5, which are presumably GCs that have become fused because of loss of 
intercellular bridges. The occurrence of MNGs is discussed in more detail elsewhere 
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(Ferrara et al., 2006), but interestingly DBP exposure at e19.5-e20.5 is sufficient to 
cause the appearance of MNGs at e21.5, suggesting that it is a late effect that is 
unconnected to GC proliferation. This late exposure to DBP (e19.5-e20.5) also 
resulted in central GC aggregation at e21.5 (data not shown), showing that this aspect 
can be induced late in gestation. One possible explanation for the failure of GCs to 
disaggregate at e21.5 is that this process involves Sertoli cell and GC interactions, so 
that Sertoli cell cytoplasm can invaginate between the GCs, which is 
delayed/prevented at e21.5 with DBP exposure (G. Hutchison, unpublished data).  
 
In DBP exposed animals, the Sertoli cells are also significantly reduced in number at 
e19.5 and e21.5 compared to controls but not at e17.5 (Scott et al., 2008), and 
comparison of GC:Sertoli cell ratios in control and DBP exposed testes showed no 
significant difference at these ages (data not shown). This timing of Sertoli cell 
reduction at e19.5 and the early effects of DBP exposure on GC development 
suggests a limited involvement with Sertoli cells in the fetal GC effects after DBP 
exposure. However, if DBP is somehow interfering with Sertoli-GC interactions, it 
may explain both the early effect of DBP exposure on GC (reduced numbers) and 
why the disaggregation of GCs fails to occur later. As described above, GC effects of 
DBP exposure are noticeable by e14.5, 24 hours after initial exposure, so one 
possible explanation is that DBP exposure interferes with Sertoli-GC interactions 
during initial cord formation (which occurs by e14.5), causing the initial reduction in 
GC number and delaying all of the subsequent GC development. The use of an early 
window of DBP exposure from e13.5-e15.5 supported this conclusion, as described 
below. At e19.5, DBP exposure may also interfere with Sertoli-GC interactions and 
delay Sertoli cell invagination and cause the GCs to fail to disaggregate, which 
would match published data on DBP exposure only between e19.5-e20.5 (Ferrara et 
al., 2006). Regrettably this is just supposition, but the possible role of DBP on 
Sertoli-GC interactions warrants further work. 
 
Having examined how DBP exposure from e13.5 onwards delayed GC development, 
different DBP exposure time windows were examined to gain more understanding 
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into how DBP exposure is affecting GC development and to possibly support some 
of the conclusions drawn from this previous data. Three different exposure time 
windows were used; an extended exposure window of e11.5-20.5(Ext), an early 
exposure window of e13.5-e15.5 (EW) and a middle exposure window of e15.5-
e17.5 (MW). 
  
The first aspect of GC development investigated using these different treatment time 
windows was GC number at e21.5. The results showed that the Ext DBP treatment 
window significantly reduced GC number by e21.5 to the same degree as did the 
standard DBP exposure window. The EW DBP treatment also showed a significant 
reduction in GC number, but not as great as with the standard DBP exposure 
window. The MW DBP treatment slightly reduced GC number at e21.5, but not 
significantly. This suggested that DBP exposure between e11.5-e13.5 had no greater 
effect on GC disruption than did treatment from e13.5, whilst treatment between 
e13.5-e15.5 was crucial to reduce GC number by e21.5. This time window 
corresponds with sex determination and seminiferous cord formation suggesting that 
this is the time when GCs are susceptible to DBP exposure, not when they are 
migrating into the gonad prior to e11.5.  
 
When GC mean nuclear volume was examined at e21.5 for the different DBP 
treatment time windows, the Ext treatment window induced the same reduction in 
GC nuclear size as did the standard DBP treatment window, supporting the notion 
that earlier DBP exposure had no greater effect. The EW DBP exposure reduced GC 
nuclear size, but not significantly, whereas MW DBP exposure did significantly 
reduce GC nuclear size, suggesting that DBP exposure within the period e15.5-e17.5 
is required for this particular GC effect. This would further suggest that the effects of 
DBP may not be due to a single event that permanently delays GC development in 
the manner observed for the standard DBP treatment window.  
 
DBP induced prolongation of OCT4 expression at e17.5 was examined after 
treatment during the EW and MW time windows. In this instance, only the EW 
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treatment significantly increased the percentage of GCs expressing OCT4, but not as 
significantly as did the standard window DBP exposure. This suggests that the EW 
time period is the most important for delayed differentiation, whilst continued 
exposure is perhaps needed to maintain this delay. The use of these two windows of 
DBP exposure indicated that it is not a direct effect of DBP exposure on GCs at 
e17.5 that results in the increased OCT4+ GCs, as it was the EW DBP exposure 
rather than MW DBP exposure that caused the significant increase in OCT4+ GCs.  
 
It was also examined whether EW DBP exposure significantly increased the 
percentage of DMRT1+ GCs at e19.5 similar to the standard DBP treatment window. 
EW treatment did cause an increase in DMRT1+ GCs, but not as significantly as did 
the standard DBP treatment, suggesting again that although early DBP exposure is 
required to induce these effects, their persistence requires prolonged DBP exposure.  
 
In summary, DBP exposure earlier than e13.5 has no greater effect than does 
exposure from e13.5 and that no single short DBP exposure time window is 
sufficient to induce all of the GC effects induced by the standard DBP exposure 
treatment, although the EW has been identified as being more crucial for delayed GC 
differentiation than the MW.  
 
Having examined the effects of DBP exposure on fetal GCs development, the 
postnatal consequences were then investigated. Previous work on the effects of fetal 
DBP exposure on postnatal GCs had identified that GC number was significantly 
reduced beyond puberty but was resolved by adulthood (Ferrara et al., 2006). To 
complement this observation the effect of both the standard and different DBP 
exposure time windows on early postnatal GC development was examined.  
 
At postnatal day 6, GC number, the GC proliferation index, GC position and 
DMRT1 re-expression in the GCs were examined. DMRT1 is necessary in the mouse 
for correct postnatal testis development, as its knock-out in just the GCs results in 
their failure to migrate to the basal lamina postnatally (Kim et al., 2007). In the rat, 
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DMRT1 expression was switched off in the GCs at around e19.5 and then became re-
expressed at around postnatal D6. The percentage of DMRT1+ GCs on D6 was 
significantly reduced by the standard DBP exposure, consistent with the notion that 
the DBP induced delay in GC development continued into early postnatal life.  
 
In testes from standard window DBP exposed animals at D6, there was an increased 
percentage of GCs located centrally within the seminiferous cords, illustrating that 
migration to the basal lamina was also delayed. Whilst DMRT1 expression is related 
to GC migration to the basal lamina in the mouse, in the rat there was not a clear 
relationship between DMRT1 expression and GC position at D6.  
 
The percentage of DMRT1+ GCs in testes from the Ext DBP exposure groups was 
significantly reduced but not to the same degree as occurred with the standard 
window DBP exposure. This is likely due to the inherent variability and low “n” 
number used in this experiment, rather than the Ext DBP treatment window having a 
lesser effect. With the EW DBP exposure window, the percentage of DMRT1+ GCs 
was also reduced at D6, showing that this brief early exposure window is causing a 
GC developmental delay, albeit not as severe as with the standard DBP exposure 
window. 
 
At D6 GC number had been previously reported as significantly reduced after in 
utero DBP exposure (Ferrara et al., 2006), and was confirmed here. In addition, in 
D6 testes from animals from the Ext DBP treatment group, a similar significant 
reduction in GC number was found, as expected. However, D6 testes from EW DBP 
exposed animals did not show a significant reduction in GC number. As for most 
other aspects of GC development, this treatment was either partially or fully 
effective, compared with the standard treatment window, this disparity is 
unexplained. It could simply reflect the relatively low “n” numbers used, or it could 
mean that somehow GC number is recovering from the significantly reduced GC 
number observed with EW DBP exposure at e21.5. If so, this would have to involve 
an earlier resumption of GC proliferation. In this regard, when the GC proliferation 
Chapter 4  Effect of exposure to DBP on fetal GC development  152 
 
index was evaluated at D6, D8 and D10 for testes from control and standard DBP 
exposed animals, there was only a significant reduction at D6. This suggests that 
there is a delay in the resumption of proliferation in the postnatal testes of DBP 
exposed animals.  
 
At D15 there was a significant reduction in GC number in testes from standard DBP 
exposed animals compared with controls, as well as a noticeable difference in GC 
location within the cords/tubules. In testes from control animals, GCs were beginning 
to enter meiosis (differentiate) and move into the centre of the cords, whilst in testes 
from DBP exposed animals GCs were sparse and were still mainly located at the 
basal lamina.  
 
In summary of these postnatal investigations, several early postnatal events of GC 
development also showed a DBP induced delay that continued until at least D15. The 
Ext DBP exposure window had no greater effect on postnatal GC development, 
matching observations in fetal life. Furthermore, the EW DBP exposure window 
resulted in a less pronounced GC delay postnatally, once again matching data from 
the fetal studies. It should be noted that even with this early postnatal GC 
developmental delay, by adulthood GC numbers in DBP exposed rats have recovered 
to control levels in normally descended testes (Ferrara et al., 2006). However, the 
delayed GC development could have more subtle effects that might contribute to the 
reduced fertility in DBP exposed rats in adulthood, as delayed GC development may 
result in abnormal GCs. 
  
In general summary of DBP exposure effects, the standard DBP exposure from 
e13.5-e21.5 delayed fetal GC development when compared to controls, as 
summarized in Table 4.4. That GC development is delayed but not stopped may 






Table 4.4 Summary of effects of in utero DBP exposure from e13.5-e20.5 on GC 
development in the rat. 
GC Process Effect of DBP exposure 
Number Consistently reduced GC number from e14.5 until D15 
Proliferation Delayed end of proliferation and delayed postnatal resumption 
Nuclear volume  Delayed or prevented expansion at e21.5 
Apoptosis No difference detected 
OCT4 expression Delayed switching off of OCT4 expression at e17.5 
DAZL expression Possible delay in reduction of DAZL expression at e19.5 and 
significant reduction in Dazl mRNA at e21.5 
VASA expression No difference in protein detected but significant reduction in Vasa 
mRNA at e21.5 
Fetal DMRT1 
expression 
Delayed switching off of GC-specific DMRT1 expression at e19.5 
“cKIT” expression Possible delay in re-localization at e17.5 
Fetal aggregation/ 
Migration 
Delay in disaggregation and migration to basal lamina at e21.5, 
occurrence of MNGs 
Postnatal DMRT1  
Expression 
Delayed re-expression of GC-specific DMRT1 expression at D6 
Postnatal migration Delayed migration to basal lamina 




5 Investigation of methylation as a potential mechanism 
for effects of Di (n-Butyl) Phthalate on germ cells  
 
5.1 Introduction 
DNA methylation is the addition of a methyl group to a CpG dinucleotide in the 
DNA, and is one of several mechanisms involved in epigenetic regulation of the 
genome, as reviewed in Section 1.4. In the mouse, fetal germ cells (GC) lose 
genomic methylation pattern during migration to the gonad, and then undergo 
gradual remethylation as a new genomic imprint is established (Oakes et al., 2007b). 
DNA methylation is also involved in gene silencing that occurs during cellular 
differentiation. As described in detail in Chapter 4, in utero exposure to Di (n-Butyl) 
Phthalate (DBP) alters several aspects of GC development and differentiation during 
the last week of fetal life in the rat testis, and in this chapter DNA methylation in the 
fetal testis was examined as a possible mechanism for DBP effects.  
 
Three approaches were taken to investigate DNA methylation in the fetal rat testis 
after DBP exposure. First, it was examined how normal global methylation by the 
action of DNA methyl transferases occurred in the fetal rat testis and if this was 
disrupted by DBP exposure. Then the use of a chemical DNA methylation inhibitor 
was used to examine if GC differentiation could be prevented in the fetal rat testis, 
and whether DBP effects were altered when it was combined with methylation 
inhibition. Finally, gene specific methylation of the Oct4 promoter was examined 
during the last week of fetal life, as OCT4 protein expression is altered by DBP 
exposure and the Oct4 gene is regulated by promoter methylation in the mouse and 








5.2 Materials and methods 
5.2.1 Animals and in vivo treatments 
Briefly, pregnant Wistar rats were treated with DBP or corn oil from e13.5 onwards, 
or injected with 5-aza-2’deoxycytidine (AZC) or saline on e16.5, or a combination of 
both treatments (Section 2.2). These treatments and the ages of tissue collection are 
summarized in Table 5.1.  
 
Table 5.1 Summary of maternal AZC and DBP treatments and collection ages used 


















- - 500 e13.5-e20.5 DBP500 e15.5, e17.5, 
e19.5, e21.5 
5 e16.5 - - AZC5 e17.5, e19.5 
10 e16.5 - - AZC10 e17.5, e19.5 
10 e16.5 500 e13.5-e20.5 AZC+DBP e17.5, e19.5 
 
Testes from control and AZC±DBP exposed animals were dissected out (Section 2.3-
2.3.4) and were either fixed in Bouin’s and processed for immunohistochemical 
analysis, or stored at -80C for RNA analysis or bisulphite sequencing (Section 
2.10).   
5.2.2 Immunohistochemical (IHC) analysis 
Briefly, IHC staining (Section 2.6) was performed on processed and sectioned fetal 
testes as summarised in Table 5.2. The number of fetal testes used for IHC was a 
minimum of 5 testes in each age and treatment group and came from a minimum of 




Table 5.2 Details of antibodies used in Chapter 5. 
Antibody Source Retrieval Species 
DAZL AbD Serotec Yes Mouse 
DMRT1 
Gift from David 
Zarkower, MN 
Yes Rabbit 
DNMT1 Abcam, Cambridge Yes Rabbit 
DNMT3A Abcam, Cambridge Yes Rabbit 
DNMT3L Abcam, Cambridge Yes Rabbit 
OCT4 Santa Cruz, CA Yes Goat 
VASA Abcam, Cambridge Yes Rabbit 
5MeC 
 




In addition to standard single IHC, several IHC analyses were performed to calculate 
the percentage of OCT4 or DMRT1 expressing GCs (Section 2.8.4). Specialised IHC 
for 5-methyl cytidine (Section 2.6.6.1) and TUNEL for apoptotic cells (Section 
2.6.12) was also performed in Chapter 5.   
5.2.3 Bisulphite sequencing 
To investigate the methylation status of the Oct4 gene promoter and proximal 
enhancer in the fetal rat testis, whole testis DNA from 3x pooled (3-4) e15.5 control 
testes and 3x e19.5 control testes was isolated (Section 2.10.1) and converted by 
bisulphite treatment (Section 2.10.3) to alter the DNA sequence to allow methylation 
status of CpGs to be identified. The converted DNA was amplified (Section 2.10.4), 
sequenced and analysed for three regions of the Oct4 gene promoter and proximal 
enhancer (Section 2.10.5).    
5.2.4 GC sorting by MACS 
To isolate GC DNA from whole rat testes, Magnetic-activated cell sorting (MACS) 
using a GC-specific cell surface antigen was performed (Section 2.4). Briefly, testes 
from postnatal day (D)0 were physically and enzymatically digested to produce a 
single cell suspension (Section 2.4.1), that was incubated with 2μg Anti-SSEA 
antibody (Abcam, ab16285) and prepared magnetic Dynabeads (Section 2.4.2). A 
magnet was then used to isolate the Dynabeads with attached GCs (Section 2.4.3). 
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Isolated cell fractions (Bound, Unbound and Unsorted) were then stored at -80C for 
RNA or DNA analysis.   
 
5.2.5 RNA analysis 
Briefly, RNA isolated from frozen testes was converted into cDNA (Section 2.11.2) 
and Taqman quantitative RT-PCR performed (Section 2.11.5), to establish 
quantitative mRNA expression levels. The genes investigated, and primers used, are 
listed in Table 5.3. 














Forward Primer  
5’  3’ 
Reverse Primer 












Dazl GCTCAGTTCATGATGCTGCT ATGCTTCGGTCCACAGATTT 110 
Dmnt1 CGATGACGATGAAAAGGACA GTCTCCGTTTGGTGGCTAGA 26 
Dmnt3A AACGGAAGCGGGATGAGT TGCAATCACCTTGGCTTTCT 75 










5.3.1 Global germ cell methylation 
Studies in the mouse have shown that when germ cells (GC) arrive in the gonad, they 
have undergone global demethylation to provide a “blank epigenetic slate”. The GCs 
then undergo establishment of new methylation patterns and genomic imprinting that 
is not complete until postnatal meiosis in the testis (Oakes et al., 2007b). To examine 
if similar demethylation and gradual remethylation occurs in the fetal rat testis, 
examination of the global methylation state of the GC genome during testis 
development was performed. Immunohistochemical (IHC) staining for 5-methyl 
cytidine (5MeC) was performed as described in Section 2.6.6.1, on testis sections 
from fetal rats during the last week of fetal life and the results are shown in Fig 5.1. 
Testes from both control and DBP exposed fetal rats were examined to see if DBP 
exposure altered global GC methylation. 
 
The amount of staining for 5MeC in the nuclei gives a simple visualization of the 
degree of methylation of CpG dinucleotides in the genome of a cell. At embryonic 
day (e)15.5 and e17.5, the GCs showed noticeably less 5MeC staining than 
surrounding somatic cells, as highlighted in Fig 5.1A. This difference in 5MeC 
staining showed that at these ages GCs are globally demethylated in comparison to 
the somatic cells of the testis. Later in fetal life, GC nuclear staining for 5MeC 
increased until at e21.5, when GC nuclei appeared comparable to somatic nuclei.  
 
This pattern of 5MeC staining showed the increasing level of methylation in the 
whole GC genome that occurred during GC development, as germ-line epigenetic 
imprinting patterns are being established and GC differentiation occurs. This pattern 
of 5MeC staining was unaffected by DBP exposure (Fig 5.1), suggesting that DBP 





Figure 5.1 Representative photomicrographs of immunostaining for 5MeC (Dab = 
brown) in fetal rat testes from control (left) and DBP500 exposed animals (right) 
animals from e15.5 (top) through to e21.5 (bottom). Scale bar in panel A represents 




5.3.1.1 Methylation maintenance by DNMT1 
Having established that the global methylation state of GCs increased during the last 
week of fetal life in the rat and that it was unaffected by DBP exposure, the 
expression levels of some of the enzymes involved in DNA methylation were then 
examined. DNA methyl transferase 1 (DNMT1) is the methyl transferase that is 
reported to perform the methylation of the newly synthesized hemi-methylated DNA 
strand during DNA replication and as such is responsible for maintaining DNA 
methylation patterns in the daughter cells after each mitotic replication, discussed in 
Section 1.4.4. IHC staining for DNMT1 showed protein expression in both somatic 
and GCs, but this was highly variable and unaltered by DBP exposure (data not 
shown). Dnmt1 mRNA levels were examined by Taqman analysis, as described in 











































Figure 5.2 Quantitative analysis of Dnmt1 mRNA levels at e15.5, e17.5, e19.5 and 
e21.5 in fetal rat testes. (n=6 for e15.5 and e17.5 testes, n=5 for e19.5 testes, n=4 
for e21.5 control testes and n=6 for e21.5 DBP exposed testis). Values are means  
SEM. Student’s unpaired t test was performed, * P<0.05 between control and 
DBP500 testes.  
 
 
Dnmt1 expression increased during the last week of fetal life in the testis and 
consistently showed a higher level of expression than in the adult testis. DBP 




As DNMT1 protein is detected in both soma and GCs and fulfils an essential role in 
maintaining methylation patterns during cellular replication, the DBP exposure effect 
at e21.5 is interesting. If Dnmt1 is solely involved in methylation maintenance during 
DNA replication, the increased expression of Dnmt1 after e19.5 (when no GCs are 
proliferating, Fig 3.5) may be due to the increase rise in somatic replication (Scott et 
al., 2008) and Fig 4.2), which is also altered by DBP exposure and which may 
explain the significant difference between control and DBP exposed testes at e21.5.    
 
5.3.1.2 De Novo Methylation by DNMT3A and DNMT3L 
De Novo methylation is the establishment of new methylation patterns on 
unmethylated DNA and is an important process in fetal GC development, as 
described in Sections 1.4.2-1.4.4. De novo methylation is thought to occur by the 
action of the DNMT3 family of DNMT3A, 3B and the non-catalytic 3L, with 
DNMT3A and 3L thought to be the most important in fetal GC methylation in the 
mouse (La Salle and Trasler, 2006). IHC staining was performed for DMNT3A on 
testes from both control and DBP exposed animals during the last week of fetal life, 




Figure 5.3 Representative photomicrographs of immunostaining for DNMT3A (Dab = 
brown) in fetal rat testis from control (left) and DBP500 exposed animals (right) from 




IHC staining for DMNT3A on fetal rat sections showed expression is not confined to 
the nuclei of cells as might be expected for a DNA methyl transferase. DNMT3A 
staining was more highly detected in GCs and increased during GC development. In 
testes from DBP exposed animals, the expression of DNMT3A was unaltered until 
e21.5 when a slight reduction in staining was detected. This possible DBP effect on 
GC DNMT3A could not be quantified. Dmnt3A mRNA expression was then 









































Figure 5.4 Quantitative analysis of Dnmt3A mRNA levels at e15.5, e17.5, e19.5 and 
e21.5 in fetal rat testes, (n=6 for each age and treatment). Values are means  SEM. 
Student’s unpaired t test was performed, ** P<0.01 between e21.5 Control and 
DBP500 testes. 
 
As with Dnmt1, mRNA levels for Dnmt3A were much higher than in the adult testis 
and were unaltered by DBP exposure until e21.5, when a significant reduction of 
expression occurred. 
 
DNMT3L is a non-catalytic member of the DNMT3 family that is thought to be 
involved in the regulation of DNMT3A and 3B activity (La Salle et al., 2004; La 
Salle and Trasler, 2006). Previous studies in the mouse have highlighted that 
DNMT3A and 3L are highly expressed in the testis and stimulate de novo 
methylation in vitro (Chedin et al., 2002). IHC staining for DNMT3L was examined 




Figure 5.5 Representative photomicrographs of immunostaining for DNMT3L (Dab = 
brown) in fetal rat testis from control (left) and DBP500 exposed animals (right) from 
e15.5 (top) through to e21.5 (bottom). Scale bar in panel A represents 50µm. White 





DNMT3L expression varied during the last week of fetal life. At e15.5 and e17.5, 
DNMT3L was detected as one or two punctate dots within the nuclei of both somatic 
cells and GCs (highlighted in Fig 5.5 A). At e19.5, DMNT3L staining became more 
diffuse throughout the nuclei of the cells and by e21.5 DNMT3L expression was 
barely detectable in testes from control and DBP exposed animals. Dnmt3L mRNA 
expression levels were then investigated by Taqman to see if a similar expression 








































Figure 5.6 Quantitative analysis of Dnmt3L mRNA levels at e15.5, e17.5, e19.5 and 
e21.5 in fetal rat testes (n=6 for age and treatment). Values are means  SEM.  
 
 
Dnmt3L mRNA expression showed an increase over time in the fetal testis, in 
opposition to the IHC detection of the protein. Thus, at e21.5 mRNA was highly 
expressed but the protein was barely detectable. DBP exposure had no significant 
effect on Dnmt3L mRNA expression.  
 
5.3.1.3 Regulation of imprinting sites by BORIS  
Brother Of the Regulator of Imprinted Sites (BORIS) is a gene associated with both 
cancer and the testis in the mouse, in which it is involved in regulating imprinting 
sites in the fetal GCs and primary spermatocytes (Klenova et al., 2002; Loukinov et 
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al., 2002). BORIS binds to imprinting control regions, such as Igf2/H19, during male 
fetal GC development in the mouse and regulates histone modifications (Jelinic et 
al., 2006). To investigate the role of BORIS in the fetal rat testis, IHC staining was 
attempted for BORIS expression but was unsuccessful (data not shown). Boris 
mRNA analysis by Taqman was then investigated and is shown in Fig 5.7. This 
epigenetic imprinting regulator was highly expressed in the developing rat testis in 








































Figure 5.7 Quantitative analysis of Boris mRNA levels at e15.5, e17.5, e19.5 and 
e21.5 in fetal rat testes, (n=6 for each age and treatment). Values are means  SEM.  
 
5.3.2 Methylation inhibition by AZC with and without DBP 
Having established how global methylation of GCs increased during fetal rat testis 
development and that this process was seemingly unaffected by DBP exposure, 
methylation inhibition was investigated to see if could disrupt GC development in a 
similar manner to DBP. The chemical methylation inhibitor 5-aza-2’deoxycytidine 
(AZC) was investigated using a single I.P. injection in the pregnant female rat at 
e16.5, as described in Section 2.2. Methylation inhibition by AZC is due to both 
direct inhibition of the DNA methyl transferases and through incorporation into 
DNA during replication as a modified cytidine that cannot itself become methylated. 
Injection at e16.5 with AZC was selected as a time when GCs are proliferating and 
before OCT4 expression begins to be lost (Figs 3.4, 3.5 and 3.6), so that AZC can 
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become incorporated into some GC genomes during replication and result in CpGs in 
the OCT4 promoter that cannot be methylated, so that OCT4 would continue to be 
expressed into the adult. A single dose was used to minimize the side effects of 
inhibiting methylation throughout the whole developing fetus. Two different doses of 
AZC alone (5mg/kg and 10mg/kg) were examined for GC effects, and the AZC 10 
dose was also combined with DBP to see if methylation inhibition altered DBP 
effects. Methylation inhibition by AZC alone or with DBP unfortunately proved to 
be fatal, with no offspring from treated females surviving to e21.5.  
 
However the effects on fetal GC development could still be investigated at e17.5 and 
e19.5, to provide some insight into the role of methylation in fetal rat GC 
development. An examination of some broad aspects of the fetal testis was 
performed by IHC to examine if methylation inhibition by AZC completely 
dysregulated the fetal testis, these are summarized in Table 5.4.  
 
Table 5.4 Summary of methylation inhibition by AZC  DBP on some aspects of 
testis development.  
Treatment
AZC5 AZC10 AZC+DBP
AMH No change No change No change 
VASA No change No change No change 
DAZL No change No change No change 
GC Proliferation No change No change Same as DBP alone
GC TUNEL No change No change No change  
 
 
Global methylation in the fetal rat testes of the different maternal treatments was then 




Figure 5.8 Representative photomicrographs of immunostaining for 5MeC (Dab = 
brown) in e17.5 (left) and e19.5 (right) fetal rat testes from control (A and B), AZC5 
exposed (C and D), AZC10 exposed (E and F) and AZC+DBP exposed (G and H). 




In the testes of AZC  DBP exposed animals, 5MeC staining was still present in the 
somatic cells of the testis and reduced in the GCs at both e17.5 and e19.5. This 
illustrated that methylation inhibition by AZC does not remove existing methylation 
in the somatic cells but does reduce global remethylation in the GCs at e19.5. 
 
5.3.2.1 Effect of methylation inhibition by AZC on OCT4 expression   
As the aim of the methylation inhibition study was to see if OCT4 expression could 
be altered by preventing methylation during GC development, examination of OCT4 
protein by IHC was performed at e17.5 and e19.5 in testes from AZCDBP exposed 
animals. In e17.5 testes from AZC  DBP exposed animals, the percentage of OCT4 
positive GCs was counted, as described in Section 2.8.4, and shown in Fig 5.9.  






























Figure 5.9 Percentage of OCT4 positive germ cells at e17.5 in testes from control 
(n=7), DBP500 (n=7), AZC5 (n=4), AZC10 (n=4) and AZC+DBP (n=4) treatment 
groups. Values are means  SEM. Student’s unpaired t test was performed, ** 
P<0.01 and *** P<0.001 between treatment and control. 
 
 
Methylation inhibition at e16.5 by either dose of AZC caused a significant increase 
in the percentage of OCT4+ GCs at e17.5 compared to controls, with AZC5 
treatment causing a slightly more significantly difference than AZC10. When AZC 
was combined with DBP exposure there resulted in a higher percentage of OCT4+ 
GCs than with DBP exposure alone. Importantly, the treatments were not 
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significantly different from each other, only when compared with control testes. It 
should also be noted that AZC did not cause the expression of OCT4 in non GCs.  
 
To examine if the observed increase in OCT4+ GCs at e17.5 was due to prevention 
of promoter silencing and increased mRNA expression levels for Oct4, Taqman 











































Figure 5.10 Quantitative analysis of Oct4 mRNA levels in testes at e17.5 and e19.5 
for Control (n=6 both ages), DBP500 (n=6 both ages), AZC5 (n=6 at e17.5, n=3 at 
e19.5), AZC10(n=3 at e17.5, n=6 at e19.5) and AZC+DBP(n=1 at e17.5, n=5 at 
e19.5) treatment groups. Values are means  SEM. No significant differences within 
each age group. 
 
 
In e17.5 testes, Oct4 mRNA levels were unaltered by either AZC dose or when 
combined with DBP. In the e19.5 testes, Oct4 mRNA levels had reduced noticeably 
from e17.5 levels, even with methylation inhibition by AZC treatment. This suggests 
that inhibiting methylation at e16.5 does not prevent Oct4 promoter methylation, 
however a slight increase in Oct4 mRNA can be seen. 
 
Having examined OCT4 expression at e17.5, it was also examined if AZC-induced 
methylation inhibition allowed GCs to continue to express OCT4 after e17.5 by 
examining e19.5 testes for OCT4 expression by IHC. OCT4+ GCs were detected in 1 
of 6 testes from AZC10 treated mothers, and in 1 of 5 testes from fetal rats exposed 
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to AZC+DBP, as shown in Fig 5.11. This expression was not present in every section 
of testis examined from the affected animals, suggesting that AZC exposure may 
delay the loss of OCT4 expression for longer than DBP, but did not prevent it.  
   
 
Figure 5.11 Photomicrographs of immunostaining for OCT4 (Fast blue = blue) in 
e19.5 fetal testes from AZC10 and AZC+DBP treated groups (A and B). Scale bar in 
panel A represents 50µm. Insert in panel B is a negative control for OCT4. 
 
 
5.3.2.2 Methylation inhibition by AZC on DMRT1 expression 
As described in Section 3.3.10, loss of DMRT1 expression in GCs is an event of GC 
differentiation that occurs around e19.5. To investigate if methylation inhibition by 
AZC altered DMRT1 expression in a similar way to OCT4, the loss of DMRT1 
protein was examined by IHC at e19.5. The percentage of DMRT1+ GCs was 
calculated by examination of double IHC for VASA and DMRT1 in testes from 
animals exposed to AZCDBP and is shown in Fig 5.12. 
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Figure 5.12 Percentage of DMRT1 positive germ cells at e19.5 in fetal testes from 
Control (n=3), DBP500 (n=4), AZC5 (n=3), AZC10 (n=9) and AZC+DBP (n=6) 
treatment groups. Values are means  SEM. Student’s unpaired t test was 
performed, * P<0.05 between treated and control. 
 
 
In contrast to increased OCT4 expression in the GCs at e17.5, AZC exposure alone 
had no effect on the percentage of DMRT1+ GCs at e19.5 and when AZC was 
combined with DBP it showed a lesser effect than did DBP alone. This suggested 
that methylation inhibition by AZC at e16.5 has no effect on GC specific DMRT1 
expression by e19.5. 
 
5.3.3 Bisulphite sequencing of the OCT4 promoter 
Having examined global methylation and methylation inhibition, gene specific 
methylation was then investigated. During the course of this thesis, Oct4 expression 
has been of great interest as a gene that marks human CIS and is altered by DBP 
exposure in the rat, and therefore Oct4 was chosen for promoter methylation 
investigation. In both human and mouse ES cells and iPS cells the Oct4 gene is 
regulated by methylation of CpGs in the promoter region (Ben-Shushan et al., 1993; 
Takahashi et al., 2007; Yeo et al., 2007). To examine if Oct4 expression in the fetal 
rat testis is regulated by methylation of the Oct4 promoter, three regions of the Oct4 
promoter were examined by bisulphite sequencing to identify the methylation states 
of individual CpGs in these regions. The regions were selected due to the reported 
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importance of methylation in the regulatory regions of the promoter and proximal 
enhancer of the mouse and human Oct4 gene (Deb-Rinker et al., 2005; Freberg et al., 
2007; Hattori et al., 2004). To examine how methylation patterns might change 
during fetal GC development two different ages were used to extract whole testis 
DNA. These ages were chosen as times when OCT4 protein was expressed in all 
GCs at e15.5 and when OCT4 protein is not expressed in any GC at e19.5. The 
hypothesis was that at e15.5 the CpGs of the regulatory regions of the Oct4 gene 
would be unmethylated as OCT4 is expressed, and that by e19.5 the CpGs will have 
become methylated as Oct4 expression becomes silenced. Bisulphite sequencing was 
performed on the three regulatory regions and fetal ages, as described in Section 




Figure 5.13 Summary of methylation status of CpGs for three regulatory regions of 
the rat Oct4 gene at e15.5 and e19.5. (n=3 for each age) 
 
 
At all the CpGs examined, they were methylated at e15.5 and remain methylated at 
e19.5. This is most likely due to the fact that the analysis used whole testis DNA and 
not isolated GC DNA. This means that the methylation of Oct4 promoters in somatic 
cells is also being detected and any methylation change in GC DNA may be diluted 
out by somatic DNA and so undetected by sequencing.  
 
As use of whole testis DNA for Oct4 promoter methylation analysis was 
confounding, there was an attempt to isolate GCs from the whole testis and then 
perform bisulphite sequencing. Isolation of postnatal day (D)0 GCs by MACS and 
GC surface protein SSEA1, as described in Section 2.4, produced three fractions that 
were analysed for GC content. The three fractions were an Unsorted fraction (US) of 
testicular cells that were not incubated with anti-SSEA1, a Bound fraction (B) that 
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should contain only those cells that anti-SSEA1 and magnetic beads bound to and an 
Unbound fraction (UB) of those cells that did not bind anti-SSEA1. The aim of the 
MACS sorting was to produce a relatively pure GC population in the Bound fraction. 
To determine the content of each fraction, Taqman mRNA analysis for a GC gene 
(Dazl), a Sertoli cell gene (Amh) and a Leydig cell gene (3β hsd) was performed and 






















































































































Figure 5.14 Quantitative analysis of mRNA levels in the three fractions produced by 
MACS of D2 testis (n=1). A shows relative Dazl mRNA levels, B shows Amh mRNA 
levels and C shows relative Hsd 3β levels. 
 
 
This attempt at MACS to isolate GCs did not produce a pure GC population and only 
enriched GC content, as both Amh and 3β hsd mRNA were detected in the bead 
bound fraction. This technique was therefore of limited use, as whole litters of fetal 
rats would be required to produce sufficient cells for sorting and it did not succeed in 
isolating GCs. Therefore it was decided not to pursue GC isolation and bisulphite 
sequencing any further in the fetal rat. 
 
5.4 Discussion 
The aim of this chapter was to investigate fetal GC DNA methylation during the last 
week of fetal life in the rat, especially as a mechanism that could be disrupted by 
DBP exposure. To that end three different approaches were used to investigate DNA 
methylation in fetal GCs; global methylation changes during the last week of fetal 
life, the effect of a chemical methylation inhibition on GC differentiation, and 
specific promoter analysis of a candidate gene.   
 
The first approach was to examine the events of DNA methylation in fetal rat GCs in 
testes from control and DBP exposed testes. As in the mouse, migrating primordial 
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GCs lost their global DNA methylation in the rat, so that by e15.5 they appear un-
methylated in comparison to somatic cell nuclei, as visualized by IHC staining for 
5MeC. This IHC staining for methylated cytosine residues increased during the last 
week of fetal life, so that by e21.5 the nuclei of GC stained to the same degree as did 
the surrounding somatic cell nuclei. This time window of DNA methylation 
corresponds with the DBP exposure window used to generate the rat model for TDS, 
as described in detail in Chapter 4. However, the process of global GC remethylation 
was unaffected by DBP exposure based on staining for 5MeC. This loss and 
reacquisition of fetal GC methylation patterns is involved in the process of epigenetic 
imprinting, discussed in Section 1.4.2, and assuming the rat is similar to mouse 
(Oakes et al., 2007b), this process is not completed until spermatogenic meiosis. 
Failures in correct epigenetic imprinting often cause sub-fertility (Hammoud et al., 
2009), like that reported with DBP exposure in rats (Fisher et al., 2003). So, while 
DBP exposure in fetal rat testes may not be altering global DNA methylation, it may 
be affecting the epigenetic imprinting. It should be noted that if DBP exposure was 
inducing a delay in remethylation, as is most likely given the evidence in Chapter 4, 
it would be unlikely to be observable by 5MeC staining, unless the delay was severe.   
 
IHC for 5MeC is a very simple measurement of global DNA methylation level and is 
not informative about single gene methylation or more subtle changes in DNA 
methylation patterns. To further investigate the normal pattern of fetal GC DNA 
methylation, the expression of DNA methyl transferases (DNMTs) was examined.    
 
The methylation maintenance enzyme DNMT1 was found to be expressed in every 
cell of the fetal rat testis, as would be expected from its crucial role in maintaining 
methylation in hemi-methylated DNA during cell division. IHC staining for DNMT1 
was very variable, but showed no change in testes from DBP exposed animals. When 
Dnmt1 mRNA levels were examined, expression noticeably increased at e19.5 and 
showed a significant reduction with DBP exposure at e21.5. This mRNA expression 
pattern is in line with the increase in somatic replication in the testis from e19.5 
onwards. DBP exposure significantly reduced numbers of both Sertoli cells (Scott et 
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al., 2008) and GCs (Fig 4.1), which may explain this reduction in Dnmt1 mRNA per 
testis. 
 
Of more interest in fetal GC DNA methylation is de novo methylation, the 
acquisition of new methylation patterns, by the DNMT3 family (Okano et al., 1999; 
Suetake et al., 2004). The protein expression of DNMT3A by IHC was more highly 
detected in GCs and its expression increased over time. However, DNMT3A 
expression was not confined to the nuclei, as would be expected of a DNA methyl 
transferase, which may imply that localization to the nuclei is a factor in the 
regulation of de novo methylation by DNMT3A. When Dnmt3A mRNA expression 
was examined, the level of expression was fairly constant throughout fetal life, so 
that both protein and mRNA support the reported role of DNMT3A in de novo 
methylation that is occurring in the GCs during this time (Chedin et al., 2002; 
Suetake et al., 2004). DBP exposure only significantly reduced Dnmt3A expression 
at e21.5, which may be as a consequence of reduced GC number in the testes of DBP 
exposed animals at e21.5, or that at e21.5 GCs from DBP exposed animals are 
expressing less Dnmt3A. This reduction is more likely a GC only effect than that 
observed with Dnmt1, as DNMT3A protein was barely detectable in somatic cells.  
 
DNMT3L is a non-catalytic member of the DNMT3 family, and is reported to be 
involved in the regulation of de novo methylation, even stimulating DNMT3A 
activity in vitro (Chedin et al., 2002). IHC staining identified that DNMT3L 
expression occurred as punctate dots in both GCs and somatic cells of the testis at 
e15.5 and e17.5, which changed into more diffuse nuclear staining by e19.5 and 
became barely detectable by e21.5. In testes from DBP exposed animals at e21.5, 
there was slightly more DNMT3L protein detected. Whilst this DBP effect could not 
be quantified, it may follow the general pattern of delayed GC development with 
DBP exposure, discussed in detail in Chapter 4. Dnmt3L mRNA expression levels 
were also examined and showed an increase in expression during the last week of 
fetal life, in stark contrast to the IHC result. This could be due to failure of the anti-
DNMT3L antibody to detect the DNMT3L protein when it is bound to another 
member of the DNMT3 family, as such protein-protein interactions are how 
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DNMT3L may regulate de novo methylation (Jia et al., 2007). This explanation 
would tie in with the increased methylation (de novo) in GCs around e19.5 at the 
same time that DNMT3A expression was increasing in the GCs, as DNMT3A and 
3L become bound and de novo methylate the GC genome. Alternatively there may 
be an mRNA processing delay, so that the DNMT3L protein levels only increase 
after e21.5, as de novo methylation and imprinting continues postnatally until 
meiosis.     
 
The imprinting regulator, Boris, was also examined during the last week of fetal life 
in the rat. IHC for BORIS failed to work, but mRNA analysis was successful. The 
pattern of Boris mRNA expression showed a steady expression between e15.5-e19.5, 
and a small increase at e21.5. DBP exposure had no effect on Boris mRNA levels. In 
the mouse, Boris is expressed specifically in male GCs (Loukinov et al., 2002) and if 
it is GC-specific in the rat as well, the lack of DBP effect is interesting. The lack of 
an effect of DBP exposure on GC-specific Boris expression at e21.5 implies that the 
significant reduction at e21.5 observed with Dnmt1 and Dnmt3A is due to a DBP-
induced reduction in GC expression rather than a simple reduction in GC number. 
However, it is possible that the lack of reduction in Boris mRNA at e21.5 indicates 
that DBP exposure induced higher Boris expression in the fewer GCs present, though 
there is no other evidence to support this. Also of interest is that the mRNA 
expression levels of each Dnmt investigated and Boris were much higher than that of 
the adult testis control (used as the reference standard), highlighting the importance 
of DNA methylation in the fetal rat testis, and in particular the role of the DNMT3 
family in de novo methylation.  
 
In summarising the first approach, the effects of DBP exposure on fetal GC DNA 
methylation were limited, as global methylation was unaltered. However, as DBP 
exposure delays several aspects of GC development, discussed in Chapter 4, and 
significantly reduced the mRNA expression of Dnmt1 and Dnmt3A expression at 
e21.5, it is still possible that there are effects on GC DNA methylation/imprinting 




The next approach was to use the chemical methylation inhibitor 5-aza-
2’deoxycytidine (AZC, two doses of 5mg/kg and 10mg/kg), to see if inhibiting 
methylation altered GC development similar to that of DBP exposure. AZC 
(10mg/kg) exposure was also combined with DBP exposure between e13.5-e21.5, to 
see how methylation inhibition affected the established effects of DBP exposure on 
fetal GCs in the rat. Unfortunately, AZC exposure proved to be lethal to the fetus by 
e21.5 limiting the study of methylation inhibition to the ages of e17.5 and e19.5. At 
both these ages, the AZC exposed testes remained grossly normal (displaying 
continued proliferation and most of the correct cell-specific protein expression was 
retained). The detection of 5MeC by IHC showed that GCs in AZC±DBP exposed 
rats were relatively unmethylated compared to somatic cells and untreated controls, 
illustrating that normal global methylation had been maintained in the soma whilst 
methylation had been successfully inhibited in the GCs. 
 
At e17.5, AZC±DBP exposure significantly increased the percentage of OCT4+ GCs 
in the fetal rat testis, but by e19.5 only rare GCs still expressed OCT4 and the mRNA 
level still reduced normally at e19.5. This suggests that AZC exposure delayed the 
loss of OCT4 expression in GCs but did not prevent it, similar to that observed with 
DBP exposure alone. When DMRT1 expression was examined at e19.5, AZC 
exposure did not increase the percentage of DMRT1+ GCs, in contrast to DBP 
exposure. This suggests that either Dmrt1 does not become methylated or that the 
methylation inhibition is gone by the time GC-specific Dmrt1 gene silencing is 
occurring. These results suggest that AZC exposure is most probably only inhibiting 
the DNMT enzymes and has not become incorporated into GC DNA. This transient 
inhibition would explain why OCT4 expression was affected, whilst DMRT1 was 
not (the inhibitory AZC having been cleared by e19.5). This also matches reports of 
AZC preferentially inhibiting DNMTs rather than becoming incorporated into DNA 
(Oakes et al., 2007b).  
 
In summary, these studies into chemical methylation inhibition were originally 
conceived to produce a subset of GCs with Oct4 promoters that could not become 
methylated, such that OCT4 expression would continue into adulthood. The failure 
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of AZC to become incorporated into the GC genome, and the rare number of OCT4+ 
GCs detected at e19.5, combined with the fetal mortality suggest that this method of 
inducing OCT4+ (CIS) cells in the rat is not a viable option. Whilst lower doses and 
different timings of AZC exposure may have a stronger effect on OCT4/DMRT1 
expression, they would likely still prove to be lethal to the rat fetus. 
 
The final approach to examine fetal GC methylation was gene-specific examination 
of the Oct4 promoter. Three candidate regions of the Oct4 promoter were examined 
by bisulphite sequencing for CpG methylation of whole testis DNA. It was hoped 
that with the relatively high GC content in an e15.5 testis combined with the fact that 
OCT4 is expressed in every GC at that age, a change in DNA methylation could be 
detected. And if any CpGs were unmethylated at e15.5, they would become 
methylated by e19.5 (when no GCs express OCT4), allowing this change to be 
investigated with regard to DBP exposure. Unfortunately, at both e15.5 and e19.5 all 
the CpGs investigated by bisulphite sequencing were fully methylated. This is most 
likely due to the somatic DNA present in the whole testis DNA used for sequencing, 
so that any subtle differences in DNA methylation in GC would be undetectable.  
 
However, there are other possibilities for a lack of difference in CpG methylation 
between e15.5 and e19.5. It is possible that the wrong regions of the Oct4 promoter 
were examined and that those chosen are not involved in methylation/gene silencing,  
even though in both human and mouse, methylation of the Oct4 promoter and 
proximal enhancer regions regulates expression (Deb-Rinker et al., 2005; Freberg et 
al., 2007; Hattori et al., 2004). Alternatively, methylation of the Oct4 promoter is not 
as important in the rat as it is in the mouse. A further alternative is that in the testis a 
different method of Oct4 silencing occurs, due to a lack of retinoic acid induced 
silencing, as mentioned in Section 3.4 (Bowles and Koopman, 2007; Li et al., 2007). 
Furthermore, whilst methylation is important in Oct4 expression in embryonic stem 
cells and induced pluripotency cells (Ben-Shushan et al., 1993; Takahashi et al., 




As the presence of somatic DNA is the most likely reason for the result of Oct4 
promoter analysis and to attempt to remove this confounding factor, cell sorting to 
produce a pure GC population for bisulphite sequencing was attempted. However, 
the MACS protocol attempted was nowhere near good enough to commit the animal 
numbers required for robust analysis and could not be optimized during the course of 
this thesis. This is highly regrettable as the ability to isolate fetal rat GCs from a 
whole testis would allow a thorough investigation of both DBP exposure effects on 
GCs and how fetal GC DNA methylation occurs.  
 
In conclusion, DBP does not alter global methylation of GCs in the rat, but does 
affect DNMTs and may have more subtle effects on imprinting sites that the 
techniques used were unable to detect. Methylation inhibition can prolong OCT4 
protein expression in GCs, (but it is eventually removed) and causes fetal lethality. 
Bisulphite sequencing identified no changes in the Oct4 promoter regions 
investigated for the whole testis, but could not be attempted on isolated GCs. 
Therefore, while the DBP exposure effects reported in Chapter 4 are not causing (or 
caused by) global DNA methylation changes, there may be gene-specific methylation 
delays and/or more subtle changes that could not be identified. 
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6 Studies on in vitro manipulation of fetal testis explants  
 
6.1 Introduction 
The process of fetal germ cell (GC) development in the rat and how that process can 
be disrupted by in utero exposure to Di (n-Butyl) Phthalate (DBP) has been 
discussed in Chapters 3 and 4. However the reported effects of in utero DBP 
exposure on the fetal rat testis are confounded by both the maternal and fetal 
metabolism and endocrinology, such that the direct action of phthalate exposure on 
the fetal testis alone is unknown. To investigate this further, several studies have 
isolated the fetal rat testis which has then been cultured in vitro with one or other 
presumptive active phthalate metabolites (Chauvigne et al., 2009; Hallmark et al., 
2007; Li and Kim, 2003).  
 
Previous in vitro culturing with the active metabolite of DBP, monobutyl phthalate 
(MBP) has been attempted on fetal rat testis from e19.5-21.5, but MBP treatment 
failed to match the steroidogenic suppressing effects observed with in vivo DBP 
exposure (Hallmark et al., 2007; Mahood et al., 2005). However that study was not 
focused on GC effects. In other phthalate in vitro studies, the use of testes from 
younger (e14.5) animals in in vitro culture has shown effects on GCs (Li and Kim, 
2003; Livera et al., 2006). Therefore the utility of e14.5 fetal rat testis for in vitro 
manipulation with MBP was investigated for early phthalate effects on GCs and to 
complement the previously described in vivo DBP exposure experiments on GCs. 
 
A further advantage of in vitro studies of fetal rat testis is that chemical treatments 
that are lethal or that severely damage wider aspects of embryogenesis in vivo can be 
used directly on the fetal testis. To take advantage of this, cyclopamine (Cyc) was 
used to bind and block SMO protein action treatment to block Hedgehog signalling, 
which is important in the mouse testis for Leydig cell differentiation and cord 
formation, as described in Section 1.2.3.3, was also investigated in e14.5 fetal rat 
testis explants.  
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6.2 Materials and methods 
6.2.1 In vitro culture 
Briefly, testes and mesonephros were removed from e14.5 fetuses collected from 
untreated dams (Section 2.3), and were then cultured for 48-72 hours (Section 2.5) 
with; either no treatment, with MBP (10-3M) or DMSO control, or with cyclopamine 
(25µM) or ethanol control (Section 2.5.5). Half of the culture media was removed 
every 24 hours and replaced with fresh media and treatment. Then, 45 minutes to 1 
hour before the end of culture time, culture media was replaced with media 
containing BrdU to enable cell proliferation analysis (Section 2.8.3). All media 
collected was stored at -80oC for testosterone analysis. 
At the end of the in vitro culture time, testis explants were either frozen or fixed 
(Section 2.3.5). Frozen testis explants were then homogenised and RNA extracted 
(Section 2.11.1) for Taqman quantitative RT-PCR (Section 2.11.3). Fixed testis 
explants were processed (Section 2.3.6) and sectioned (Section 2.6.2) for IHC 
analysis. 
6.2.2 Immunohistochemical (IHC) analysis 
Briefly, IHC staining was performed on processed and sectioned testis explants as 
summarised in Table 6.1. The number of testis explants used for IHC was a 
minimum of 6 testis explants in each treatment group and came from a minimum of 
three different culture experiments. 
 
Additional IHC analyses were performed to calculate the GC proliferation index 
(Section 2.8.3) and the percentage of GCs expressing OCT4 (Section 2.8.4). Cell 
apoptosis was also examined using the modified IHC staining protocol for TUNEL 








Table 6.1 Details of antibodies used in Chapter 6. 
Antibody Source Retrieval Species 
AMH  Santa Cruz, CA No Goat 
BrdU Fitzgerald industries, 
MA 
Yes Sheep 
CYP11A Chemicon No Rabbit 
DAZL AbD Serotec Yes Mouse 
DMRT1 
Gift from David 
Zarkower, MN 
Yes Rabbit 
OCT4 Santa Cruz, CA Yes Goat 
PTCH1 Abcam, Cambridge Yes Rabbit 
PTCH1 Santa Cruz, CA Yes Goat 




6.2.3 RNA analysis 
Briefly, RNA isolated from frozen testis explants was converted into cDNA (Section 
2.11.2) and Taqman quantitative RT-PCR performed (Section 2.11.5), to establish 
quantitative mRNA expression levels. The genes investigated, and primers used, are 
listed in Table 6.2. 
Table 6.2 Taqman primers and Universal Probe Library probes used in Chapter 6.  
Gene  
Forward Primer  
5’  3’ 
Reverse Primer 






















6.3.1 Untreated in vitro testis explant culture  
In order to investigate the viability of this in vitro culture system, an untreated 48 
hour in vitro culture period was performed to examine if e14.5 testis explants could 
be cultured for that length of time and the testis develop reasonably normally under 
these conditions. Immunohistochemical (IHC) analysis of untreated testis explants 
was performed and compared to fetal rat testes collected at e16.5 to provide an in 
vivo comparison. The core developmental processes of fetal testis development that 
were examined in these untreated testes were; GC proliferation by double IHC 
staining for DAZL and BrdU, GC differentiation by double IHC for DAZL and 
OCT4, seminiferous cord structure by double IHC for DAZL and AMH and Leydig 
cell function by IHC staining for 3β HSD. These IHC examinations are summarized 
in Fig 6.1.  
 
Testis explants cultured for 48 hours showed reasonably comparable development to 
in vivo e16.5 testes, though development was clearly not as good as in vivo. 
Untreated testis explants contained cells that continued to proliferate (both GCs and 
somatic cells), showed that normal GC differentiation occurred by the continued 
expression of OCT4, by the maintenance of seminiferous cord structure with Sertoli 
cells organized around the GCs, and Leydig cells continued to express the 
steroidogenic enzyme 3β HSD. This illustrated that after 48 hours of in vitro 
culturing, testis explants were still viable and did not degenerate and/or lose 
testicular organization. This supported the further use of in vitro testis explant 




Figure 6.1 Representative photomicrographs of IHC staining from e16.5 fetal rat 
testis (left) and 48 hour in vitro cultured rat testis explants (middle and right) and 
magnified for detail (right). Panels A shows IHC staining for DAZL (Dab = brown) 
and BrdU (Fast blue = blue), B-C show IHC staining for BrdU (Dab = brown) and 
DAZL (Fast blue = blue). D-F show IHC staining for OCT4 (Dab = brown) and DAZL 
(Fast blue = blue). G-I show IHC staining for DAZL (Dab = brown) and AMH (Fast 
blue = blue). J-L show IHC staining for 3β HSD (Dab = brown). Scale bars in Panels 
A and C represents 50 µm. 
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6.3.1.1 Apoptosis in untreated testis explants 
To examine if the level of apoptosis was increased in the untreated testis explants, 
TUNEL was performed as described in Section 2.6.12. The TUNEL IHC staining of 
48 hours untreated testis explants is illustrated in Fig 6.2. 
 
 
Figure 6.2 Representative photomicrographs of immunostaining for TUNEL in 48 
hour untreated fetal rat testis explants (Dab = brown). Black arrow depicts damage 
during dissection. Scale bars represent 50µm. 
 
 
There were a few TUNEL+ cells in the untreated testis explant after 48 hours of in 
vitro culture. There was increased TUNEL+ cells in areas where the testis has been 
damaged during extraction from the rat fetus, as highlighted in Fig 6.2A. This result 
indicated that the testis explant did not become obviously necrotic after 48 hours and 








6.3.2 In vitro MBP treatment of testis explants 
6.3.2.1 Effect of MBP treatment for 48 hours on GC development 
Having established the utility of the 48 hour cultures of fetal rat testis explants, the 
model was then investigated for chemical manipulation during the 48 hour culture 
period. The effects of DBP exposure on fetal GC development have been covered in 
Chapter 4, and it is believed that it is not DBP that acts in vivo, but rather the primary 
metabolite, MBP. Such in vitro investigations using MBP and MEHP have been 
attempted before, as described in Section 1.5.3.2. To investigate if MBP treatment of 
testis explants produced a similar effect to DBP exposure in vivo, e14.5 testis 
explants were cultured for 48 hours using the high (10-3M) concentration, as 
optimized by Nina Hallmark (Hallmark et al., 2007), with DMSO used as the vehicle 
control. As with the untreated 48 hour in vitro cultures, the testis explants were 
analysed by IHC for the core developmental processes of fetal testis development 
including - GC proliferation by double IHC staining for DAZL and BrdU, GC 
differentiation by double IHC for DAZL and OCT4 and seminiferous cord structure 






Figure 6.3 Representative photomicrographs of IHC staining from 48 hour in vitro 
cultured rat testis explants treated with DMSO (A-F) or MBP (G-L). Left-hand panels 
show IHC staining for BrdU (Dab = brown) and DAZL (Fast blue = blue). Middle 
panels show IHC staining for OCT4 (Dab = brown) and DAZL (Fast blue = blue). 
Right-hand panels show IHC staining for DAZL (Dab = brown) and AMH (Fast blue 
= blue). Scale bars in Panels A and D represent 50 µm. 
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As in the untreated testis explants, in vitro treatment with MBP or DMSO did not 
prevent GC proliferation, GC differentiation or organization into seminiferous cords. 
As GC number could not be calculated from testis explants, an MBP treatment effect 
on GC number, as occurs with in vivo DBP exposure (Section 4.3.1), could not be 
investigated. To investigate if in vitro MBP treatment altered GC proliferation as 
occurs after in vivo DBP exposure, the proliferation index for GCs was calculated as 
shown in Fig 6.4. 
 
 




















Figure 6.4 Germ cell proliferation index of fetal rat testis explants treated for 48 
hours with DMSO or MBP, (n=4). Values are means ± SEM. No statistically 
significant difference.  
 
 
48 hours of in vitro MBP treatment did not alter the GC proliferation index in testis 
explants in comparison to vehicle control. However, in vivo DBP exposure only 
caused effects on proliferation at e17.5, whilst these testis explants were comparable 
to e16.5 in vivo testes, so it may have been too early a time window for any effect to 
have been observed.  
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6.3.2.2 Effect of MBP treatment for 72 hours on GC development 
As in vivo DBP exposure had effects on GC development at e17.5, an extended 
culture and treatment time to 72 hours was used to investigate if MBP treatment 
prolonged OCT4 expression as did DBP exposure in vivo (Section 4.3.1.3). Double 
IHC staining for OCT4 and DAZL was performed on 72 hour cultured testis explants 
with either DMSO or MBP treatment, as shown in Fig 6.5. 
 
 
Figure 6.5 Representative photomicrographs of immunostaining for OCT4 (Dab = 
brown) and DAZL (Fast blue = blue) in 72 hour fetal rat testis explants treated with 
DMSO or MBP. Scale bar in panel A represents 50µm. 
 
 
In both DMSO and MBP 72 hour treated testis explants, OCT4 expression was 
absent in some GCs after 72 hours, showing that the normal GC differentiation 
process was still occurring in the in vitro testis explants, and there was some 
evidence that MBP treatment might prolong OCT4 expression (Fig. 6.5). Therefore, 
quantification of the percentage of GCs expressing OCT4 after 72 hours in culture 
was performed and results shown in Fig 6.6. 
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Figure 6.6 Percentage of OCT4 expressing germ cells in 72 hour fetal rat testis 
explants treated with DMSO or MBP, (n=6). Values are means ± SEM. No 
statistically significant differences.  
 
 
There was no significant increase in the percentage of OCT4+ GCs in testis explants 
after 72 hours of in vitro MBP treatment, as compared to DMSO. However, there 
was high variability between testis explants as the percentage of OCT4+ GCs could 
vary in each treatment group between 10-90%. Oct4 mRNA expression levels were 
then analysed by the Taqman system in 72 hour cultured fetal rat testis explants 
treated with DMSO and MBP, and results shown in Fig 6.7. 
 





































Figure 6.7 Quantitative analysis of Oct4 mRNA levels in 72 hour fetal rat testis 




As with Oct4 mRNA expression levels in testes from DBP exposed animals in vivo 
(Fig 4.9), 72 hours of MBP treatment did not significantly increase Oct4 mRNA 
expression in comparison to vehicle control. As with the in vivo DBP exposure 
effect, this could be due to fewer GCs after 72hrs treatment with MBP that are each 
expressing more Oct4 mRNA.  
 
6.3.2.3 Effect of MBP treatment for 48 hours on Leydig cells 
Having examined GC development with 48-72 hours of MBP treatment, Leydig cell 
development in the 48 hour cultured testis explants treated with DMSO or MBP were 
examined by IHC staining for 3β HSD, as shown in Fig 6.8. 
  
 
Figure 6.8 Representative photomicrographs of immunostaining for 3β HSD (Dab = 
brown) in 48 hour fetal rat testis explants treated with DMSO or MBP. Scale bar in 
panel A represents 50µm. 
 
 
IHC staining for 3β HSD was severely reduced in testis explants after 48 hours of 
MBP treatment in comparison to DMSO vehicle control. IHC staining for another 
Leydig cell protein, the steroidogenic enzyme CYP11A also showed the same loss of 
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expression (data not shown). This suggested that MBP treatment severely reduced 
either Leydig cells or steroidogenesis after 48 hours. Culture media were assayed for 
testosterone, as described in (Fisher et al., 2003), but the results obtained were far too 
variable for useful analysis (1000 fold difference between similarly treated wells in 
the same culture experiment). To further examine the possible in vitro effect of MBP 
treatment, 3β hsd mRNA levels were analysed by the Taqman system in 48 hours 









































Figure 6.9 Quantitative analysis of 3β hsd mRNA levels in 48 hour fetal rat testis 




There was no significant difference between MBP and DMSO treatment in 3β hsd 
mRNA expression after 48 hours of in vitro culture, but it is likely that high 
variability in the expression level in DMSO treated testis explants may have masked 
an inhibitory effect of MBP treatment. This observation has led to other members of 




6.3.3 In vitro treatment of testis explants with cyclopamine  
Having established the utility of the 48 hour testis explant to be chemically 
manipulated, the model was then investigated for treatments that would not be 
possible in vivo, such as cyclopamine (Cyc) blockade of Hedgehog signalling. As 
described in Section 1.2.3.3, Desert Hedgehog signalling is important in fetal Leydig 
cell differentiation in the mouse (Clark et al., 2000; Yao et al., 2002). In Dhh null 
mice, there are also irregular cords by em16.5, and some GCs are found outside the 
cords (Clark et al., 2000), suggesting a role for Desert hedgehog signalling in cord 
formation. To examine if blocking Hedgehog signalling in the fetal rat testis affected 
cord formation and Leydig cells, e14.5 testes were cultured for 48 hours using 
cyclopamine at the 25 µM dosage, with ethanol (EtOH) used as the vehicle control. 
As with the untreated 48 hour cultures, the testis explants were analysed by IHC for 
the core developmental processes of fetal testis development including - GC 
proliferation by double IHC staining for DAZL and BrdU, seminiferous cord 
structure by double IHC for DAZL and AMH and Leydig cells by IHC for 3β HSD. 
These IHC examinations are summarized in Fig 6.10.  
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Figure 6.10 Representative photomicrographs of IHC staining from 48 hour in vitro 
cultured rat testis explants treated with EtOH (A-F) or Cyclopamine (Cyc) (G-L). 
Left-hand panels show IHC staining for BrdU (Dab = brown) and DAZL (Fast blue = 
blue). Middle panels show IHC staining DAZL (Dab = brown) and AMH (Fast blue = 
blue). Right-hand panels show IHC staining for 3β HSD (Dab = brown). Black arrow 




48 hours of in vitro treatment with EtOH or Cyc on testis explants did not prevent 
proliferation, or organization into seminiferous cords or Leydig cell expression 
development, based on 3β HSD immunoexpression. However a consistent reduction 
in GCs was detected in Cyc treated explants, highlighted (arrow) in Fig 6.10K. These 
remaining GCs continue to proliferate, as seen by the BrdU+DAZL+ cells present in 
Fig 6.10J. This was unexpected as Desert Hedgehog signalling has not been 
described as important in GC survival previously. To further examine if Cyc 
treatment altered both Leydig cell development and GCs, Taqman analysis for 3β hsd 
and Dazl mRNA expression in testis explants cultured for 48 hours with EtOH or 
Cyc was performed, as shown in Fig 6.11 and Fig 6.12.  
 



































Figure 6.11 Quantitative analysis of 3β hsd mRNA levels in 48 hour fetal rat testis 




There was no significant difference in 3β hsd mRNA expression in 48 hour cultured 
testis explants treated with Cyc, suggesting that blocking Desert Hedgehog signalling 
in the fetal rat testis did not alter 3β hsd expression. 
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Figure 6.12 Quantitative analysis of Dazl mRNA levels in 48 hour fetal rat testis 
explants treated with EtOH or Cyc (n=6). Values are means  SEM. * P<0.05 
between EtOH and Cyc treated. 
 
 
Forty eight hours of Cyc treatment significantly reduced Dazl mRNA expression in 
comparison to EtOH vehicle control. This matched the IHC staining result in Fig 
6.10.  To examine if this was just a reduction in DAZL expression, other GC markers 
(OCT4 and VASA) were examined by IHC in 48 hour in vitro cultured EtOH and 
Cyc treated testis explants and showed the same reduction in GCs (data not shown). 
To further investigate the role of Hedgehog signalling in the fetal rat testis, IHC 
staining for PTCH1 (the DHH receptor) using an antibody purchased from Abcam 
was performed on in vivo rat testes, as shown in Fig 6.13A and C. The staining 
detected with this Abcam antibody stained every cell in the rat testis at e16.5, before 
becoming more highly expressed in the cords than in the interstitium at e21.5. IHC 
staining using this antibody on postnatal rat testes showed GC specific staining at 
D25 and spermatogonial specific staining in adulthood (data not shown). This pattern 
of staining supported the Cyc treatment result, with GCs expressing PTCH1, but the 
IHC staining was consistently nuclear for a membrane receptor. To examine if this 
was true PTCH1 staining, a different antibody from Santa Cruz was used for IHC on 
e16 and e21.5 in vivo testes, shown in Fig 6.13B and D. This staining was more 
membrane bound and also seemed to be GC-specific, in fact IHC detection of 
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PTCH1 using the Santa Cruz was never found in Leydig cells at any age (fetal and 
postnatal), contradicting the reported role of DHH signalling in the testis.  
 
Figure 6.13 Representative photomicrographs of IHC staining using two antibodies 
to PTCH1 (Dab = brown) in fetal rat testes from e16.5 (A-B) and e21.5 (C-D). 
Antibody raised to PTCH1 purchased from either Abcam (left) or from Santa Cruz 
(right). Scale bar in Panel D represents 50 µm. 
 
 
Due to the lack of consistency with reported PTCH1 expression by this IHC 
detection, it remains undetermined how PTCH1 protein is expressed in the fetal rat 
testis. IHC examination of the first downstream target after PTCH1, SMO was 




This made the identification of which cells in the fetal rat testis were expressing the 
Hedgehog signalling proteins uncertain, and this would be vital in order to establish 
if there is a fundamental difference between rats and mice in the role of Hedgehog 
signalling in the fetal testis. Taqman mRNA analysis for Ptch1 and Smo was then 
performed on testis explants after 48 hours of EtOH or Cyc treatment, as shown in 
Fig 6.14 and Fig 6.15.   




































Figure 6.14 Quantitative analysis of Ptch1 mRNA levels in 48 hour fetal rat testis 
explants treated with EtOH or Cyc (n=6). Values are means  SEM. No statistically 
significant differences. 
 




































Figure 6.15 Quantitative analysis of Smo mRNA levels in 48 hour fetal rat testis 
explants treated with EtOH or Cyc (n=6). Values are means  SEM. ** P<0.01 




In cultured testis explants, 48 hours of Cyc treatment noticeably reduced Ptch1 
mRNA expression and significantly reduced Smo mRNA expression in comparison 
to EtOH vehicle control. This is similar to the reduction in Dazl mRNA expression 
shown in Fig 6.12. This may be due to a reduction in GCs, seen in Fig 6.10 and 6.12, 
if it is the GCs that are expressing Ptch1 and Smo in the fetal rat testis. This is further 




The aim of this chapter was to investigate if in vitro culture of isolated fetal rat testes, 
free from both maternal and fetal metabolism and endocrinology, could be used to 
support investigations into phthalate exposure and germ cell (GC) development. To 
that end, testis explants from e14.5 aged animals were cultured without treatment for 
48 hours to examine how in vitro culturing affected testis development, before 
investigating the effects of in vitro chemical treatment with either monobutyl 
phthalate (MBP) or cyclopamine (Cyc) on testis explant development.  
 
When testis explants from e14.5 aged animals were cultured for 48 hours without 
any chemical treatment, gross IHC examination showed that cells within the explants 
continued to proliferate (including GCs), continued to express cell-specific markers 
(for GC, Sertoli and Leydig) and Sertoli cells and GCs remained broadly organised 
into cord structures. When these testis explants were examined for apoptosis, an 
increased number of apoptotic cells were seen, as opposed to in vivo (data not 
shown) and were generally located around areas of damage that occurred during 
isolation. This demonstrated that the testis explants cultured for 48 hours did not 
become disorganised or lose structure, the different cell types appeared broadly 
functional, and could show somewhat similar development to e16.5 aged testes from 
in vivo animals. 
 
It should be noted that a great degree of tissue variability was present after in vitro 
culture, with some testis explants appearing very similar to in vivo testes while some 
degenerated and appeared quite abnormal, although this could not be assessed until 
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after fixation and processing. Over the course of these thesis studies, dissection 
became more skilled and there was less variability, making this less of a negative 
factor. Usually to get around the variability of tissue, a careful IHC analysis was 
performed on each testis explant and those explants that had lost testis structure were 
excluded from any subsequent analyses. Another consideration is that whilst TUNEL 
analysis did not indicate widespread apoptosis, it was still increased compared to in 
vivo, raising the possibility that the testis explant is ‘slowly dying’ and therefore, 
with time, will become increasingly non-representative of the corresponding in vivo 
testis.   
 
Having established that testis explants could be cultured in vitro for up to 48 hours 
and survive, they were then used to examine the effects of chemical disruption on a 
variety of aspects of testis development. As in vivo DBP exposure is of particular 
interest in this thesis, the active metabolite MBP was used as an in vitro chemical 
treatment to be investigated for similarities to in vivo DBP exposure on GC 
development (Chapter 4), and to determine whether in vitro phthalate studies could 
complement or replace in vivo studies.  
 
After 48 hours of in vitro MBP treatment, testis explants continued to survive and 
cells continued to proliferate (including GCs), and all GCs remained OCT4+ and 
were organized into seminiferous cords, much the same as in untreated testis 
explants. With in vivo DBP exposure, there are limited GC effects observable early 
in testis development, mainly a significant reduction in GC number at e14.5 and 
e15.5, and an increase in proliferation index at e17.5. When in vitro MBP treatment 
for 48 hours was examined for similar effects, only the GC proliferation index could 
be reliably calculated, and was unaltered in comparison to DMSO controls. As there 
was only a DBP effect on GC proliferation at e17.5, it is possible that 48 hours of in 
vitro MBP treatment was simply too early a time point to observe an effect on the 
proliferation index.  
 
GC number in testis explants was not calculated as testis explants could not be 
weighed, and variability between testis explants would make deriving weights 
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(Section 2.8.2.2) wholly inaccurate, as well as being highly labour intensive. Other 
studies on phthalate exposure have attempted to quantify GC number (Chauvigne et 
al., 2009; Li and Kim, 2003), but were deemed similarly labour intensive and limited 
to attempt here.  
  
Of more interest in this study was to extend culture time and examine if a similar 
delay in loss of OCT4 expression, as seen with in vivo DBP exposure at e17.5, could 
be induced with in vitro MBP treatment. In MBP treated testis explants there were 
seemingly more OCT4+ GCs present than in DMSO controls, but when the 
percentage of OCT4+ GCs was quantified, no significant difference was found. This 
is most likely due to the variability in the treatment groups, where between 10-90% 
of GCs could be OCT4+. It should be noted that in both MBP and DMSO treated 72 
hour cultured testis explants, the percentage of OCT4+ GCs was higher than in vivo 
at e17.5 (~20%, Fig 4.8), suggesting that delayed GC development was already 
occurring in vitro. When Oct4 mRNA expression was examined in 72 hour testis 
explant cultures after exposure to MBP or DMSO, no difference in expression was 
observed, which may be due to MBP treatment having no effect on GC expression of 
Oct4, or possibly, as in vivo at e17.5 with DBP exposure (Fig 4.9), there are fewer 
GCs that are more highly expressing Oct4 than in DMSO controls.    
 
In vitro MBP treatment of testis explants failed to produce the same GC effects as 
reported after in vivo DBP exposure and therefore proved to be an inadequate tool in 
this regard, especially as testis explants are limited in what can be examined in terms 
of delayed GC development (DMRT1 at e19.5, GC aggregation at e21.5, MNGs at 
e21.5, reduced GC number). One of the other uses of in vitro culture is that different 
doses of phthalates can be used directly on testis explants (as attempted in Chauvigne 
et al., 2009; Li and Kim, 2003), however when GC effects in both controls and MBP 
treated explants were so variable, such dose response investigations would also be 
limited.   
 
However, the testis explant experiments using MBP did yield one interesting result, 
with the identification of a possible phthalate effect on early testis development, as it 
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caused a dramatic reduction in 3β HSD and CYP11A1 expression after 48 hours of 
in vitro culture with MBP. This showed that MBP is either severely inhibiting 
steroidogenesis or differentiation of fetal Leydig cells, with presumably the same net 
effect. The limitations of in vitro testis explants become a factor again, as 
testosterone levels could not be reliably examined in MBP or DMSO treated culture 
media, making this MBP effect on steroidogenesis/Leydig cells observational. This 
early phthalate effect matches reported in vivo DBP exposure effects on Leydig cells, 
but at an earlier time than previously examined. This effect (of MBP on testis 
explants) is similar to what has been reported to occur in vivo after DBP exposure, 
but only at e15.5 (Hutchison et al., 2008).   
 
Having established the relative merits and drawbacks of in vitro phthalate 
investigations to support in vivo studies, a chemical treatment that could not be 
attempted in vivo was then examined. Cyclopamine (Cyc) inhibits Hedgehog 
signalling through binding and blocking SMO protein action. In vitro treatment with 
Cyc has been used before on fetal mouse gonads to disrupt Leydig cell differentiation 
(Yao et al., 2002). Furthermore, in Desert Hedgehog null mice, both cord formation 
and Leydig cell development are disrupted (Clark et al., 2000). Therefore it was 
expected that Cyc treatment would disrupt seminiferous cords and Leydig cells in the 
fetal rat testis explants.  
 
After 48 hours of in vitro Cyc treatment of testis explants, both seminiferous cord 
formation and Leydig cell steroidogenesis appeared unaltered in comparison to 
ethanol (EtOH) control treatment, when examined by both IHC and Taqman 
analysis. It is possible that this lack of effect of blocking Desert Hedgehog signalling 
in the fetal rat testis, when compared to the fetal mouse testis, may be due to the 
timing of Cyc treatment. Cyc only altered Leydig cell differentiation in mouse 
explants that were collected prior to em12.5, and after that time Cyc had no effect 
(Yao et al., 2002). This temporal aspect of Desert Hedgehog signalling may be 
similar in the rat, but testes from younger ages than e14.5 could not be dissected out 
in a manner suitable for in vitro culture.       
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Interestingly, after 48 hours of in vitro Cyc treatment of rat testis explants, a 
noticeable reduction in GCs was observed in comparison with EtOH treated controls. 
Previously, the only GC effect of blocking Desert Hedgehog signalling in the mouse 
testis was that some GCs were found outside of the cords, as a side effect of 
disrupted cord formation (Clark et al., 2000). However in the rat testis explants 
cultured for 48 hours with Cyc, GCs were all found within the cords and some were 
still proliferating (BrdU+). As GCs and Sertoli cells are organised into seminiferous 
cords by e14.5, the time of testis explant collection, the Cyc-induced loss of GCs was 
not due to disrupted cord formation, as that was relatively unaltered after 48 hours of 
in vitro Cyc treatment. Overall this suggests a possible role of Desert Hedgehog 
signalling from Sertoli cells (as in the mouse) that promotes GC survival in the fetal 
rat testis.  
 
Attempts to further investigate the role of Desert Hedgehog signalling in the fetal rat 
testis were limited by inability to conclusively show that GCs express the Hedgehog 
signalling machinery (PTCH1 and SMO). The only support for GC expression of 
Hedgehog signalling molecules in the fetal testis was that mRNA levels for Ptch1 
and Smo were reduced in the whole testis to a similar degree as was the GC gene 
Dazl. In the postnatal (mouse) testis there is more evidence for a role of Desert 
Hedgehog signalling in spermatogenesis (Bitgood et al., 1996), and identification of 
PTCH1 and SMO in the meiotic and post meiotic GCs in the mouse testis (Morales 
et al., 2009) and the detection of a male GC-specific Patched-domain gene Ptchd3, 
the protein for which is found in the sperm of mice, rat and human (Fan et al., 2007). 
 
Recently a study using fetal rat testis explants from e14.5 that were cultured up to 
three days in the presence of Cyc (at the same dose used here) or recombinant mouse 
Sonic Hedgehog has been performed (Brokken et al., 2009). In this study, no GC 
effects were reported, but the focus was more on Leydig cell effects and only a 
limited IHC analysis of the explants was performed. However after three days of 
culture, a significant reduction in Ptch1 mRNA expression was reported with Cyc 
treatment, similar to reported here, as well as a significant reduction in both 3β hsd 
and Cyp11a mRNA expression levels (Brokken et al., 2009). Taking all these factors 
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into account, any further conclusions about Desert Hedgehog signalling in fetal rat 
GCs remains a possibility but requires considerable further work.  
 
These studies into Cyc treatment highlight both the strength and weakness of in vitro 
testis explants. Cyc treatment would not be possible in vivo, so blocking Hedgehog 
signalling in the developing fetal rat testis would be otherwise very hard to achieve. 
The data generated from Cyc treatment on testis explants has shown a clear reduction 
in GCs compared to controls and has suggested a possible new role of Hedgehog 
signalling in GCs that could not have been determined otherwise. Unfortunately, no 
further support could be generated from the testis explants and the same data 
contradicts several aspects of published work in the mouse and the rat (Brokken et 
al., 2009; Yao et al., 2002).   
 
In summary, the MBP studies illustrate that in vivo studies are clearly a better way to 
examine testis development and disruption, whilst the Cyc studies illustrate the 
utility of testis explants when in vivo manipulation cannot be done. Generally the 
testis explants were useful in detecting gross changes caused by chemical treatment, 
such as MBP on 3β HSD and Cyc on GCs, that can be easily observed, but if more 
subtle changes are caused they may be missed due to the high variability. The 
inability to quantify GC number or testosterone levels from testis explants is also a 
consideration, though other groups have managed to collect reliable hormone data 
(Chauvigne et al., 2009; Hallmark et al., 2007; Lambrot et al., 2009; Li and Kim, 
2003). Nevertheless, there is still considerable disagreement between the published 
data, for example phthalate effects on testosterone production on testis explants 
(Chauvigne et al., 2009; Stroheker et al., 2006), and this may reflect the inherent 
variability of the in vitro approach. In this regard, the notion that in vitro testis 
explants are a slowly dying tissue means that it will always have limited resemblance 
to the normal function of that tissue. However it remains the only way to disrupt 
certain aspects of testis development and allows a way to examine disruption on 
human tissue, which altogether makes in vitro testis explants a useful tool, but one 
that requires very careful application.  
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7 General discussion 
The general aim of this thesis was to obtain new insights into regulation of fetal GC 
development in the rat and the susceptibility of these processes to disruption by DBP. 
As there is currently no accepted model for human CIS/TGCT, it was hoped that 
examining GC development in an animal model in which a TDS-like phenotype has 
been induced by DBP exposure might provide some insight into how perturbed fetal 
GC differentiation in the human can result in CIS cells and eventually TGCT. More 
generally, it was hoped that gathering more information on the process of fetal GC 
differentiation, especially in regard to methylation events in fetal life, might shed 
light on events that might predispose to CIS and/or to infertility in adulthood. In 
addition, in vitro fetal testis explants were evaluated as an additional tool to 
investigate early testis development, especially in regard to GC development.   
 
To achieve these aims, normal GC development in the fetal rat testis and ovary was 
characterised, as described in Chapter 3, and identified a variety of events that could 
be investigated for possible DBP disruption. When the DBP exposure effects were 
examined in Chapter 4, a general pattern of delayed GC development was identified, 
which persisted into early postnatal life. In addition, it appeared that early exposure 
(between e13.5-e15.5) was a crucial time window in inducing the observed DBP 
exposure effects on GCs. Having thoroughly examined the effects of fetal exposure 
to DBP on GC development, the process of DNA methylation in the fetal testis was 
focussed upon as a possible mechanism for how DBP exposure may be exerting 
some of its effects, covered in Chapter 5. Examination of global DNA methylation in 
relation to DBP exposure showed no obvious DBP effect, whilst the relationship 
between methylation of the candidate gene Oct4 and its protein expression was 
examined by chemical DNA methylation inhibition and bisulphite sequencing of the 
Oct4 promoter region. Finally, in vitro studies using testis explants as an additional 
tool to investigate fetal GC development and phthalate exposure, described in 
Chapter 6, suggested a Leydig cell effect of phthalate exposure earlier than 
previously reported and a possible new role of Hedgehog signalling in fetal rat GCs. 
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When GC development was examined in both the fetal rat testis and ovary, it was 
found to be broadly similar with some small differences (OCT4 expression at e17.5) 
and some major (meiotic/mitotic arrest), which matched the published literature for 
the mouse (Bowles and Koopman, 2007). As well as providing the first data on these 
events for the rat, this characterisation detailed the processes and specific timings 
that were then examined for effects of in utero DBP exposure from e13.5 until birth. 
Two major effects of DBP on GC development were observed, which may be related 
or not. They were a consistent reduction in GC number at every age examined (even 
after only 24 hours of DBP exposure) and a delay in the timing of GC development.  
 
The origin of the consistent reduction in GC numbers after DBP exposure seemed to 
be early in testis development, as a significant reduction in GC numbers was found 
by e14.5. Use of different exposure windows showed that starting DBP exposure 
earlier than e13.5 did not exacerbate this reduction in GC number and that DBP 
exposure after e15.5 did not significantly reduce GC number by e21.5. This indicated 
that DBP exposure between e13.5 and e15.5 is the crucial time when GC number 
reduction is established. This most probably occurred by increased GC apoptosis, but 
this was not directly shown. Phthalate exposure in vitro has been reported to increase 
GC apoptosis, but only at specific times (Lambrot et al., 2009; Li and Kim, 2003). It 
may be possible that fetal rat GCs are especially susceptible to DBP induced 
apoptosis between e13.5-e15.5, as no increased GC apoptosis was detected at e15.5 
and e17.5. Associated with the reduction in GC number was altered GC proliferation 
after DBP exposure, which was increased at e17.5 in testes from DBP exposed 
animals compared with controls, and rare, single proliferating GCs were even 
observed at e19.5 in testes from DBP exposed animals. It was concluded that DBP 
exposure prolonged GC proliferation, but this increased proliferation could not 
recover final GC number in fetal life to control levels. The effect of DBP on GC 
proliferation may indicate a different explanation for the consistent reduction in GC 
number induced by DBP exposure, as it could be that DBP delays the progress of GC 
through the cell cycle. If DBP exposure was slowing down the GC cell cycle, a 
reduction in GC number would be observed as well as a prolonged detection of 
slower proliferating cells. However, as no difference in GC proliferation index was 
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observed at e15.5 between control and DBP exposed animals, as might be expected if 
DBP exposure slowed GC progress through the cell cycle, it is more likely that DBP 
exposure is instead delaying the end of GC proliferation. Further work is needed to 
identify the mechanisms underlying the early origin of reduced GC number after 
DBP exposure, for example by examining GC apoptosis at short time intervals after 
dosing with DBP on e13.5; these same samples could also be used to investigate if 
the progress of GC through the cell cycle is altered after DBP exposure. 
 
The reduction in GC number after DBP exposure may be related to the described 
delays in GC development, as summarized in Table 4.4. Briefly, several processes of 
GC development showed a consistent, but transient, delay in their timings, such as 
the end of proliferation, the switching off of OCT4 and DMRT1 expression, “cKIT” 
localization and fetal GC disaggregation at e21.5. This consistent delay in fetal GC 
development after DBP exposure even continued into early postnatal life with 
delayed re-entry into proliferation, GC-specific re-expression of DMRT1, postnatal 
migration to the basal lamina at D6 and delayed entry into meiosis at D15. However, 
given enough time the GCs of DBP exposed animals managed to “catch-up” to 
control animals by adulthood (3 months old) (Ferrara et al., 2006). This consistent 
delay in so many aspects of GC development is very convincing evidence that in 
utero DBP exposure is somehow causing the endogenous GC program to run late, 
and that this effect is triggered by exposure during the period of initial cord 
formation.  
 
As with the reduction in GC number throughout fetal life, the delay in GC 
development appeared to be an early event in testis development after DBP exposure. 
DBP exposure between e13.5-e15.5 resulted in a significant increase in OCT4+ GCs 
at e17.5, a noticeable increase in DMRT1+ GCs at e19.5, and significant decrease in 
DMRT1+ GCs at D6, though these delayed events were not as marked as with 
continued DBP exposure from e13.5 until birth. DBP exposure between e15.5 and 
e17.5 showed no significant induction of GC effects reported with standard DBP 
exposure, but did tend to show a slight change. These shorter windows of DBP 
exposure suggested that while delayed GC development in DBP exposed animals 
Chapter 7  General Discussion  210 
originated from some event between e13.5-e15.5, continued DBP exposure after that 
point may be necessary to maintain and/or enhance this delay. As with the reduction 
in GC numbers, identification of the early event in GC development which DBP 
disrupts to cause this delay would be a major avenue of future investigation. This 
might also have relevance to CIS origins, as any process that can be perturbed and 
affect GC differentiation would be a step towards the block in differentiation that 
leads to CIS.  
 
As the gross histology of e14.5 testes from DBP exposed animals was similar to 
e14.5 testes from control animals (though testes were slightly smaller) and 
seminiferous cord formation was not observed to be disrupted by e14.5 (data not 
shown), a subtle origin for both reduced GC number and delayed GC development is 
most likely. At such an early stage of testis development, relatively minor changes to 
GC development by DBP exposure could cause major consequences by the end of 
fetal life and postnatally. Investigating a possibly subtle change during the very early 
stages of testis development makes further in vivo investigations of DBP exposure a 
challenging task.    
 
Ideally, in vitro manipulation of e14.5 fetal testis explants would be useful in trying 
to identify the origin of the DBP-induced delay in GC development. As described in 
Chapter 6, e14.5 testis explants can be cultured, but show a delayed development in 
longer culture times (i.e. a high percentage of OCT4+ GCs after 72 hours culture) 
and the high variability of morphology and phenotype may make identifying a subtle 
change difficult. However, improvements in the in vitro culture system that would 
allow e13.5 gonad pairs (to reduce tissue damage during extraction) to be cultured 
could provide a way to examine early testis development with MBP treatment. As 
seminiferous cords can be viewed using a transilluminated stage (during 
microdissection), cord formation between e13.5 and e14.5 could possibly be 
followed using live cell imaging, and examined for a possible MBP treatment effect.    
 
The most obvious way to gain more insight into the early origin of DBP exposure 
effects on GCs would be to use narrower early windows of DBP exposure in vivo, 
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i.e. e13.5-e14.5 and e14.5-e15.5 and then examine the delay in switching off of 
OCT4 and DMRT1 and the effect on GC number at e21.5. This would hopefully 
identify if the early effect of DBP exposure was occurring prior to cord formation, 
which is complete by e14.5, or after. Should DBP exposure be required between 
e13.5 and e14.5 to cause disrupted GC development, this may explain the lack of 
MBP treatment effect on GCs in e14.5 testis explants in Chapter 6.      
 
Whilst cord formation was not prevented in DBP exposed animals by e14.5, it is still 
possible that the early GC-Sertoli interactions and organization during cord 
formation may be susceptible to DBP interference, and that early interference may 
initiate the delay in GC development. This might be the most important area to 
investigate, as extended DBP exposure treatment has established that the GCs are 
only susceptible to DBP exposure once they have arrived in the gonad. The later 
event of GC disaggregation at e21.5 may provide a more convenient way to examine 
how GC-Sertoli interactions may be altered by DBP exposure effects, as illustrated 
by previous work on a late DBP exposure window from e19.5-e20.5 (Ferrara et al., 
2006).    
 
The importance of early exposure between e13.5-e15.5, when GCs are in the gonad 
but prior to reported DBP effects on other cell types (Hutchison et al., 2008b; Scott et 
al., 2008) suggests that the described effects of DBP exposure are a combination of 
both direct DBP exposure effect on the GCs and a necessity of the GCs to be present 
within the somatic environment of the gonad for DBP exposure to have an effect. 
Further work to identify how DBP exerts both the direct effect and indirect effect on 
GCs would be worth pursuing.   
 
This thorough examination of GC development in the rat and DBP exposure 
encountered a few technical limitations, which if they could be overcome would 
provide further evidence of DBP exposure effects. For example, if the observed 
difference in DAZL protein reduction at e19.5 could be quantified, that would 
support the DBP induced delay in GC development. Taqman analysis was also 
limited by the use of whole testis RNA from control and DBP exposed animals, that 
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made it impossible to determine if a change in mRNA expression reflected a change 
in GC expression of that gene, or reflected a change in the number of cells 
expressing that gene (as happened for OCT4 at e17.5 in DBP exposed animals).   
 
A major consequence of this thorough examination of GC development in the fetal 
rat is that it demonstrated fundamental differences in organisation and co-ordination 
of fetal GC development between rat/mouse and the human, as highlighted in 
recently published data on GC development in the human fetal testis (Anderson et 
al., 2007; Mitchell et al., 2008). These differences may account for why DBP 
exposure does not induce CIS/TGCT in the rat. As described in Section 3.4, fetal 
GCs within the human testis have heterogeneous sub-populations of GCs within 
individual seminiferous cords, whilst in the rat the seminiferous cords contain largely 
synchronised GC populations. In addition, there are sub-populations of OCT4+, 
VASA+ and DAZL+ GCs in the human, which were not found in the rat (Anderson 
et al., 2007). These differences probably reflect the differentiation of GCs in the 
human from one stage to another, whilst the comparatively rapid GC development in 
the rat may require quicker/more efficient GC differentiation. This difference 
between synchronised GC development in the rat and “unsychronised” GC 
development in the human may explain why CIS/TGCT were not induced with DBP 
exposure like the other TDS disorders. However the DBP exposure induced delay in 
rat GC development may provide some insight into the origin of CIS cells in the 
human, where a “delayed” GC may be a precursor to a “blocked” GC. As the 
described delay in rat GC development after DBP exposure is largely synchronised 
and isolated, “blocked in differentiation” GCs were not present, suggesting that rat 
GCs are more tightly regulated, either within the GC themselves or through external 
signals from the Sertoli cells or other GCs. In the human testis, where there are GC 
sub-populations and a lack of such synchronicity, it is more likely that if isolated 
GCs become delayed in development, it would be possible that a “block in 
differentiation” could occur, resulting in CIS.  
  
If CIS is indeed the result of a developmentally delayed human GC that then 
becomes blocked from differentiating further, identification of the mechanisms 
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responsible for the early DBP-induced delay in GC development in the rat might 
enable the delay to be prolonged or enhanced and might then be capable of leading to 
CIS-like cells in the rat. Alternatively, a more appropriate animal model for human 
GC development than the rat could be used to investigate delayed differentiation and 
CIS cells. Recently, the marmoset has been described as an animal model with 
similar asynchronised fetal and neonatal GC development to the human (Mitchell et 
al., 2008), and has been examined for fetal and neonatal MBP exposure effects on 
testis development, with possible effects on OCT4 expression neonatally (McKinnell 
et al., 2009). Another option to investigate phthalate exposure on human GC 
development would be to use in vitro MBP treatment on fetal human testis explants, 
as previously attempted (Hallmark et al., 2007), but with a focus on GC development 
to compare with the results of MEHP on fetal human testis explants (Lambrot et al., 
2009). However, if the rat is any guide, such in vitro studies may have to use 1st 
rather than 2nd trimester fetal human testis explants (unlike the studies to date), as it 
is possible that very early events are those susceptible to disruption to induce CIS 
cells; from studies of CIS cell protein expression patterns this is likely to be the case 
(Rajpert-De Meyts et al., 2003; van de Geijn et al., 2009). 
 
One important aspect of CIS/TGCT that could be further investigated using the DBP 
exposure model of delayed GC development, is determining what is regulating the 
silencing of OCT4 expression in the fetal testis. In mouse and human ES (and iPS) 
cells, Oct4 gene expression is related to promoter methylation that is regulated by 
retinoic acid (RA) signalling (Li et al., 2007; Yeo et al., 2007). In the fetal rat ovary, 
Oct4 mRNA was significantly reduced around the time of meiotic induction 
supporting the role of RA in both initiating meiosis and silencing Oct4 (Bowles et 
al., 2006; Bowles and Koopman, 2007). However, in the fetal testis, should the 
theory of RA signalling initiating GC meiosis be correct, RA would be absent, 
having been metabolised by CYP26B1, implying that another mechanism separate 
from RA signalling may be involved in Oct4 silencing in the fetal testis. Use of the 
chemical methylation inhibitor AZC in Chapter 5 showed that inhibiting methylation 
can prolong the expression of OCT4 protein in GC until even e19.5, supporting the 
importance of methylation in the regulation of Oct4 gene expression. Whilst 
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methylation may be important in Oct4 gene expression, other forms of gene 
regulation (i.e. post-translational regulation) could also be occurring. This is a 
possibility as Oct4 mRNA was still detected in both late fetal and postnatal rat testes, 
when OCT4 protein expression was completely absent, whereas in the ovary Oct4 
mRNA was never detected after e17.5. By taking advantage of the significant 
difference in OCT4 expression between testes from control and DBP exposed 
animals, a greater understanding of how Oct4 expression is regulated in the absence 
of RA in the fetal testis would be a logical further study. Such insight into Oct4 
expression in the fetal testis would be of great interest with regard to the expression 
of OCT4 and the maintenance of pluripotency in human CIS cells.    
 
Whilst in utero DBP exposure does not block GC differentiation and the observed 
delay in GC development eventually recovers to “normal” levels, DBP exposed 
males still have impaired spermatogenesis and reduced fertility (Fisher et al., 2003). 
This suggests that there may be subtle DBP exposure effects on GCs that have not so 
far been identified. One mechanism that is associated with reduced fertility is altered 
DNA methylation, especially at imprinted gene loci (Hammoud et al., 2009). The 
examination of DNA methylation for the first time in the fetal rat testis (Chapter 5) 
illustrated the importance of this process during testis development, with increased 
global methylation in GCs and high expression of DNA methyl transferases in 
comparison to the adult rat testis. Attempts to identify disrupted DNA methylation 
with DBP exposure were unsuccessful, but differences in timing and gene specific 
methylation would probably not have been detected. As GC development was 
consistently delayed after DBP exposure, it seems likely that GC de novo DNA 
methylation could also be delayed and if that delay was severe enough to cause 
aberrant genomic imprinting, this could lead to postnatal consequences such as 
reduced fertility.  
 
To further investigate DNA methylation in regard to in utero DBP exposure, two 
approaches may be the most effective. First, examination of the methylation of 
imprinted genes in sperm from control and DBP exposed animals. Second, to use 
global comparative methylation analyses to look at the methylation of a wide variety 
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of genes in control and DBP exposed animals. By focussing on imprinted genes in 
sperm, the problems of somatic DNA contamination would be limited, and several 
imprinted genes have already been associated with altered methylation and reduced 
fertility to provide good target genes for investigation. Should global methylation 
differences between control and DBP exposed animals be examined, methods such 
as Restriction Landscape Genome Scanning (RLGS) would be a relatively simple 
way to compare groups. RLGS generates a 2 dimensional map of “spots” that are 
dependent on the methylation status of restriction sites and these maps can be used to 
visualise the methylation in a wide variety of genes in the sample. By comparing the 
“spot” maps between control and DBP exposed animals, or from different aged 
animals, regions that are differentially methylated could easily be identified and 
further examined (Costello et al., 2009).  
 
If an efficient and robust method of isolating fetal rat GCs was developed, gene 
specific methylation investigations could be performed, as was attempted for Oct4. 
The ability to isolate fetal rat GCs would allow many questions about the DBP 
induced delay in GC development to be answered more clearly. For example, 
isolated GCs could be counted by a flow cytometer to determine the number of GCs 
in control and DBP exposed testes from any age, and isolated GCs could be used for 
Taqman analysis to determine if the DBP induced reductions in gene expression 
reflect a loss of mRNA or simply a loss of GCs. 
 
In summary, the present studies have provided the first detailed analysis of GC 
development in the fetal rat and have identified the processes of GC development 
that are susceptible to disruption by DBP exposure. Whilst these effects of DBP 
exposure failed to provide specific new insight into the origin of human CIS/TGCT, 
they have identified processes that are of likely relevance to the origin of CIS cells, 
and have highlighted the potential vulnerability of very early GC development and 
differentiation to disruption by an environmental chemical such as DBP. DBP 
exposure delayed, but failed to ultimately block, GC differentiation in fetal life, and 
this delay continued into early postnatal life. The use of different DBP exposure time 
windows identified that early testis development was most susceptible to the effects 
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of DBP exposure on GCs. Although no direct evidence could be provided to show 
that altered DNA methylation was a mechanism via which DBP exposure affected 
GC development, studies using an inhibitor of methylation suggested this was a 
distinct possibility.  Finally, in vitro culturing of testis explants was found to have 
limited utility for the study of fetal GC development and its manipulation in the rat, 
though further studies to refine techniques and reduce variability might improve this. 
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